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Abstract 
Background: Persistent postsurgical pain (PPP) is an increasingly recognised 
complication of surgery. Various putative risk factors have been identified over 
the last ten years. However the prevention of this phenomenon has proven 
difficult. I studied PPP following cardiac surgery to identify both means of 
prediction and prevention.  
Methods: With ethics committee approval, I followed up 312 patients 
undergoing cardiac surgery over a six-month period in our hospitals. This 
established pilot data and allowed power calculation for the following 
prospective studies: 
1. Randomised controlled trial (RCT) of pregabalin alone (P) or pregabalin 
combined with ketamine (PK), as compared to usual care (UC) for the 
prevention of PPP. 
2. Quantitative Sensory testing before and after surgery, to identify central 
nervous system changes predictive of PPP, as well as any protective effect 
of P and PK in the active arms. Patients were risk stratified into 
vulnerable and resilient phenotypes, with the use of dynamic pain 
assessments of Conditioned Pain Modulation (CPM), Temporal 
Summation (TS) and Zone of Hyperalgesia (ZoH.) 
Results: In the observational pilot cohort, 39.7% of patients described PPP 
following elective first-time cardiac surgery.  The age of the patient, duration of 
surgery and acute pain during the recovery period all seemed to act as strong 
predictors for the development of PPP in this cohort study. 
In the prospective RCT, pregabalin was protective for future PPP.  The study 
demonstrated a significant improvement in PPP; OR= 0.11 and 0.046, for groups 
P and PK respectively at three months, as compared to the UC group. The 
addition of ketamine to pregabalin, as part of a multimodal regimen, had no 
significant effect on PPP outcomes in this trial. 
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Tolerability of both drugs on the first day of treatment was an issue. As an 
example, NNH (Number Needed to Harm) for diplopia was equal to 6.3 and 4.5, 
in P and PK respectively.  This failed to impact on recovery, however, with 
improvements in median length of stay of 1 and 1.5 days respectively (p=0.023 
and 0.002.)  
The powerful and protective effects of pregabalin in the perioperative period are 
demonstrated by: 
1. Increases in pressure pain threshold (PPT) at a site remote to the incision 
2. Prevention of the development of new TS 
3. Reduction in the zone of peri-incisional hyperalgesia 
The likelihood of developing PPP in any cardiac surgical patient may be 
predicted by a combination of the following perioperative risk factors: 
1. Perioperative QST markers of new TS and increased ZoH, at the site of 
surgical incision, as well as decreased PPT remote to the incision. 
2. Inefficiency of CPM 
3. Poor preoperative quality of life, measured with EQ-5D 
4. Increased levels of state anxiety and catastrophising 
5. Young age  
6. Surgical risk factors of increased duration of surgery and poorly managed 
acute pain - but not surgical technique and extent of dissection.  
Conclusion: This study suggests a potential to risk-stratify cardiac surgery 
patients and allow targeted preventive intervention for PPP. 
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Lay Abstract (Press Release at the ASA Annual Scientific Meeting 2013)  
Also available at http://www.asahq.org/painaftercardiacsurgery 
Persistent pain following cardiac surgery 
can be predicted and reduced 
10.13.13 
The incidence of chronic pain following cardiac surgery can be reduced in 
patients when the drug pregabalin is used before surgery and for 14 days 
post-surgery, according to a study presented at the ANESTHESIOLOGY™ 
2013 annual meeting. The study also found that patients at risk of developing 
long-term post-operative persistent pain could be predicted by conducting 
pain sensitivity tests at the time of surgery. 
“Heart disease can be painful and disabling; however, heart surgery to treat 
the disease often leaves patients with a new persistent pain around the 
incision site, which can be equally disabling and burdensome,” said Sibtain 
Anwar, M.B., M.A., F.R.C.A., research fellow at Barts and the London School 
of Medicine and Dentistry, England. “In the study we discovered a way to 
identify patients at risk for developing persistent postsurgical pain, as well as 
to prevent it with a regimen of pregabalin.” 
In this double-blind, randomized and controlled study, 150 patients scheduled 
for elective cardiac surgery were divided into three groups. The first group 
received pregabalin preoperatively and for 14 days following surgery. The 
second group received the same regimen of pregabalin as the first group, plus 
an infusion of ketamine for 48 hours after surgery. The third group received an 
entirely placebo-based regimen. All other surgical and anesthetic care was 
unchanged and included patient controlled morphine following surgery. 
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Before and after surgery, quantitative sensory testing of the patients’ nervous 
systems was performed. This was based on the idea that the nervous system 
response to the experimental pain in the laboratory may give insight into how 
it will respond to subsequent surgical pain. One technique involved inducing 
pain by applying measured pressure at four points on the chest, followed by a 
second “distracting” pain in the arm with the use of a very tight blood pressure 
cuff. Measuring a person’s change in pain sensitivity before and after the 
distracting arm pain, as well as before and after surgery, predicted whether 
they would develop pain that persisted many months later, the study found. 
The study also found that using pregabalin reduced the incidence of 
persistent postsurgical pain to 10 percent and 8 percent of the patients at 
three and six months, respectively. The incidence of pain in the placebo group 
was 50 percent at three months and 46 percent at six months.  The addition of 
ketamine for the second group did not significantly affect pain after surgery, 
the study found. 
This study demonstrated that an individual’s psychology is also important. 
“Interestingly, a patient’s anxiety and worry about the procedure in the days 
leading up to the surgery had a direct and independent effect on his or her 
acute and persistent postsurgical pain. Positive thoughts and attitude about 
pain in general improved long-term pain outcomes,” explained Dr. Anwar. This 
observation has the potential to help doctors identify vulnerable individuals 
prior to surgery and to allow informed consent and discussion regarding risk 
of chronic pain. 
Chronic pain following cardiac surgery is a serious side effect of the curative 
surgery. The prevalence of chronic pain after cardiac surgery ranges from 11 
to 56 percent. More than 500,000 heart surgeries are performed in the United 
States each year, according to the National Heart, Lung and Blood Institute. 
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1.1 Overview and opening remarks 
Pain after surgery is common and expected. Patients may undergo surgery to 
treat pre-existing pain or present pain-free to the hospital, and experience it 
postoperatively.  In both cases, pain pathways are activated leading to acute 
pain. Patients expect this discomfort or pain to be short lasting (1). The 
management of acute pain is important, not only for comfort during recovery, 
but also to facilitate early rehabilitation (2, 3). 
In the majority of cases, acute postsurgical pain is treated well and does not 
return. In some cases this recovery is not seen and pain persists beyond the 
expected duration of tissue healing. This duration to allow a diagnosis of 
persistence of pain is not clear in the literature, and can vary from two to three 
months, or even to six months and beyond. 
Persistent pain could represent a worse tissue injury at the time of surgery 
leading to difficulty in managing pain in the immediate postoperative period and 
with changes persisting beyond the expected duration of tissue healing.  
Historically, this has been attributed to surgical technique and inadvertent 
intraoperative nerve damage but evidence is gathering that nerve-sparing 
technique may not make a significant difference to long-term pain outcomes (4).  
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The evidence suggests a smaller incision and less invasive techniques may 
improve analgesia in the recovery period.  However the translation of this 
improved analgesia into lower prevalence of persistent postsurgical pain (PPP) 
is only seen in some procedures and certainly not all types of surgery (5, 6). 
Patient related factors are also important. Age plays a significant role in the risk 
of developing PPP (7), whereas other factors such as gender and patient 
psychology are less clear, in terms of their contribution to the risk of developing 
persistent pain. Acute pain following surgery is the most consistent predictor of 
subsequent PPP (8) 
Past experiences of pain may predispose an individual to PPP. The pain 
experience is shaped by the effects of pre-existing pain - from local disease or 
other remote sites - as well as psychological attitude to the potential threat of 
new injury (9). These factors may explain the link between acute and chronic 
pain, with some of the same risk factors potentially predisposing to both (10). 
In this thesis, I will explore the transition from acute to chronic pain state using 
the PPP model, and specifically sternotomy (for cardiac surgery.) In addition to 
studying the mechanisms of transition, I will aim to intervene in this process, in 
the form of an efficacy study of analgesics to prevent this transition. 
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1.2 Cardiac surgery: the ideal surgical model? 
Cardiac surgery today is common in the UK with over 30000 sternotomy cases 
carried out per year. Effective analgesia in the recovery from cardiac surgery is 
particularly important to prevent cardiovascular responses of tachycardia and 
hypertension as well as to ensure optimal respiratory mechanics. Analgesia 
facilitating recovery of lung function minimises pulmonary hypertension and 
resulting ventricular dysfunction secondary to heart-lung interaction, as well as 
ventricular interdependence (11). 
Pain relief techniques following sternotomy vary from intravenous infusions, to 
nurse-led regular administration, to patient controlled analgesia (PCA) devices 
delivering opioids- typically morphine- on patient request. There is however 
considerable evidence that inadequate analgesia remains a problem (3). There is 
also good evidence that typically between a third and over half of all patients 
undergoing first-time cardiac surgery develop PPP (12) although this may be as 
high as 88%(13). 
However, compared to other examples of major surgery cited in this chapter, 
PPP following cardiac surgery remains understudied.  Most studies are 
retrospective, whereas prospective studies tend to include small numbers of 
patients and examine certain aspects of the transition to persistent pain, rather 
than a comprehensive assessment of the whole process. This is likely a result of 
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the high-risk nature of patients undergoing surgery and relative reluctance to 
include them in detailed clinical studies. 
1.3 Study structure and rationale 
Persistent postsurgical pain is a common problem but yet is severely lacking in 
evidence for its prediction as well as prevention (12, 14). 
Previous study of PPP has tended to involve either identification of risk factors 
or effectiveness studies of various preventive analgesic regimens.  Even in the 
study of potential risk factors, very few investigations have prospectively 
assessed the whole surgical pathway of preoperative pain, perioperative 
neuroplastic changes and postoperative recovery with an adequate duration of 
preventive analgesia. 
 
The recent challenge put forward by Kehlet and Rathmell in Anesthesiology is to 
include all potential risk factors before, during and after surgery (14). This 
editorial also calls for procedure-specific study rather than comparing across all 
surgical procedures, operative techniques and underlying pathologies. 
I also set out to challenge the notions that providing adequate perioperative 
analgesia alone is sufficient to block or reduction the nociceptive input to the 
Central Nervous System and this in turn can reduce the likelihood of developing 
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persistent pain. My aim was to demonstrate that an additional antihyperalgesic 
effect of an intervention is important in preventing sensitisation and the 
neuroplastic changes, which can subsequently be difficult to reverse. In order to 
achieve this, it was important to test hyperalgesia and sensitisation before, as 
well as following, surgery. This could also provide a mechanistic explanation for 
the link between acute and persistent postsurgical pain (15). 
It was also important to learn lessons from the shortcomings of previous studies, 
as described above, in particular as regards control groups with minimal 
confounders as well as searching for a large enough effect to power the studies 
against i.e. clinically significant (rather than statistically significant) differences. 
Therefore I set out to design the a series of studies to incorporate as many facets 
of the above suggested ideal study as possible and in a surgical model with 
moderate to severe acute pain, as well as sufficient prevalence of PPP to allow a 
decrease to be feasible in a reasonably sized intervention trial.    
I originally considered thoracotomy as a model to study but the efficacy and 
assessment of the regional block again remained difficult to ascertain, even with 
surgically placed and directly viewed paravertebral catheters (16). It seemed 
potentially difficult to eradicate variability in quality of block simply by 
randomisation – without studying very large numbers. The role of the intensity 
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and efficacy of afferent blockade has not been fully reported and appreciated in 
previous studies (17). The other important variable in the case of surgery for 
cancer is the recurrence of tumour contributing to long-term pain, as well as 
treatment effects of radiotherapy and potentially chemotherapy (18).   
Although cardiac patients may well be sensitised before surgery, by repeated 
episodes of ischaemic chest pain, they are free of continuous background tumour 
pain - as compared to other surgical models such as thoracotomy.  There are also 
no treatment effects from radiotherapy and chemotherapy and, although 
symptoms can persist or remain untreated and refractory following surgery, 
persistence of pain as a result of tumour recurrence is not a confounder. 
I considered the alternative of studying thoracotomy for benign disease such as 
recurrent pneumothorax, but this would seriously limit recruitment rates due to 
the relative infrequency of such cases. 
I decided to study sternotomy (for elective cardiac surgery), as there are also 
several additional factors in favour of this particular surgical model.  
Sternotomy involves a standardised incision in the absence (in most institutions, 
including our own) of a regional anaesthesia blockade of the subarachnoid, 
epidural or paravertebral spaces. 
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Post cardiac surgery analgesia is usually protocoled to include patient controlled 
analgesia (PCA) in the form of morphine, with adjunctive paracetamol only in the 
first instance. Soon after the removal of chest drains at approximately 36 hours, 
following uncomplicated surgery and recovery, the PCA is also removed and 
replaced with codeine and paracetamol.  It is therefore possible to ensure 
adherence to this standard by developing a standardised anaesthetic and 
surgical protocol, agreed to by all teams responsible for the care of patients 
recruited to such studies.  
In addition, cardiac surgical patients remain in hospital for a minimum of five 
days and with a median length of stay, in the NHS for elective cardiac surgery, of 
9 days (http://www.drfoster.com) and therefore adherence to an analgesic drug 
trial can be monitored accurately during this period. Such interventions, 
especially drug trials, can be difficult to ensure compliance otherwise as 
demonstrated by diary-card measures in outpatient RCTs, for example (19). 
The use of anxiolytic premedication for cardiac surgery in the form of 
benzodiazepines is in common place. Therefore this offered a unique 
opportunity to add to, rather than institute a new practice of, premedication. 
This is particularly attractive as pregabalin is also an anxiolytic and ranked first 
in terms of tolerability in a recent meta-analysis (20). 
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1.4 Justification for a retroactive modelling study 
Prior to embarking on the prospective randomised controlled study, it was 
important to identify prevalence and confirm the need for further investigation 
in this particular group of patients, and in our particular institution and 
catchment area.  In addition, this was an opportunity to model risk factors to be 
tested and confirmed with subsequent prospective study.  There is also some 
evidence of increased risk of PPP following dissection and harvesting of chest 
arteries for coronary artery grafting (21) and therefore there was an opportunity 
to examine any differences in LIMA harvesting, as compared to sternotomy 
without this additional dissection. 
I therefore set out initially to convenience sample all patients within a six-month 
cohort at our principal site of St Bartholomew’s Hospital. Retrospective study of 
this nature is typically limited by under-reporting, as patients in pain are less 
likely to respond to a posted questionnaire (22).  Healthy, pain-free patients are 
potentially more able to comply with such query and study.  My intention was to 
attempt to reduce this somewhat by ‘retroactively’ recruiting patients to this 
study by means of direct conversation and query during a phone interview, with 
patient consent and ethics committee approval, as opposed to postal approach 
with paper questionnaire. 
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1.5 Hypotheses and study plan 
The hypothesis of this work is that PPP is both predictable and preventable.  
The thesis chapters address the following specific aims: 
CHAPTER ONE: Introduce the concept of PPP and set out the study plan. 
CHAPTER TWO: Review the current body of literature regarding mechanisms 
and risk factors for the development of PPP, as well as potential for its 
prevention. 
CHAPTER THREE: Identify the scale of the problem in our population and model 
risk factors for the development of PPP. 
CHAPTER FOUR: Trial potential preventive strategies in a prospective, 
randomised, clinical trial. 
CHAPTER FIVE: Study the mechanisms of transition from acute to persistent 
pain with the use of QST. 
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CHAPTER SIX: Identify risk factors for the development of PPP and phenotype 
individuals based on preoperative and early postoperative assessment. 
CHAPTER SEVEN: Summarise and discuss findings. 
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Chapter 2  A review of the literature 
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Surgery remains a most common and predictable source of pain (23). In 
addition, long term, persistent postsurgical pain is the most common 
complication following surgery, and yet the problem been only been recognised 
within the last fifteen years (24). In the case of inguinal hernia repair, for 
example, it is not only the most common complication but also the most serious 
(25). 
Fortunately, most patients do recover from surgery within weeks and return to 
normal life. However, a strikingly large proportion of the surgical population 
continue to describe persisting pain at post operative periods of two to six 
months after surgery and beyond.  
As set out in Table 1.1 prevalence of this phenomenon has been estimated to be 
as high as 40-70%, following surgery involving a high risk of nerve injury (e.g. 
breast surgery, thoracic surgery, limb amputation.) Rates of 10–30% are 
reported following other forms of surgery (e.g. joint replacement or bowel 
surgery) (12). 
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Procedure 
Prevalence of overall 
PPP 
Prevalence of severe 
PPP (NRS = 7-10) 
Amputation 30 – 50% 5 -10% 
Thoracotomy 30-40% 10% 
Cardiac surgery 30 – 50% 5 – 10% 
Inguinal hernia repair 10% 2-4% 
Caesarian section 10% 4% 
Table 2.1 Procedure specific prevalence, overall and for severe pain, as a percentage of 
total patients undergoing surgery 
 (Adapted from Kehlet et al 2006 (12)) 
Improving cancer and trauma surgery survival (26) is resulting in an increasing 
cohort of patients liable to develop PPP, which negatively impacts on the 
functioning and quality of life. With breast cancer surgery, the pain issues last for 
at least five years and affect half of all patients (18). 
Cardiac surgery is no different, in this sense, although it has not been as 
extensively studied as other types of surgery. The incidence of persistent pain is 
not as high as thoracotomy or breast surgery but is nevertheless significant, 
ranging from 30-56% (27). One recent study, however, reports a much higher 
prevalence of PPP at three months of 88.3% in those undergoing LIMA 
harvesting and 75.5% in valve surgery patients (13). 
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Historically, acute and chronic forms of pain were viewed as separate disease 
processes. The study of PPP, in particular, has contributed to the view that these 
disease entities are more likely to represent a continuum, with a transition from 
one to the other over time. It is also important to consider that all chronic pain 
was once acute. Therefore the unique feature of PPP as a pain model, where the 
onset is fixed and can be identified in advance, allows controlled and detailed 
study of this transition. In addition, there is a potential for controlled assessment 
of possible preventive strategies.  
2.1 Defining the phenomenon 
The working definition of PPP is that set out by the Aberdeen Pain Clinic, which 
first described the epidemiology of this phenomenon in 1998(28). They defined 
PPP as a new pain developing after surgery and persisting for at least two 
months, where other causes for the pain have been excluded (29).  
This arbitrary duration of two months contradicts the IASP (International 
Association for the Study of Pain) definition of chronic pain in general, which is 
defined as persisting for at least three months (30).  An alternative, increasingly 
used definition includes duration beyond expected tissue healing. However, the 
lack of a clear and unanimously accepted definition for the duration of 
persistence of pain does hamper comparison across the literature. Consensus is 
gathering for an assessment of PPP at a sufficient time period following surgery 
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to allow tissue healing and recovery from acute pain – there is considerable 
debate whether this is at three months or six months, but considerable 
agreement that pain at two months is still likely to be a continuation of the 
perioperative period of acute pain (14, 31). I have therefore chosen to consider 
the three and six-month time points as the most relevant and important in my 
studies. 
In addition to the debate regarding duration of PPP, there is no clear threshold 
for intensity of pain. Some studies include any patient with pain, while others 
include only moderate pain (32) - a score of either 3 or 4 on the VAS, depending 
on the study - or severe pain (usually 7 and above on the VAS.)  The impact on 
quality of life and function is rarely included as a defining feature, unlike other 
forms of chronic pain (33, 34).   
Incidences of PPP vary between different surgical procedures. However reports 
about the same procedure can also vary hugely in terms of outcomes. This may 
be due to different surgical technique or extent of disease.  
Study design is also likely to have an influence. This has been hampered by 
continuing reliance on retrospective analyses, small sample sizes (Figure 2.1) 
and poor questionnaire response rates leading, in turn, to selection and response 
biases.  Although retrospective studies are useful for initial inquiry and 
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hypothesis generation, suitably powered prospective studies are necessary to 
provide unbiased data, and in order to draw firm conclusions (14). 
 
Figure 2.1 Procedure specific prevalence for PPP depending on sample size 
Prevalence of PPP represented on x-axis and the total number of patients included in each study is represented 
by the size of the yellow circle (Available at: http://www.medicine.ox.ac.uk/bandolier/band103/b103-4.html 
Accessed on 10/12/14) 
These limitations have contributed to the uncertainty regarding incidence and 
prevalence within populations, as well as the wide prevalence ranges quoted for 
a specific procedure.  There is however little doubt that, even taking the most 
conservative values, this pain syndrome causes significant morbidity, with at 
least 40,000 cases per year in the UK (28). Considering the increasing numbers 
of surgical cases performed per year, the socio-economic impact is significant 
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and also rising.  There is therefore clear consensus throughout the literature for 
prospective and procedure specific study of this important phenomenon (14). 
2.2 Mechanisms of transition from acute to persistent pain states 
It is important to consider mechanisms of transition in general before examining 
properties unique to PPP. 
Acute nociceptor activity is transmitted to the dorsal horn of the spinal cord, 
where peptide and amino acid transmitters activate second order neurons to the 
brain.  These nociceptive signals are processed in higher centres, utilising 
sensory-discriminative, motivational-affective and “top-down” modulatory 
pathways, in order to produce the emergent, subjective experience of pain.   
However, a persistent, severe barrage of nociceptive input up-regulates both 
cyclooxygenase and interleukin 1β in the periphery, eventually sensitising 
second order neurons via the NMDA receptor. It is this sensitisation, in both the 
peripheral and central nervous systems, which leads to spontaneous as well as 
evoked pain, in and around the incision site. 
Features of evoked pain, following sensitisation, include allodynia and 
hyperalgesia (35):  
Allodynia:  Pain in response to a non-nociceptive stimulus e.g. light brush stroke 
to skin 
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Hyperalgesia:  Increased sensitivity to a nociceptive stimulus. This can include 
both a decrease in pain detection threshold or an increase in suprathreshold 
response (e.g. pain score.) Hyperalgesia can also be described in terms of: 
Primary hyperalgesia: occurs in the periphery as a result of incision or surgical 
injury, in and around the wound.  Release of local mediators sensitises a 
multitude of nocioceptors in the primary afferent neuron (figure 2.2.) This 
results not only from inflammation but also secondary to tissue ischaemia and 
acidosis.  As one example, low pH activates several receptors and ion channels 
responsible for transducing nociception e.g. potassium channels, vanilloid 
(TRPV1, etc.) and purinergic receptors.  
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Figure 2.2 Peripheral sensitisation: ligands and sites of action 
(PGE2= prostaglandin E2, Ach= acetylcholine, ATP= adenosine-5-triphosphate, 
IL-6= interleukin-6, TNF= tissue necrosis factor, TRPV-1 = transient receptor 
potential V1, P2X = purinergic receptor subtype P2X) 
 
Secondary hyperalgesia: is observed in adjacent uninjured tissue as a result of 
changes within the dorsal horn (figure 2.3.) Prolonged firing of nociceptors in 
the periphery leads to the release of glutamate, the major excitatory 
neurotransmitter, in the central nervous system (35). Multiple receptors exist on 
the pre and post-synaptic membrane for glutamate: G-protein coupled, 
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metabotropic (mGluR) receptors, AMPA receptors – particularly for brief stimuli 
– and the NMDA receptor for persistent, high frequency c-fibre stimulation. The 
latter is blocked by magnesium ion at rest but this block is removed by, in 
particular, substance P and CGRP released from the c-fibre. The combined effect 
of this stimulation is to shift the dose response curve to the left leading to an 
enhanced sensitivity of dorsal horn neurons to peripheral inputs.  
GABA	 AMPA	 NMDA	 VGCC	NK1	
5HT	
Opioid	
Substance	P	
	
Glutamate	
Gabapen noids	Ketamine	
 
Figure 2.3: Mechanisms of central sensitisation at the dorsal horn and two potential 
targets for prevention 
NK1= Neurokinin 1 receptor, 5-hydroxytryptamine receptor, GABA= gabba 
aminobutyric acid, NMDA=N-methyl-D-aspartate acid receptor, VGCC= voltage 
gated calcium channel, 
This increased sensitivity or amplification may be seen in response to changes in 
both the magnitude and frequency of stimulus, with the latter observed wind-up 
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in the electrophysiological setting, with its in vivo correlate of temporal 
summation, as observed clinically in response to repetitive stimulation. 
These changes spread segmentally around the primary site before involving 
supraspinal pathways, via effects on descending facilitation, in particular. This 
leads to increased sensitivity at the incision site or entirely remotely – 
eventually, becoming independent of the peripheral pain input, with non-painful 
stimuli eliciting pain (allodynia.) These changes are termed ‘spreading’ or 
central sensitisation, as illustrated in figure 2.4 (36). Activated microglia 
further maintain this state of excitation (35, 37, 38) by further up-regulating 
COX-2 to produce PGE2, as well as to release further neuromodulating agents 
such as IL-1, IL-6 and TNF α. 
The complex interplay between peripheral and central sensitisation is difficult to 
study in isolation and requires a systems-based or integrative approach – 
utilising tools, which are able to measure the overall phenotype and behavioral 
response.  This ‘systems neuroscience’ approach to studying complex neural 
networks, interactions and responses to environmental stimuli makes it possible 
to understand the mechanisms underpinning PPP and therefore aim to predict 
and, in turn, prevent the early changes. 
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Figure 2.4 Mechanisms of sensitisation 
Schematic representation of pathways for hyperalgesia and allodynia (36) 
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This neurophysiological phenomenon of central sensitisation can be clinically 
assessed using the surrogate measure of secondary hyperalgesia and it is 
hypothesised that this may play a role in the development of persistent pain 
states. This may be assessed in the clinical setting by the measurement of a zone 
of hyperalgesia around the surgical incision, for example (39). Interestingly, 
there seems to be very little correlation between this zone of secondary 
hyperalgesia and acute pain scores or analgesic requirement (17). In addition, 
most conventional treatments for acute postoperative pain have only minimal 
effects on this secondary hyperalgesia and therefore may be ineffective in 
treating this potentially relevant component in the development of pain 
persistence (40).  In summary, the mechanisms of secondary hyperalgesia and 
central sensitisation are distinct from primary incisional sensitivity, 
hyperalgesia and pain. 
These descriptions of evoked pain are in addition to the features of spontaneous 
pain e.g. burning, lancinating pain, dysaesthesia, hypoaesthesia or paraesthesia 
(41) These are also useful descriptors of changes, perhaps suggestive of the 
development of (acute as well as chronic) neuropathic pain, but difficult to 
measure objectively. 
As well as considering the differences between spontaneous and evoked pains, it 
is also important to separately evaluate pain at rest and movement evoked pain. 
Importantly, the latter may interfere with the patient’s rehabilitation, delaying 
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restoration of function and mobility, and is a highly relevant measure in studies 
as well as increasing their sensitivity and specificity (14, 42). 
2.3 “Increasing the gain in pain” 
Clifford Woolf and Michael Salter first used the above phrase in the context of 
amplification within nociceptive pathways in their seminal paper published in 
Science (43).  The paper describes plasticity, which is activity dependent, and 
over time, sensitises the nervous system by the following processes: 
Activation of nociceptors: Activity dependent and therefore rapidly reversible 
physiological process, which augments transmission and transduction. 
Modulation: slow reversible changes but also early manifestations of functional 
pathology.  These includes changes such as phosphorylation of receptors (Na and 
TRPV in the periphery and, centrally, AMPA and NMDA receptors as well as ion 
channels (Ca2+ in particular.)   
Modification:  structural changes e.g. cell connectivity, cell death and 
cytoarchitecture changes. Remodelling of the neuronal cytoarchitecture, in 
particular by glial cells, also occurs early in the presence of persistent severe 
acute pain. This example of neuroplasticity may be crucial in the transition from 
acute to chronic pain (35).   
Therefore, the plastic nervous system is able to amplify or “increase the gain” 
either as an appropriate response to injury, or pathologically, in the presence of 
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a persisting painful stimulus, both manifesting as hyperalgesia. 
2.4 Why study the surgical model? 
Transition from acute to chronic pain has been studied in the nonsurgical 
population.  A prospective investigation of the development of chronic 
temporomandibular join pain in 202 healthy female subjects led to 15 emergent 
cases over a three year period and allowed identification of patient-related risk 
factors (44). However no clear causative triggers were identified during this 
period.  The relatively low likelihood of individuals developing spontaneous pain 
during the observation period makes study very difficult. 
In comparison, surgery allows investigation and identification of predictive risk 
factors in initially pain free patients, in a timely manner, prior to initiation of a 
likely causative trigger. The likelihood of developing pain is also high, for 
example in surgery with a higher risk of nerve injury. Choosing a surgical setting, 
in which a high rate of developing chronic post-surgical pain is to be expected, 
provides a setting in which recruitment is feasible to achieve sufficient statistical 
power in a prospective study. (17). 
2.5 Mechanisms for the development of PPP  
The notion of a flexible plastic nervous system, incorporating hyperalgesia and 
subsequent sensitisation, has challenged the classic view of nociceptor activity 
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driving pain in a linear manner (31). However, following surgical incision, 
hyperalgesia results not only from this nociceptor activity (Nociception-Induced 
Hyperalgesia; NIH) but also in response to treatment of the surgical pain. 
The mainstay of conventional treatment of moderate to severe acute 
postsurgical pain is the use of opioids titrated as necessary, with breakthrough 
pain in the recovery period. A paradoxical and undesirable effect of potent 
opioids is hyperalgesia (45) termed ‘Opioid Induced Hyperalgesia’ (OIH.) 
Although OIH has been claimed to result from opioid tolerance (46) (i.e. loss of 
efficacy) it is instead a pronociceptive process, resulting in increased pain 
sensitivity. This may well explain the failure of certain preemptive analgesic 
trials where opioids formed the mainstay of preventive therapy (47). 
Further evidence of the potential for OIH to affect opioid titration is seen in the 
quantal dose response relationship seen during treatment for acute 
postoperative pain. A linear relationship is observed for experimental pain if no 
hyperalgesic component is present (48). 
In addition, the preventive effect of antihyperalgesics (on either NIH or OIH) may 
be potentiated by their opioid sparing effect, as this further reduces opioid 
induced hyperalgesia (17). The effect is mediated mainly via the NMDA receptor 
but the role of mu opioid receptors in descending modulatory centres, such as 
the Periaqueductal Grey (PAG) and eventually the Rostral Ventromedial Medulla 
(RVM), have also been implicated in this protective effect (49, 50). 
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The accurate and reliable diagnosis of hyperalgesia is impossible when based on 
clinical measures of pain and analgesic requirement. Standardised objective 
measures of pain thresholds and zones of hyperalgesia, using quantitative 
sensory testing (QST), therefore become essential, as I outline later in this 
chapter.  Furthermore, any study of protective or “preventive” analgesics, 
targetting the process of hyperalgesia, requires QST alongside drug efficacy 
components of the trial (14, 51). 
2.6 Patient related risk factors - identifying risk as a means to 
predicting pain outcomes 
Identifying those at risk of PPP encompasses pre-surgical individual risk factors 
as well as the specific surgical insult (14). Potential risk factors include age and 
gender as well as the presence of pre-existing pain, in the prospective surgical 
site or elsewhere. Elicited features such as pain thresholds under experimental 
conditions are also considered as patient related factors, and are discussed later. 
The following section sets out the current understanding of patient specific risk 
factors, including demographics, as well as pre-existing pain.  Subsequent 
sections of this chapter will cover patient risk in terms of psychological 
contributors and “somatic” or surgery related risk - in the form of operative 
technique but also pain score in the immediate postoperative period.  Acute 
postoperative pain could also be considered a patient related factor, if the same 
characteristics contributing to chronic pain are also believed to play a role in 
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acute pain.  It may be an oversimplification to simply attribute acute pain to 
surgery related effects alone (10).  
2.6.1 Demographics 
There is strong correlation between decreasing age and increasing postsurgical 
pain, both acute as well as persistent (31) (1).  The cancer literature attributes 
some of this relationship to larger tumour size and worse histological grading at 
diagnosis, and in breast cancer, as an effect of hormonal levels or negative 
oestrogen receptor status (52, 53).  However the same age correlation has also 
been shown with joint replacements and hysterectomies for non-cancer 
indication, and therefore needs to be examined further (54). 
Gender has not been shown to be a risk factor.  The evidence is equivocal in 
terms of both acute and persistent pain after surgery, as well as treatment 
response to analgesics (55, 56) This is in contrast to the general pain literature, 
where there is a higher preponderance for pain amongst females (57). 
2.6.2 Pre-existing pain 
Pre-existing pain, at the site of operation or elsewhere in the body, predisposes 
individuals to PPP (58) (12). Non-surgical models also corroborate this finding. 
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The likelihood of postherpetic neuralgia, for example, can be predicted by the 
severity of acute Herpes Zoster pain (59). 
Surgical examples are equally convincing, with phantom limb sensation and pain 
(60), PPP following hernia repair (5) and following thoracotomy (61) all 
demonstrating independent association with preoperative levels of pain in and 
around the incision site.  
It can be conceptually difficult to tease this effect apart from other putative 
predisposing risk factors, such as psychology, or difficult to manage acute pain 
after surgery, resulting from this preexisting sensitisation- as well as any pre-
existing opioid induced hyperalgesia. 
2.7 Psychological risk factors: resilience versus vulnerability 
2.7.1 Current literature 
The psychology literature for acute pain following surgery is well developed with 
preoperative anxiety and depression long understood to influence postoperative 
pain (9). More recently, there has been increased interest in the effects of 
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neuroticism, preoperative fear, and vigilance and, in particular, catastrophising 
on surgical outcomes, including pain (62, 63). 
Pain catastrophising describes dwelling on the worst possible outcome to pain, 
or more formally: a negative cognitive–affective response to anticipated or actual 
pain (64).  There is some evidence of a correlation between scores on the Pain 
Catastrophising Scale (PCS, Appendix three) and pain in the acute recovery 
period specifically (65).   This particular scale also demonstrates adequate 
internal consistency and construct validity (66). 
The literature is not as clear regarding psychological risk factors and PPP. 
Conflicting data has included one series that demonstrated a lower incidence of 
PPP in those catastrophising or lacking optimism (67).  
A prospective study of 625 patients examined psychological as well as somatic 
risk factors. In this work, Peters et al (67), demonstrated that catastrophising 
and low optimism were not predictive of PPP and, surprisingly, acute 
preoperative pain was protective. However their results were biased by the 
exclusion of patients admitted to the intensive care unit. Similar observation 
biases exist in retrospective collection of data by postal questionnaire, whereby 
the sickest patients are most unable to comply with study.  
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Two recent systematic reviews argue in favour overall of the role of 
catastrophising and to some extent anxiety in the development of PPP (9, 68). 
Hinrichs-Rocker and colleagues describe the concept of psychological 
vulnerability but lack the data to conclude confidently about the effects of 
perioperative anxiety or catastrophising (68).  The paucity of data is cited as a 
limitation of this work and therefore prevents meta-analysis.  
However the addition of more recent studies in a meta-analysis three years later 
by a different group concludes that catastrophising is indeed associated with 
PPP.  They also conclude that anxiety, especially in musculoskeletal surgery, also 
seems to be associated, if not casual (9).  There seems to be less certainty for 
other forms of surgery and therefore procedure specific study is once again 
suggested. 
Another commonly studied risk factor for PPP, along with PCS, is anxiety, 
typically measured using the Hospital Anxiety and Depression scale (HAD) or the 
Spielberger State and Trait anxiety scales (69-71).  
The literature is inconsistent however in the choice of other assessments for 
psychological risk, especially across differing surgical procedures (14). 
Reference is often made to overall psychological phenotype e.g. vulnerability, 
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resilience, flexibility (72) but this makes it difficult to make comparisons across 
different cohorts, either in individual studies or in a pooled manner. 
There appears to be more agreement regarding fear (of surgery and the recovery 
period) specifically (67). Despite the lack of correlation with PCS and anxiety 
described at the beginning of this section, the same group also used a fear 
questionnaire and found that this correlated well with pain at six months. This is 
relevant to my work as one study of cardiac surgical patients provides 
qualitative evidence of fear and anxiety behaviour, in hospital prior to surgery 
but also at home while awaiting surgery (63).  
2.7.2 Surgery specific study of psychological risk 
Recent surgery-specific study confirms evidence for psychological risk of 
developing PPP.  Studies in cohorts, undergoing hysterectomy for benign disease 
(54)and total knee replacement (TKR) (73), confirm the effects of 
catastrophising and preoperative anxiety, in particular.  
The same group, based in Montreal, reported two series of persistent pain 
patients in the same year, one postsurgical (TKR) (74) and the other nonsurgical 
(75), confirming the similarities in psychological influence This interesting 
comparison implies that the mechanism of transition from acute of chronic 
following surgery are likely to share common principles with other forms of 
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pain, in particular catastrophising and fear of disability. 
There are other psychosocial factors to consider. The spinal surgery model, in 
particular, has been used to study positive and negative affect and pain 
outcomes. Interestingly, preoperative affect was not significant in a 141 patient 
cohort but measurement at 6 weeks after surgery did significantly predict 
subsequent pain at 3 months.  If corroborated, this could justify surveillance and 
potential intervention at 6 weeks after all spinal surgery (76). 
It is however difficult to separate the interplay between psychological state 
before surgery and other risk factors such as preceding pain. In a large series of 
464 patients, Aasvang and Kehlet’s group were unable to find an effect of 
psychology above those of preceding pain, postoperative acute pain and QST 
measures.  Psychology may play a role in these other risk factors but may not be 
solely responsible (5).  
Once again, disparate study designs prevent meaningful comparison across 
studies.  However it is interesting that there seems to be a consistent pattern of 
negative psychological factors impacting on long-term pain outcomes after 
surgical intervention (62, 65, 77). 
2.7.3 The importance of psychological risk 
The biopsychosocial model therefore seems to be important in the development, 
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maintenance and treatment of PPP (78) and this lead me to hypothesise that 
identifying risk factors may be useful in assessing their role in the development 
and transition form acute to persistent pain states during my thesis studies. 
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2.8 Surgery related risk: does technique matter? 
It is important to consider the duration, extent and type of operation as potential 
risk factors for PPP. Intraoperative complications, in particular nerve damage, 
may also play a role.  These are often described as ‘somatic’ risk factors to 
contrast them with the psychological risk described above. In addition, the 
perioperative period includes potentially modifiable risk factors such as acute 
pain as well as treatment effects of analgesics such as opioids. Each of these will 
be discussed in further detail: 
2.8.1 Duration and invasiveness of surgery 
Evidence has shown that duration and complexity of the surgical procedure may 
play a role. Peters et al, mentioned in the psychology section above, reported the 
association between the duration of surgery and the development of PPP (67).  
In addition to duration of exposure and extent of surgery, surgical technique may 
also play a role. Laparoscopic approaches result in lower reports of chronic pain 
as compared to open cholecystectomy and hernia repair (5). It is difficult to 
attribute this to extent of incision, exposure and dissection or specifically 
reduced likelihood of nerve injury.  In the case of lung surgery, however, the data 
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is conflicting as regards open versus video assisted thoracoscopic (VATS) 
approach to the lung.  Earlier retrospective data implied equal incidences 
between the two techniques (79) (80). Prospective study and subsequent 
systematic review confirmed this equivocal finding, with only one large 
retrospective study demonstrating improved PPP outcomes with VATS (6). In 
the case of hernia surgery, for example, there is more agreement that less 
invasive surgery (namely laparoscopic incisions) may reduce the subsequent 
prevalence of PPP (81). This disparity between different surgical procedures 
gives extra weight to the argument for procedure specific study of PPP.  
Additionally, in hernia repair, repeat surgery (in patients free of PPP) has been 
shown to have a higher incidence of moderate to severe pain at 12 months as 
compared to first time surgery.  Similarly, repeated surgery in the case of breast 
cancer also independently increases the likelihood of developing PPP (32).  This 
suggests sensitisation from each surgical procedure, which despite the lack of 
clinically identifiable pain on presentation for repeat surgery, can increase the 
likelihood of developing subsequent PPP. The identification of subclinical signs 
(e.g. temporal summation or hyperalgesia) may therefore identify these at-risk 
patients (36, 82). 
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2.8.2 Nerve injury as a cause 
There is considerable debate in the literature regarding the importance of nerve 
damage in the development of persistent pain (83, 84). The issue is confused by 
the fact that not all PPP is neuropathic in nature. Conversely, not all patients with 
nerve damage develop PPP (85).  Apparent pain-free recovery from surgery 
involving an original occult nerve injury also does not protect from subsequent 
chronicity (86), although this may also be an example of sensitisation rather than 
nerve injury per se. 
The argument for the necessity of nerve damage to allow PPP is based on the 
higher incidences in procedures associated with a high likelihood of nerve 
damage. Over half of patients undergoing thoracotomy, mastectomy and limb 
amputation report pain at 6 months and beyond (12). 
However, PPP may not always be neuropathic. Taking the example of 
thoracotomy, there is no association between intercostal nerve damage at the 
time of thoracotomy by nerve conduction study and subsequent PPP (4). 
Likewise, the mandibular osteotomy model demonstrates almost universal 
(90%) likelihood of nerve dysfunction but only 5% of these inferior alveolar 
nerve injuries resulted in neuropathic pain (10, 87) This disconcordance 
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suggests a more complex interaction between early nerve injury and persistence 
of pain symptoms. 
Similarly in the case of mastectomy, confirmed injury to the intercostobrachial 
nerve (observed as postoperative numbness) does not result in neuropathic pain 
in many patients (88). There is more objective evidence for thoracotomy, with 
the use of validated questionnaires demonstrating that a significant portion of 
PPP patients do not exhibit neuropathic signs or symptoms (89) (90). There is 
also a significant incidence of PPP in procedures where very little postoperative 
sensory loss is seen e.g. laparotomy, hysterectomy. (91, 92). 
Even in the case of thoracotomy, only half of patients with confirmed PPP 
demonstrate a neuropathic nature to their pain (89).  It is important to bear in 
mind that this is only evidence from a single surgical procedure and therefore 
comparison across all types of PPP is difficult. 
Although it is tempting to associate PPP to neuropathy and specifically to nerve 
injury during a long and difficult procedure, is this really the case or is the extent 
of other tissue exposure and damage, resulting in sensitisation in a vulnerable 
individual, more relevant?   
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Macrae also uses the analogy of an adverse drug reaction as an accepted 
iatrogenic complication and consequence of medical treatment with a general 
reluctance to blame the administering health practitioner (29). He compares this 
to the PPP situation where the operating surgeon is often blamed and potentially 
stigmatised for causing the complication. This could potentially lead to a 
difficulty with open discussion of the phenomenon and could explain the current 
reluctance to accept this common complication in the surgical literature, as well 
as the reluctance to discuss it during informed consent for elective surgery (93). 
2.8.3 Acute pain as an independent risk factor  
The effect of acute postsurgical pain on the development of PPP was first 
reported by Katz et al in 1996 in a follow up study of thirty patients previously 
recruited to a preemptive analgesia study for thoracotomy (94). They found that 
pain at rest and on movement at 24 hours following surgery correlated with pain 
scores at 18 months. 
The easiest explanation for the association between acute postoperative pain 
and subsequent PPP is to assume causality (12). Likewise the approach to 
preventing PPP since the 1990’s has centred on attempts to preemptively 
institute pain relief, especially regional anaesthesia and opioids, to 
perioperatively block noxious perioperative impulses from reaching the CNS.  
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However, if the relationship between acute postoperative pain and PPP is merely 
associative, and both are caused by one or more factors that are related, no 
degree of pain reduction in the acute period will prevent the development of 
PPP.  This argument is supported by data from patients who develop PPP, on 
serial follow up, having been free of symptoms in both the acute period and at a 
previous assessment for PPP (86). Could this be an example of subclinical 
sensitisation in the first instance, which does not result in acute pain, but goes on 
to develop into PPP? Targetting acute pain alone may not help these patients. 
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2.9 Quantitative sensory testing: experimental pain response as a 
biomarker 
As early as the nineteenth century, German experimental psychology 
laboratories were using the principle of psychophysics to test different sensory 
modalities, including pain (95). Psychophysics is the study of sensory stimuli and 
the psychological impression they create.  The quantification and assessment of 
the relationship between physical stimuli and the sensory experience and 
perception they produce is known as Quantitative Sensory Testing (QST.) 
Most clinical trials of analgesics measure subjective pain experience in terms of 
pain scores only, or indirectly using analgesic consumption. However the 
objective sensory changes resulting from injury are rarely recorded.  Only QST 
allows the measurement of post-incisional neuroplasticity and its potential 
modulation by drugs (96). 
Pain is a combined sensory, psychological and social experience and therefore 
psychophysical testing using QST is superior to the neurophysiological 
assessment of nociceptor field or range of activity alone. The latter is not 
sufficient to study pain mechanisms.  It is necessary to integrate higher centre 
function and psychological perception of pain as much as possible with 
peripheral nociceptor activation.  This approach of integrative or Systems 
Neuroscience is in its infancy in the field of pain research (97). It may go some 
way towards explaining why some patients transition from the ubiquitous 
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experience of pain, onto worse acute pain following surgery, and subsequently to 
persistent pain states, such as PPP.  
An example of this integrated or systems neuroscience approach to the 
assessment and study of pain mechanisms is the increased attention, over the 
last decade, to mechanisms of diffuse noxious inhibitory control (DNIC.) DNIC is 
an individual’s ability to engage endogenous analgesic pathways to inhibit 
painful transmission to the central nervous system and has been linked to 
decreased levels of postoperative pain. Intuitively this makes sense as it is akin 
to using regional anaesthesia perioperatively to prevent the transmission of 
sensory afferent barrage from reaching the nervous system. Failure of either of 
these systems could conceivably lead to pain.  
This endogenous analgesic mechanism of DNIC, as an example of “top down 
control of pain, is separate from other descending inhibitory (and facilitatory) 
pathways, such as those from the ON and OFF cells of the Rostral Ventromedial 
medulla, as described in the next section (98). These mechanisms of modulation 
(in either direction) are important for the full range of biological function, from 
protection and rest of injured tissue (facilitatory) to survival by escape from 
threat, in an evolutionary “fight or flight” type manner (inhibitory) (99). 
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DNIC is assessed in the pain laboratory setting by comparing response to 
experimental pain stimulus before and after another, remote, conditioning 
stimulus. An effective or efficient system is one that is able to reduce the pain 
response to the initial stimulus.  This simulated laboratory assessment of DNIC, 
termed Conditioned Pain Modulation (CPM) or the “DNIC-like” effect, is therefore 
assessing more than simple nociception (100).  
CPM assessments of this DNIC-like effect are only one example of QST. This 
paradigm consists of a battery of very different, standardised stimuli ranging 
from single fibres, known as Von Frey hairs, to computerised applications of 
pressure (algometry) and temperature. Therefore perioperative QST allows 
standardised, structured and objective experimental pain assessment of an 
individual’s basal pain perception and modulation, prior to new additional pain 
from the surgical insult. 
2.10 Static versus dynamic assessments of pain  
QST typically measures the three static thresholds of sensation, pain detection 
and tolerance. In addition a magnitude estimation by the subject of a fixed level 
of painful stimulus (“suprathreshold” – above the pain detection threshold but 
importantly below tolerance to allow testing), has also been shown to predict the 
postoperative pain experience more reliably than the pain detection threshold 
alone (101). It is also worth considering that tolerance can vary simply as a 
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result of the motivation of the subject and therefore may not be appropriate in 
the case of anxious clinical patients recruited to studies around the time of their 
surgery (102). 
Static single assessments of sensory or pain threshold to pressure, for example, 
are practically easier to perform than repeated measures around dynamic 
changes in pain stimulus.  There is also good evidence for their reliability in 
predicting pain outcomes.  Brandborg demonstrated the reliability of pressure 
pain thresholds taken before gynaecological surgery in predicting acute 
postoperative pain, in particular, but also in predicting pain at 4 months 
following surgery. However these patients presented with pain and therefore 
may have implications for sensitivity to pain (15).   
In a large prospective study of over 400 herniotomy patients, Aasvang and 
colleague demonstrated that suprathreshold measurements, in their case to heat 
at a temperature of 47 degrees Celsius for five seconds, were able to predict PPP. 
This corroborated the earlier findings of Granot and colleagues in caesarian 
section, albeit only predicting acute postoperative pain in the latter case (5, 101). 
The measurement of zones of secondary hyperalgesia as predictors of 
subsequent pain began in the mid 1990’s with Stubhaug’s work demonstrating 
the effect of NMDA antagonism with ketamine (39).  Lavand’ Homme and 
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colleagues, in particular, have continued this work by assessing the protective 
effects of regional anaesthesia, as well as ketamine, as set out in the next section 
(103, 104).  This is an important finding mechanistically, as it confirms the 
importance of hyperalgesia as a prelude to central sensitisation and the 
development of PPP. 
However there has been a recent vanguard away from these static measures and 
towards dynamic assessments. These are designed to engage pain modulatory 
system and assess responses to an additional pain challenge, in an analogous 
manner to clinical pain (such as postsurgical pain.) 
CPM assessments, as mentioned earlier, demonstrate that some individuals can 
inhibit their response to painful stimulus whereas others are unable to - and in 
fact summate (105, 106). 
Likewise, in the case of chronic pain sufferers in general, some individuals are 
not able to efficiently inhibit pain but may in fact summate or even, at one end of 
the biological spectrum, be pronociceptive.  Whether this pronociceptive state of 
pain modulation is a cause or effect of persistent pain is not so clear. 
In the case of PPP specifically, only one study has examined the predictability of 
the development of pain using preoperative CPM assessments.  Yarnitsky and 
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colleagues demonstrated in a series of 62 patients that impaired CPM response 
prior to thoracotomy was predictive of pain at six months following surgery: 
odds ratio of 0.52 (95% CI 0.33 – 0.77 and p = 0.0024) (107). 
In addition, the concept of temporal summation, akin to wind-up in spinal wide 
dynamic range (WDR) neurons and demonstrated to be enhanced in idiopathic 
pain syndromes, has been shown to predict acute pain outcomes following 
thoracotomy with linear regression coefficients from 84 patients of r2 = 0.225 (p 
= 0.008)(82).  
 
Wind-up is an electrophysiological phenomenon. It is observed in nociceptive 
neurons in response to repetitive stimulation of primary afferent C-fibers. 
Repetitive stimulation of these fibres leads to an increased discharge rate of the 
postsynaptic neurons, temporarily, before reaching a plateau or declining.  This 
normal coding property of dorsal horn neurons is not a mechanism of 
hyperalgesia per se. However lowering of the threshold frequency or increasing 
the response rate is believed to indicate signal amplification. Therefore it may 
useful in predicting increased responsiveness of the neurons of the dorsal horn.   
The principle of temporal summation is to simulate wind-up, in the in vivo 
environment, by repeatedly stimulating the same dorsal horn neurons to elicit a 
frequency-dependent response over time (108). There is some evidence from 
the acute pain literature of the utility of temporal summation in predicting pain 
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scores and analgesic requirement (82) but very little assessing the relationship 
with PPP.  
2.11 Why not carry out more extensive testing and profiling? 
In 2006, a protocol was proposed by the German Research Network on 
Neuropathic Pain (DFNS) details included an extensive battery range of mainly 
static assessments with the addition of summation. Developed in 180 healthy 
subjects and validated in 1236 patients, this extensive protocol is setting a gold 
standard of assessment for research as well as clinic-based diagnosis of 
neuropathy and is appropriate in the laboratory setting, as well as the neurology 
clinic (108).   
However my assessments centred on the dynamic assessment of pain 
modulatory pathways which are not an integral part of the DFNS protocol and 
were also designed to be carried out in the clinical bedside setting, without 
access to the full range of equipment stipulated by the DFNS. Therefore for 
pragmatic reasons of limited experimental time and patient fatigue, especially in 
the anxious (63) preoperative cardiac surgical patient or postoperative intensive 
care patient, I used a modified QST schedule.  In addition, my aim in this series of 
studies was to develop bedside/ ‘point of care’ screening and assessment tools, 
specific to sternotomy, as opposed to screening tools for neuropathic pain, as per 
the DFNS. 
  65        
2.12 Preventive analgesia – is it more than just effective analgesia? 
Preventive analgesia aims to reduce sensitisation from persistent afferent neural 
barrage and therefore achieve protection from the mechanisms described at the 
beginning of this chapter. The effects of this approach outlast the expected 
pharmacokinetic effect of the drug, usually described as 5.5 times the half-life 
(t1/2 x 5) (109). 
This is different from preemptive analgesia, which times the analgesic 
intervention prior to incision in the hope of achieving superior analgesia and 
neuroprotection- as compared to delivering analgesia once pain is established. 
Preemptive analgesics have not stood the test of controlled prospective study in 
the acute or PPP setting (110).   
Common examples of preventive analgesics with their respective evidence of 
efficacy are set later in this chapter.  These include neuraxial blockade (spinal 
anaesthesia or epidural), NMDA antagonists (ketamine) and the gabapentinoids 
(gabapentin and pregabalin) with their sites of action described in figure 2.3. 
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However it is important to acknowledge the potential effects of the following: 
Local anaesthetic in and around the incision site (111). 
Nitrous oxide as a NMDA antagonist (112) may prevent the development of PPP 
(113) as well as protecting from OIH e.g. from remifentanil infusion 
intraoperatively.  
Future potential targets include Glial Derived Nerve Factor, Neurokinin and 
Purinergic receptor blockade and Sodium channel blockade (114). 
Returning to the topic of opioid induced hyperalgesia (OIH), these agents all 
provide analgesia and spare the use of perioperative opioids but may also, as a 
result, be beneficial by reducing OIH. The antihyperalgesic role of all the 
candidate agents either directly or by sparing opioid use must be considered and 
specifically studied. A study of epidural ketamine failed to find a difference 
compared to saline in preventing PPP after limb amputation but surprisingly 
found a reduced prevalence of stump pain in both arms of 21% and 33% as 
compared to 70-80% reported in the literature (22). One explanation for this is 
the absence of opioids throughout the postoperative period as part of this 
particular protocol of local anaesthetic and ketamine only. Therefore opioid 
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sparing may be more important than simply allowing earlier mobilisation and 
rehabilitation. 
Complete avoidance of opioids may of course be as inappropriate as the 
complete dependence on opioids, especially in surgery where the regional 
blockade of an extremity is not sufficient e.g. surgery on the chest or abdomen. 
The judicious multimodal use of antihyperalgesic agents along with careful 
dosing of opioids, with the aim of providing analgesia and sparing the need for 
opioids, is the alternative approach, utilising the relative advantages of both in 
moderation (115). 
2.13 The importance (and limitations) of animal models 
Most of the evidence for neuroprotection using preventive analgesics comes 
from the preclinical setting. However this has not proven easy to translate to 
human beings.  The following reasons are cited for particular success in animal 
models: 
 Animals are healthy and pain free before surgery 
 Lack of polypharmacy or co morbidities 
 Easier to control for confounders and to ensure homogenous population 
tested. 
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 Small sample size not an issue 
 Surgical insult is typically to a limb/ extremity with segmental somatic 
innervation only and therefore easier to ensure continuous sensory 
blockade  
 Surgery is short lived 
 Different pain pathophysiology and neuropharmacology with differences 
in neuronal hyperexcitability and sensitisation with rats, in particular 
(more susceptible and induced to this state and therefore more readily 
blocked?) 
 
Therefore their exists a huge disparity between the convincing animal data and 
the conflicting human studies of preventive analgesics. 
2.14 Examples of successful translation to humans 
I found a large body of literature examining different modalities and classes of 
preventive analgesics but with mixed results.  There are three main categories to 
consider. In each case, I will consider the evidence for acute analgesic effect prior 
to discussing the prevention of PPP.  The largest approach studied is the use of 
regional anaesthesia. 
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2.14.1 Regional anaesthesia  
Most of the original work was based on the preemptive analgesia principle and 
sought to establish the importance of the timing of regional blockade on 
subsequent pain- namely whether the administration of analgesia prior to 
incision affected pain outcomes differently from delivery at the end of surgery. 
Multiple studies have contributed to this, with an overall impression that time at 
which the block is instituted has no overall effect (110) 
I examined these studies further though as they give useful information 
regarding clinically meaningful - as compared to statistically significant - 
differences in pain studies. Some early studies of single doses of analgesic, via 
the epidural route, found statistically significant difference in postoperative VAS 
scores but only at certain time points, and not throughout the entire 
postoperative period (116). Furthermore, another study demonstrated 
reduction in VAS score of only 20mm (117). The remainder of the studies of 
single bolus, from the late 1990’s and collated in a recent systematic review, all 
concluded non significant differences (110).   
A similar pattern is seen with the continuous infusion literature. Likewise 
though, early reports of positive studies are plagued by VAS differences less than 
20 mm (118, 119) and in some cases as low as 8mm (120).  Later studies refute 
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these differences and overall systematic review, in 2002, again concludes 
equivalence in terms of timing of analgesia (110). 
Only one of these studies examined the effect of regional analgesia on 
subsequent PPP. In a double blind manner, Obata and colleagues randomised 70 
patients to mepivicaine, either before or following thoracotomy (119). This small 
study does demonstrate a reduction in the numbers of patients describing pain 
at three months and six months after surgery as a result of preincisional 
analgesia. This study is limited by small numbers and further compounded by 
the exclusion of twelve patients for postoperative epidural failure (2 patients), 
loss to follow up (5 patients), death before six month assessment (3 patients) or 
recurrence of malignancy within a year (2 patients) – all reasons to include and 
analyse data (on an intention to treat basis) rather than to exclude patients. It is 
possible to speculate however that the additional blockade of hyperalgesia 
during the early perioperative period, may have contributed to improved PPP 
outcomes- while not translating into improved pain scores in the acute period, 
for the reasons given earlier (17, 39). 
Despite this paucity of data, the practice of preoperative (and not necessarily 
preemptive) insertion continues, mainly for logistic reasons. This approach 
allows the perioperative physician to establish and test the anaesthetic block in 
readiness for emergence from anaesthesia at the end of surgery. 
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Having refuted the role of timing the ‘preemptive analgesic’ regimen and 
established the importance of measuring clinically significant changes, it is now 
necessary to consider the effect of regional anaesthesia (RA) on preventing acute 
pain as well as PPP. 
The analgesic benefit in the acute setting is clear from two recent systematic 
reviews (121, 122). Both these studies conclude in favour of RA, in terms of 
reducing pain scores and analgesic consumption. 
PPP prevention is not as clear. Most of the evidence comes from early studies in 
thoracotomy and often involves comparison between paravertebral block (PVB) 
and thoracic epidural analgesia (TEA), with similar outcomes. This was therefore 
followed by enthusiasm for the use of PVB as an alternative to the neuraxial 
insertion of TEA, especially as epidurals may cause more complication (123). 
This approach followed study of PVB in the acute setting but also to prevent PPP, 
with evidence from intercostal nerve somatosensory evoked potentials from the 
chronic pain setting, demonstrating reduced firing and therefore afferent 
blockade (124, 125). 
Comparison between either of these techniques and opioids alone favours the 
regional anaesthetic block (126). Study design is however an issue with only a 
few studies and only of small numbers of patients. This is compounded in 
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particular by post hoc analysis of long-term outcomes in studies designed with 
the intention of assessing acute pain only (127). Although these provide a useful 
signal for hypothesis generation, caution is suggested, as these are not a priori 
examination of the data.  
A very recent Cochrane review reiterates this caution despite a positive 
conclusion in favour of PVB and TEA in preventing PPP following lung and breast 
surgery (128). Small numbers and examination centred on these two surgical 
groups specifically makes it difficult to generalise and extrapolate to other 
surgical procedures. 
2.14.2 Ketamine 
The next most commonly studied preventive agent is the NMDA receptor 
antagonist ketamine. The role of the NMDA receptor in central sensitisation was 
described at the beginning of this chapter. 
Systematic review of ketamine supports its use in the acute pain setting, via the 
intravenous or epidural routes (129). However this study evaluates the addition 
of ketamine to opioids only. The PPP literature for ketamine is particularly 
confused though due to variability in duration and dose of ketamine used, as well 
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potentially due to the variable – and often underreported - efficacy of 
superimposed RA. 
Outdated and qualitative systematic review by McCartney in 2004 (109) 
described poor quality studies but found in favour of ketamine overall for 
preventing PPP. Since then, study has continued with mixed results. 
Suzuki and colleagues carried out a more recent confirmatory study, 
administering three days of ketamine infusion, but at only 0.05mg/kg/hr. 
Despite the small dose – as compared to routine clinical doses of 0.1-0.5 
mg/kg/hr - they achieved a reduction in PPP at three months, but not at six 
months following thoracotomy (130).   
Dualé and colleagues have refuted these Suzuki results, with a negative trial 
following the use of twice the dose of ketamine infusion per hour, as well as 
1mg/kg bolus administered before surgery and then repeated during the 
procedure (131). The key limitation however with this study was the 
postoperative infusion was continued for only 24 hours and hyperalgesia would 
be expected to continue beyond that duration. In addition, neither of these 
studies reported epidural failure rates or block success e.g. in terms of levels of 
dermatomal block achieved. 
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The confusion arises when studies are designed to test the addition of agents 
such as ketamine and the gabapentinoids to RA.  The variation in block success 
and duration of efficacy is difficult to control and is rarely reported. This is 
particularly important in studies of small numbers of patients where 
randomisation may not account for this variability of block. This may be 
contributing to the conflicting conclusions.  This is indeed pragmatic, real world 
study of the effectiveness of these drugs in thoracotomy, where RA is standard 
practice and can fail postoperatively. However these conditions are not ideal for 
efficacy studies of additional ketamine or the gabapentinoids.   
This is also a discussion on the power of a study, as both agents may be 
contributing to the same prevention of PPP and therefore to assess additional 
benefit, it is necessary to study larger numbers. As an example, a study of the 
effects of preoperative gabapentin as an analgesic following thyroidectomy 
concluded no effect in the acute setting of coexisting local anaesthetic block of 
the neck (superior cervical plexus block) (132). Despite the lack of difference at 
24 hours, neuropathic pain at six months after surgery was reduced in the 
gabapentin arms suggesting either single dose preoperative gabapentin was 
protective or that there may have been sufficient variation in the efficacy of 
cervical plexus block in 24 patients analysed per group. In addition, if study 
numbers were much larger, randomisation would remove some of the effects of 
this variability in block success amongst groups. Failing that, it is important to 
report in detail the quality of RA achieved throughout the postoperative period.  
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Nevertheless there is sufficient overall and good quality evidence, from 
individual studies as well as systematic review, to include ketamine in further 
study of the prevention of PPP. 
2.14.3 Gabapentinoids 
The gabapentinoids, comprising gabapentin and pregabalin, have received the 
most recent attention in the study of preventive analgesia.  Both gabapentin and 
pregabalin bind to the α2δ (alpha-2-delta) subunit of the voltage-gated channel 
and lead to a decrease in the release of neurotransmitters such as glutamate, 
norepinephrine and substance P - thereby targeting the putative role of these 
transmitters in central sensitisation. Both agents are established in the 
treatment of neuropathic pain. This neuromodulatory effect is not only used to 
treat neuropathic pain but also other centrally driven processes such as the 
suppression of the sensitised cough reflex observed in refractory cough (133)  
As with the other techniques discussed so far, there is good evidence of acute 
pain reduction with both gabapentin and pregabalin. Historically, most studies 
investigated gabapentin but with recent interest in pregabalin.  The gabapentin 
studies typically used varying doses and duration.  Efficacy is seen in acute pain 
reduction with doses above 400mg (134) or duration beyond one postoperative 
day (111, 135). Likewise, pregabalin also shows efficacy, even at a single time 
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point, as long as it given at a high dose of 300mg (136). Systematic review and 
meta-regression confirms (137) good evidence for both these gabapentinoids in 
terms of analgesia, opioid sparing properties and tolerability (with Number 
Needed to Harm (NNH) for sedation of 35 and dizziness of 12.)  
In terms of prevention of PPP, most studies again investigated gabapentin, with 
only three controlled trials of pregabalin. The effects of both on PPP is less clear 
due to short duration of regimen, but particularly so for gabapentin. When the 
issue of adequate duration has been addressed, promising studies have provided 
a strong signal of efficacy. 
In a group of 240 patients undergoing total knee replacement Buvanendran and 
colleagues tested a prolonged regimen of oral pregabalin against a placebo in a 
randomised controlled trial.  The active arm received 300mg pregabalin before 
surgery and then continued postoperatively at 150 mg twice daily for ten days 
before weaning doses for a further four days (138).  This 14-day regimen 
reduced the incidence of neuropathic pain at 6 months from 5.2% to 0% (6/113 
to 0/115 patients, no CI description but with a p = 0.014). They observed a 
significantly increased rate of sedation and confusion in the first day after 
surgery, which settled with continued use and therefore led to an overall 
recommendation of lower doses of pregabalin, with the hope of to reduced side 
effects and to allow physiotherapy and intensive rehabilitation. 
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These preventive findings were also confirmed in same year by a lumbar 
discectomy study but in patients with established neuropathic pain, therefore 
assessing a treatment effect in addition to surgery.  This study demonstrated the 
effect of high dose (300mg) pregabalin given before and one day following 
surgery on reducing persistent pain at three months. The preexisting 
neuropathic pain is difficult to separate from PPP and there is an argument to be 
made that this is an assessment of pregabalin for treating neuropathic back pain 
rather than preventing PPP. In addition, the high doses used led to visual 
disturbances in the active study arm (139). 
2.15 Important findings worth studying further? 
Based on the paper by Buvanendran et al, I also chose to study the preventive 
effects of pregabalin 150mg BD, in the same regimen and duration 
postoperatively. I did consider reducing the dose to improve tolerability but this 
would have been at risk of losing efficacy. As an alternative, I chose to study 
surgical procedures with increased pain and analgesic requirement.  The 
argument in favour of this approach is that opioid sparing in a procedure with 
relatively large use of morphine, for example, could perhaps lead to benefits in 
terms of reduced sedation, nausea and vomiting, to offset some of the pregabalin 
side effects described by Buvanendran et al.  
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Therefore instead of designing a dose finding or “duration finding” study in knee 
replacement or similarly painful surgery, my aim was to conduct a “side effect 
reducing study”. As the literature set out above demonstrates repeatedly, 
sufficient dose and duration of administration of preventive analgesia is 
important to ensure efficacy. 
The Buvanendran et al study in knee replacement was the only true study of 
preventive pregabalin published at the time of inception of my study. It felt 
appropriate to also study other surgical groups to establish reproducibility of 
this effect.  My work also focuses on a group of patients staying in a monitored 
high dependency area for longer and with less need for early mobilisation and 
intensive ambulatory rehabilitation, and therefore may lead to improved patient 
tolerability of the preventive regimen. 
2.16 Update of the literature since my studies began 
Subsequently, and therefore not impacting on my decision to study pregabalin at 
this dose and regimen, Pesonen and colleagues investigated half the dose: 150mg 
before surgery followed by 75mg twice daily and only for 5 days duration in 70 
patients.  The study was designed and powered to detect a reduction in acute 
opioid use only following cardiac surgery, which it achieved.  The secondary 
outcomes of pain at rest and during movement at 1 and 3 months were all non-
significant except pain on movement at three months. It is tempting to speculate 
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if the pregabalin had been given longer than 5 days or at doses higher than 75mg 
BD, they may have found significant differences at one month and at rest and on 
movement at one month.  However this study was designed to show safety in the 
elderly population as well as efficacy in the acute period primarily – both 
achieved with no difference in side effects between the two groups (despite 
including only patients aged above 75 years old) and a reduction in oxycodone 
use in the active arm. With only 35 patients in each group, it is likely that this 
study was underpowered for persistent pain outcomes. 
 This latter study did lead to a systematic review last year including all 
gabapentin and pregabalin preventive analgesia studies, which concluded that 
both agents are indeed effective overall (140)  In terms of pregabalin, the 
authors go as far to comment that the improvements in pain outcomes (OR 0.09, 
95% CI 0.02 to 0.79, p=0.007) is “clinically implausible” and, especially given the 
small number of studies , justifies further study in different surgical groups. They 
do however also caution against these impressive results by pointing out the 
potential publication bias resulting from omission of any negative studies (140). 
2.17 How much reduction is enough?  
There is an important distinction to be made between statistically significant 
differences in studies and clinically meaningful, relevant or important 
differences to patients. This is particularly important when preventive 
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approaches carry risk of adverse events.  There is also the consideration of the 
ideal primary outcome measure: reduction in VAS or number of patients with 
pain in each group. 
Clinical trials of analgesics report outcomes in terms of number of patients with 
pain at a fixed time point, functional ability of individuals or reduction in either 
pain score or analgesic requirement. The reduction in pain score is considered a 
success if there is a reduction of 30% and impressive if above 50% (141). 
However, patients expect even larger differences in outcomes to consider an 
intervention a success (34). 
One way to overcome this is by looking for larger reductions, either in pain 
scores or in the number of patients remaining pain free.  Both the positive 
studies of preventive pregabalin, described above, found large differences in PPP 
outcomes.  There is a risk with powering against such large differences of a Beta 
error (i.e. a false negative.) However this may be deemed appropriate if a 
positive outcome at a level below this cut off would not be considered clinically 
meaningful. In addition the tougher the outcome measured, the lower the 
placebo effect observed (34). 
There is also a debate developing over the role of preventive analgesia as simply 
additional robust multimodal analgesia delivered well or additional preventive 
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effect (56, 142). This argument is strengthened by the observed preventive 
effects of additional analgesics such as nitrous oxide to a multimodal regimen 
(113). Therefore there is perhaps an even stronger argument to demonstrate 
large treatment effects, which are clinically meaningful, as an example of a 
separate and discernable preventive or antihyperalgesic effect?   
2.18 Study of mechanisms for preventive analgesia 
Very few studies have examined preventive analgesic effects of drugs using QST. 
This approach offers an opportunity to study the mechanisms of preexisting 
sensitisation, summation and modulatory systems, as well the changes taking 
place as a result of surgery and, in turn, the protection offered by preventive 
analgesia. This integrated approach to studying the whole system in vivo, and as 
a functioning network, allows a systems-based explanation of mechanisms as 
well as pathology.  
In addition, these tests (temporal summation, in particular) give an objective 
assessment of preoperative sensitisation, superior to patient report of 
preexisting pain (e.g. resulting from ischaemic chest pain related visceral 
hypersensitivity.) Postoperative repetition of these assessments allows 
comparison and evaluation for additional incisional sensitisation. 
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No studies of this manner had been published when I designed my studies. Other 
models have however been examined since. Wilder-Smith’s team published a 
study in chronic pancreatitis patients demonstrating that the efficacy of 
pregabalin could be predicted by the CPM paradigm testing before treatment 
(143), in a manner similar to my hypothesis below. 
A recent study demonstrated that a single dose of 300mg pregabalin reduced the 
area of secondary hyperalgesia following nephrectomy but had no effect on 
static measurement of pressure pain threshold (136). Unfortunately, this small 
group of 26 patients was not followed up to assess PPP. However this study is 
useful for hypothesis generation in terms of the effects of pregabalin on 
secondary hyperalgesia. 
2.19 Summary 
There is increasing agreement in the literature regarding the prevalence of PPP 
for different surgical interventions.  However study design remains a limiting 
factor. The study of putative risk factors and likely triggers is still in its infancy 
and prevention remains the holy grail (144). 
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Chapter 3  Identifying the scale of the 
problem in our population and 
modelling risk factors – towards cohort 
development 
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3.1 Background and rationale 
 
Figure 3.1 The risk of surgical incision 
(Image available at http://www.medicaldaily.com/history-stroke-may-increase-risk-adverse-surgical-complications-
even-non-cardiac-procedures-293190 Accessed 10/12/14) 
All surgery leads to tissue damage but the technique deployed and extent of 
surgical exploration may affect the degree of damage.  There is evidence for 
improved recovery and shorter need for hospital stay following the use of less 
invasive techniques such as video assisted thoracoscopic surgery (VATS.)  
However this improved recovery profile fails to translate well into reduced 
incidences of PPP (79, 80). 
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Both inflammation and direct nerve damage are capable of activating the 
nociceptive system but their relative contribution following surgery is not well 
understood. Not all patients with postoperative sensory dysfunction go onto 
develop PPP (87)and conversely, preserved nerve function in the postoperative 
period does not necessarily ensure the avoidance of persistent pain – as some 
patients free of pain at six months following breast surgery subsequently 
develop PPP many years later (86).  These finding suggest that other factors, 
either affecting nerve injury or acting independently, may play an important role 
in the transition from acute to chronic pain.  
Nerve identification and preservation has been suggested as a means to reduce 
the risk of PPP.  Where it may be difficult to avoid damage, it has even been 
suggested that elective transection is preferable to inadvertent partial injury 
(83).  
The role of surgical technique or extent of dissection during cardiac surgery 
specifically is less well understood. Harvesting of the internal mammary artery 
during cardiac surgery, with associated dissection of the anterior chest under 
retraction, is believed to be associated with transection or contusion of nerves. 
The intercostal nerves are particularly susceptible to damage during this 
process. This intraoperative injury may contribute to the development of 
neuropathic pain (145).  However this has yet to be studied, alongside other 
putative risk factors, in order to assess the relative contributions of each. 
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Higher acute postoperative pain score has been cited as being associated with 
the development of PPP, while harvesting of the Left Internal Mammary Artery 
(LIMA) and prolonged surgery have also both been suggested as potential causes 
(particularly of neuropathic pain) (27). 
3.2 Aims of Investigation  
The aim of this chapter is to describe the prevalence of PPP following cardiac 
surgery in our institution.  The literature reports a wide range of figures with 
varying methods of data collection, prospective as well as retrospective (the 
latter usually carried out postal questionnaire query, with variable response 
rates.)  The measurement of prevalence in our population will also inform power 
calculations for a prospective study. 
In addition, a secondary aim is to examine the relative contribution of potential 
surgical risk factors to the development of PPP.  
3.3 Methods   
With REC (research ethics committee) approval, I convenience-sampled (146) 
the medical records of a cohort of patients undergoing cardiac surgery in our 
institution over a six-month period. This time period was chosen for this pilot 
study to allow sufficient numbers to be assessed, given the rate of approximately 
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600 cardiac surgical cases performed per year at St. Bartholomew’s Hospital. As 
this was an exploratory pilot study, I was unable to carry out a power 
calculation. 
3.3.1 Risk factors 
Patient charts were reviewed for the following potential risk factors: 
Patient related 
Gender 
Age 
Treatment related 
Duration of sternotomy 
Dissection and harvesting of the left internal mammary artery (LIMA) 
Acute pain score at 24 hours following surgery 
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Patients were contacted by telephone at six months following surgery and verbal 
consent was taken to allow interviews regarding current pain experience.  
Current pain as an ‘average for the week, in and around the sternotomy site’ was 
assessed using a Numerical Rating Scale (with anchors of zero= no pain, 1= 
mildest pain possible and 10= maximum imaginable) and the self-report form of 
the Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS). The latter 
is a validated tool – with 78% sensitivity demonstrating internal consistency and 
congruent validity - for clinical research, including postal and telephone query 
(147).  The script used to interview patients is as per the published, validated 
form and is set out in Appendix Four. 
Leg pain resulting from saphenous vein harvesting was also assessed in a similar 
manner, where applicable. In addition, quality of life assessments were made at 
the six-month time period using the validated UK data set of the EQ-5D tool (see 
Appendix One.) I also enquired about any sleep disturbance as a result of PPP as 
well as the use of current analgesia for its management. 
3.3.2 Statistical analysis 
Comparisons of PPP are made for surgical technique: sternotomy alone (for 
valve surgery) as compared to the additional harvesting of the internal 
mammary artery (for coronary artery bypass grafting.) This tests the hypothesis 
that mammary artery harvesting increases the likelihood of subsequent chronic 
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sternotomy pain.  
Logistic regression modelling compares differences for binary outcomes (e.g. 
presence or absence of PPP, neuropathic pain, medication requirement, sleep 
disturbance, etc.) whereas continuous data (e.g. pain scores on the NRS) are 
analysed with linear regression models.  
Potential risk factors are analysed in a similar manner. Risk factors with 
significant interactions on univariate analysis are then combined in multivariate 
models to test relative contribution.  Likewise hierarchical regression models are 
used to test the additional effects of individual risk factors to describe the 
strength of any relationship and potential for predicting long term morbidity. 
3.4 Results 
A total of 312 patients underwent cardiac surgery at St Bartholomew’s from 
January to June 2010. Full data sets for procedure, pain score and recovery 
profile were only available for 210 patients, of whom 174 were interviewed. The 
36 omissions were due to inability to contact (23), patient death (7) and 
unwillingness to participate (6).  
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Of the 174 patients studied, 132 (76%) were male and 42 (24%) female. 129 
(74%) of patients underwent LIMA dissection for CABG. 
3.4.1 Sternotomy pain  
In total, 69 patients (39.7%) described persisting pain at six months post 
sternotomy, of whom 55.0% satisfied the screening criteria for a diagnosis of 
neuropathic pain according to the S-LANSS tool.  
The severity of the reported PPP can be further categorised as follows: 
38/69 = 55% as mild [NRS 1-3] 
23/69 = 33% as moderate [NRS 4-6] 
8/69 = 12% as severe [NRS 7-10] 
Some authors advocate the reporting of only moderate to severe pain in studies 
(34)and this would therefore reduce the percentage of patients with PPP from 
39.7% to 18% of the 174 patients studied, in total. 
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Logistic regression analysis of the binary outcomes of presence or absence of 
sternotomy pain at six months revealed age, duration of surgery and acute pain 
score to be potential predictive factors (Table 3.1) 
PREDICTOR B  (95% CI) p value 
Age (years) B=0.896 [O.862 – 0.931]   p<0.001** 
Sex   B=1.644 [O.785 –3.444]   p=0.188 
LIMA harvesting  B=1.264 [O.625 – 2.555]   p=0.514 
Duration of surgery 
(minutes) 
B=1.018 [1.010-1.025] p<0.001** 
Acute pain score (NRS) B=3.665 [2.344-5.731] p<0.001** 
Table 3.1 Logistic regression analysis for the risk of developing PPP 
 
Multivariate regression analysis of these variables further revealed theatre time, 
acute pain score and decreasing age to be most strongly associated with PPP of a 
neuropathic nature (all p<0.001).  
Hierarchical linear regression identified the best predictive model for NRS pain 
score in the chest, given the independent variables available, to comprise patient 
age, theatre time and acute pain score. Using this model, with acute pain 
included as the first step, the NRS score is increased by one further point for 
every 90-minute increase in theatre time and every 13-year decrease in patient 
age. 
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3.4.1.1 Analysis for neuropathic pain specifically 
Although LIMA harvesting was not predictive of the likelihood of developing 
overall PPP, it did predict neuropathic pain specifically.  Logistic regression 
modelling for a S-LANSS score above 12 gives an odds ratio of 2.750 (95%CI 
1.001 to 7.553) and a p value of 0.050.  Although this just fails to achieve 
statistical significance, it does suggest a possible association of LIMA dissection 
with subsequent neuropathic pain. 
Multivariate linear regression analysis of these variables revealed theatre time, 
acute pain score and decreasing age to be most strongly associated with PPP of a 
neuropathic nature (all p<0.001). However, LIMA grafting alone ceased to be 
significantly associated with subsequent neuropathic pain when the other 
factors, especially longer theatre time, were taken into account (p=0.07).  
Hierarchical linear regression identified the best predictive model for S-LANSS 
score, given the independent variables available, to comprise patient age, theatre 
time and acute pain score. Using this model, the S-LANSS score is increased by 
one point for every 20-minute increase in theatre time and every 5-year 
decrease in patient age. 
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3.4.2 Leg pain 
Leg pain was present in 62 out of 124 (50%) of those patients undergoing 
saphenous vein harvesting.  Unsurprisingly, it is not predicted by LIMA 
dissection or theatre time – as additional time in the longer duration cases is 
usually spent operating on the chest (retraction time for LIMA harvesting, in 
particular.) 
Acute pain is again strongly predictive: B=2.500 (95% CI 1.552 to 4.026) 
p<0.001 
Age of the patient is also predictive with B=0.963 (95%CI 0.930 to 0.996) and p = 
0.031.  However when both these risk factors are combined in a multivariate 
model, age is no longer predictive with B =0.977 (95%CI 0.941 to 1.013) 
p=0.211.  This could potentially be explained in one of the follow three ways: 
1. Younger patients were less likely to require CABG and therefore undergo 
leg incision for saphenous vein harvesting.  This would therefore skew the 
study population towards elderly patients undergoing leg surgery. 
2. Increased psychological stress of undergoing sternotomy as compared to 
a leg incision and therefore less predictive powered for the PPP following 
the latter. 
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3. Underpowering as less patients underwent leg incision (124), as 
compared to sternotomy (174.) 
3.4.3 QOL Assessments 
The quality of life scores vary significantly between patients in pain and those 
who area pain free, even when potential confounders are included in an adjusted 
model of linear regression: 
 Present Absent Mean difference  Adjusted mean difference* 
Sternot
omy site 
PPP 
0.435 
(0.370) 
0.736 
(0.277) 
-0.279 (-0.373 to  
-0.185) p<0.001 
-0.161 (-0.283 to -0.039) 
p=0.010 
Leg PPP 0.499 
(0.303) 
0.739 
(0.348)  
-0.240 (-0.355 to  
-0.125) p<0.001 
-0.159 (-0.280 to -0.038) 
p=0.010 
Neurop
athic 
PPP 
0.315 
(0.362) 
0.749 
(0.258)  
-0.434 (-0.537 to  
-0. 332) p<0.001 
-0.369 (-0.490 to -0.247) 
p<0.001 
Table 3.2 Linear regression analysis for EQ-5D quality of life scores 
*adjusted for age sex acute pain score theatre time and LIMA harvesting 
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3.5 Discussion  
These results demonstrate the significant long-term pain burden of undergoing 
cardiac surgery. The overall prevalence is similar to other centres in the 
literature (12). 
Patient sex is important in most chronic pain conditions but is not necessarily 
the case following surgery (56, 57) In the current study, however, there is a 
potential for bias as males outnumbered females by 3 to 1. This may therefore 
have hidden any potential effect of, especially female, sex.  
There seems an incredibly powerful predictive power of age, pain score and 
duration of surgery on future PPP.  Of these, only pain score is modifiable but 
perhaps there is a role for aggressive pain management in young patients, 
especially in the immediate postoperative period. 
Although two or three months are quoted as the minimum post-surgical 
intervals quoted in published definitions for PPP, the patients in this study were 
assessed at six months(28).  Therefore when comparing this finding of 12% 
incidence of severe PPP to results from other studies, it should be borne in mind 
that the rate may be higher at these earlier time points post-surgery. Similarly, 
the figures for ‘more than mild pain’, of 45% of all patients reporting PPP, and 
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18% of all patients studied, may also have been found to be higher at two or 
three months following surgery. Interestingly, Kehlet and colleagues report a 
similar incidence of PPP following breast surgery at different time points, but 
with some patients improving while others reporting new PPP in and around the 
original incision site (86). Enquiry at a single time point, as in this study, 
obviously precludes such longitudinal, temporal comparisons. 
The low EQ-5D scores observed in patients with pain are comparable to the UK 
National Pain Audit  (http://www.hqip.org.uk/assets/NCAPOP-
Library/NCAPOP-2013-14/Pain-Audit-Report-2013.pdf) especially in those with 
persistent neuropathic pain and demonstrate significant long-term morbidity 
and disability. 
3.5.1 Limitations 
Retrospective study is limited by the lack of baseline values for pain (including 
medication requirement and sleep disturbance.) Objective and quantitative 
assessment of pain around the incision site is also not possible e.g. visceral 
hypersensitivity at the sternotomy site, as one example. Likewise, quality of life 
assessments before surgery are not possible to assess any changes – either 
improvement or deterioration following surgery. 
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In terms of data capture, this study was limited by the lack of complete medical 
notes in the case of over 100 patients.  It is not possible to comment on whether 
these cases were random or skewed towards those with worse (or indeed 
better) pain outcomes. 
Similarly, of the 23 patients who we were unable to contact, it is possible to 
speculate that may have resulted from increased pain compared to the 
remainder of the group. 
Six patients refused to participate and although, a small number, this may have 
reflected dissatisfaction with outcomes. Only one patient was prepared to give a 
reason: although pain free, he described a poor experience with hospital follow-
up, especially by medical teams.  
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3.6 Conclusions 
Albeit retroactive and using the approach of convenience sampling, this study 
corroborates the reported prevalence range of PPP after sternotomy. It is 
interesting however that only half of the cases satisfied the screening criteria for 
neuropathic pain.  
This study also confirms duration of surgery and the intensity of pain in the 
initial acute setting, as potential predictors of PPP. The increased prevalence of 
symptoms and signs in younger patients may justify more aggressive methods of 
prevention and management of their early postoperative pain.   
Regression modeling reveals the potentially powerful predictive value of the 
following risk factors: age, acute pain and theatre time. This analysis supports 
the need for prospective study in order to develop and validate predictive tools 
for PPP. 
Although one declared aim was to identify the role of surgical technique in the 
development of subsequent PPP, this is not clearly the case as regards LIMA 
dissection and harvesting.  Other factors related to tissue injury and exposure 
may be relevant but these findings corroborate other study where similar PPP 
outcomes were reported when comparing open and video-assisted thoracic 
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surgery.  In both examples, current analgesic regimens (centred on opioid 
analgesics) seem ineffective in managing the substantial risk for the 
development of PPP.  
It is likely that patient related factors and early pain experience following 
surgery are more important in shaping the prevalence and experience of PPP, 
than surgical technique specifically. 
Further investigation of patient related factors is therefore warranted as well as 
alternatives to opioids as a means of reducing acute postoperative pain, and 
perhaps PPP.  
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Chapter 4 Randomised controlled trial 
of preventive analgesia 
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The aim of the wise is not to secure pleasure, but to avoid pain.  
Aristotle 384-322 BC 
 
Figure 4.1Bust of Aristotle; Free Will and Antiquity 
(Available at http://en.wikipedia.org/wiki/Free_will_in_antiquity Accessed on 10/12/14) 
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4.1 Introduction 
Persistent pain following surgery is surprisingly common and difficult to treat 
once established. The identification of preventive measures therefore holds great 
promise (128, 140).  
Study of various surgical procedures has however led to contradicting results 
with some of these differences attributed to poor study design (148).  
There may also be differences in the mechanisms of persistence between 
different surgical groups, which may in turn be reflected in the varying efficacy 
of preventive analgesia (14). Very little data exists for cardiac surgery and 
therefore I took the opportunity to study this group of patients specifically. 
I chose to test the ability of the antihyperalgesic drugs pregabalin and ketamine 
in terms of preventing this phenomenon. Both these agents have shown 
particular promise in systematic review of the literature to date (140, 148).  
Similarly in the case of cardiac surgery, although the data is limited in terms of 
prospective study, there is some signal for both these agents, in particular for the 
prevention of acute pain (7, 149, 150). 
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Ketamine has been studied more extensively than the gabapentinoids, including 
during cardiac surgery.  However the preventive analgesia data, to date, is most 
compelling for the gabapentinoids, in particular pregabalin - with a recent 
systematic review reporting an odds ratio of 0.09 in terms of the reduction of the 
portion of patients with PPP following perioperative use. I also chose to test the 
combined multimodal effect of ketamine along with pregabalin to test the 
combined effect of these two anti neuropathic agents.   
This important effect of combining analgesic therapy is well established in the 
management of acute pain following surgery (151, 152). Surprisingly few studies 
however have taken this approach with chronic pain, even in established 
neuropathic pain, although the exceptions have stood out for their efficacy (153, 
154) 
4.2 Hypothesis 
The aim of this chapter is to test the hypothesis that the development of 
persistent pain after cardiac surgery can be prevented by the use of 
antihyperalgesic agents at the time of surgery, either alone or in a multimodal 
regimen.  
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4.3 Methods 
The trial was conducted as per the protocol approved by the East London and 
The City Research Ethics Committee (REC) and the Medicines and Healthcare 
Products Regulatory authority (MHRA.)  
 
The clinical trial  (Heart PPPAIN – Heart surgery and Persistent Postsurgical 
PAIN trial) was registered on clinicaltrials.gov (NCT01480765) and recruitment 
began in December 2011 with data collection ending in March 2013.  
4.3.1 Study design  
Study design for clinical trials can be described in the form of  
Patients, Intervention, Comparator and Outcomes (PICO.)  
PATIENTS 
For this parallel arm, randomised, double blind, placebo-controlled trial, I 
screened all patients satisfying the following inclusion criteria: 
INCLUSION CRITERIA: 
 Age 18 -80 years  
 Undergoing cardiac surgery via first-time sternotomy 
  105        
 
EXCLUSION CRITERIA: 
 History of chronic pain, other than angina 
 Regular use of pain medication, other than paracetamol and non-steroidal 
anti-inflammatory drugs.  
 Concurrent use of any drugs for neuropathic pain e.g. antiepileptics, 
antidepressants 
 Concurrent use of oxycodone, lorazepam or ethanol - as these drugs 
interact with pregabalin. 
 Previous sternotomy 
 Emergency surgery- decision to operate taken on the day of surgery 
 Preoperative renal failure defined as eGFR  <60 ml/min- as pregabalin is 
renally excreted 
 Allergy to pregabalin, gabapentin or ketamine 
 Pregnancy 
 Limited understanding of numerical scoring scales 
 Previous participation in other trials investigating analgesic agents, or 
any other IMP in previous three months 
 
Patients undergoing valve surgery were included along with coronary artery 
bypass graft (CABG) cases.  This gave the opportunity to examine the potential 
effect of LIMA dissection from the chest wall during CABG– usually with 
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extended diathermy for up to an hour – on subsequent PPP.  Only in rare 
circumstances in our institution is CABG carried out without LIMA harvesting 
and therefore insufficient numbers were expected to make this comparison 
within this single surgical procedure.  
When combining ischaemic heart disease patients with those with valve disease, 
is an important consideration to be made for the role of pre-existing central 
sensitisation in the chest from, for example, long standing ischaemic visceral 
pain.  Therefore as set out in the following chapters, all patients were also 
examined for preoperative preexisting sensitisation (in the form of temporal 
summation, for example), to allow for consideration of this potential confounder. 
As set out in the CONSORT diagram (figure 4.2), 150 patients were consented 
and block randomised to one of three treatment groups using a concealed 
computer-generated allocation sequence, created and managed in a blinded 
manner by the Barts Trials Pharmacy. This blinding was maintained until the full 
six-month follow-up data set was complete and submitted to the pharmacy trials 
manager. 
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INTERVENTION and COMPARATOR 
The patients were randomised to the following three groups: 
COMPARATOR = Usual Care (UC): Control group with placebo capsules and 
placebo ketamine (saline) infusion. 
INTERVENTION #1 = Pregabalin (P): Received active pregabalin capsules with 
placebo ketamine (saline) infusion. 
INTERVENTION #2 = Pregabalin and ketamine group (PK):  Received active 
pregabalin capsules and active ketamine infusion. 
All patients, medical and nursing teams, as well as research staff, were masked to 
treatment allocation.  
Nursing staff administered an identical, blinded study capsule (containing either 
150mg pregabalin or matched placebo lactose) to all patients two hours prior to 
surgery. These were supplied free of charge by Pfizer following a successful 
application to their IIR (Investigator Initiated Research) funding programme, 
with no other contribution to the design, conduct or publication of this trial.   
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Following surgery, these study capsules were continued twice daily for ten 
continuous days, followed by a dose reduction to 75mg for day 11 and 12 and 50 
mg for days 13 and 14.   
If patients were discharged from hospital prior to completion of the 14-day 
capsule regimen, pharmacy dispensed the remaining doses for the patient to 
complete the course at home. Any unused capsules were returned to the trial 
pharmacy and recorded along with any missed doses during the inpatient stay.  
Details of any missed doses during in patient stay or early withdrawal from 
either drug were also recorded.  
The infusion of intravenous ketamine or matched placebo (saline) was started at 
the end of cardiac surgery once spontaneous circulation had returned and 
continued for 48 hours. The 50 ml syringe was prepared in a blinded manner by 
the Chemotherapy Trials Unit of the Barts Trial Pharmacy as either 10mg/ml of 
ketamine or matching placebo (0.9% sodium chloride.)  This was infused at a 
rate of 0.01ml/kg/hour and therefore, in the case of the active arm, this 
amounted to 0.1mg/kg/hour of ketamine. 
OUTCOMES 
All outcomes were collected on case report forms, as set out in Appendix Five.  
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PRIMARY: Proportion of patients with pain at three and six months on the NRS  
SECONDARY: 
Acute pain scores, on the NRS, at the sternotomy site and (where applicable) the 
saphenectomy site. 
Morphine consumption in the first 24 hours 
Sedation and nausea scores 
Prevalence of diplopia 
Respiratory rate and blood carbon dioxide levels  
Adverse and Serious Adverse Events (as per the event log, set out in Appendix 
Six.) These were managed by the data monitoring committee and reported as per 
the organogram set out in the Appendix Seven. 
Extubation time 
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Length of stay on ICU and in the hospital 
Quality of life at three and six months (EQ-5D VAS and index) 
Prevalence of neuropathic pain at three and six months 
Requirement for analgesics at three and six months 
Sleep disturbance by pain at three and six months 
4.3.2 Renal failure algorithm 
In the case of renal failure during the postoperative period, the following 
protocol was followed: 
Pregabalin clearance is directly proportional to creatinine clearance and 
therefore we will use eGFR measurements throughout the dosing period for 
pregabalin (or placebo) to decide on delay of drug. As the drug is not nephrotoxic 
but simply accumulates with renal failure, all patients will receive a dose 12 
hours after the preoperative dose.  Subsequent dosing will be guided by eGFR 
results:- 
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eGFR above 60ml/min will lead to continuing dosing.  
eGFR of 45-60 will also lead to a dose being given but with vigilance and 
measurement of eGFR before the next dose, to observe the trend in renal 
function.  If the eGFR remains in the range of 45-60, each dose will be preceded 
by repeat measurements and in the case of a trend of falling eGFR, as judged by 
investigation or hospital medical team, the patient will be withdrawn from the 
study. 
eGFR of 30 – 45 will lead to an omission of IMP and again repeat measurement 
before the next dose in 12 hours time.  Two successive missed doses will lead to 
premature withdrawal of the patient from the study. A single omission with a 
subsequent return to normal renal function will continue the protocol and this 
will be reported in the published results. 
eGFR readings below 30ml/min at any point or the use of renal replacement 
therapy will lead to premature withdrawal of the patient from the study.  
  112        
4.3.3 Clinical management 
The patients were anaesthetised according to a standardised and agreed 
protocol. All patients received 20mg oral temazepam two hours prior to transfer 
to theatre along with the study capsule (pregabalin or placebo). Induction of 
anaesthesia took place with 2-3mcg/kg of fentanyl and 1-2mg/kg propofol bolus. 
Intraoperative opioid use was restricted to fentanyl in a range of 7.5 – 20 mcg/kg 
with documentation of any requirements above this dose. Anaesthesia was 
maintained with Isoflurane, prior to cardiopulmonary bypass (CPB), and 
converted to intravenous infusion of propofol for the remainder of the 
perioperative period. 
Surgery was performed via median sternotomy and CPB was established on all 
patients to allow coronary artery bypass grafting, valve replacement or 
combined surgery. This was conducted using moderate hypothermia (30– 34 
degrees Celsius), a membrane oxygenator and a roller pump. Myocardial 
protection was achieved using cold blood-crystalloid cardioplegia solution.   
All patients remained sedated and ventilated for transfer to the intensive care 
unit following surgery and extubation took place according to institution 
protocol.  
In addition to the trial regimen, all patients received usual care of patient 
  113        
controlled analgesia (PCA) in the form of morphine 1mg bolus, with a lockout 
period of five minutes. All patients also received regular paracetamol (1g four 
times per day). Both these analgesics were continued until chest drains were 
removed at approximately 36 hours following surgery. Once the PCA was 
removed, regular codeine (30mg four times per day) was added to the 
paracetamol, with breakthrough pain of NRS>4 managed by administration of 
tramadol 50–100 mg, up to a maximum of three times per day. 
4.3.4 Measurement of outcomes 
The proportion of patients with sternotomy pain was assessed at three months 
following surgery using the NRS during a phone call and formed the primary 
outcome. This was assessed by phone call query using the NRS scale along with 
secondary outcomes of evoked pain on the NRS (with 3 maximal coughs) as well 
as leg pain, both at rest and on walking. During the same phone call, I also 
enquired about secondary outcomes of neuropathic pain (on the S-LANSS scale) 
as well as use of medication and sleep disturbance by pain.  Identical questioning 
took place at six months following surgery.  
The remainder of the secondary outcomes were measured during the 
postoperative period. Sternotomy pain scores at rest and following three 
maximal coughs were measured on the numerical rating scale at 24 hours 
following surgery as well as leg incision pain scores for those undergoing 
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saphenous vein harvesting. A movement evoked pain assessment for leg pain 
was not possible, as patients remained on bed rest in this early stage of recovery.  
At the same time, side effects were recorded in terms of sedation and nausea on 
a 0-3 scale (nil, mild, moderate and severe) as well as any inpatient episodes of 
diplopia and dizziness. 
The PCA device memory display provided the cumulative total dose of morphine 
consumed at the 24-hour postoperative time point. 
Two-pass verification (or ‘double data entry’) was used to transfer all data from 
paper report forms to Excel (Microsoft Corp, USA) and SPSS (IBM Corp, New 
York, USA) for analysis. 
4.3.5 Statistical analysis 
This study was powered to detect a two-thirds reduction (34) in the prevalence 
of PPP.  Pilot data (Chapter three) revealed a PPP prevalence of 39.7% in 312 
consecutive patients undergoing elective sternotomy in our centre over a six-
month period. Based on an alpha of 5% and power of 80%, we therefore 
calculated a sample size per group of 43 patients. To allow for attrition such as 
loss to follow up, we recruited 50 patients per group. 
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Results were analysed on an intention to treat (ITT) basis with imputation of 
missing data on the basis of average values for the group, as per the Statistical 
Analysis Plan set out in Appendix Eight. Alternative imputation methods exist 
(e.g. last value carried forward, worst or best possible scenarios) but average for 
the group most closely resembles the intention to treat principle, as protocol 
deviations (leading to missing data, for example) are treated as closely as 
possible to subjects adhering to protocol (155). 
The primary outcome of proportion of patients experiencing PPP at three 
months is presented by treatment arm and compared using logistic regression 
modelling on SPSS. Results are presented as odds ratios (OR) with 95% 
confidence intervals. Similar analyses is performed for the other binary variables 
(neuropathic pain, sleep disturbance, long-term analgesic requirement.)  
The continuous outcomes (NRS score, etc) are summarised by treatment group 
using appropriate descriptive statistics and 95% confidence intervals. These 
include numbers and percentages for categorical data, mean and standard 
deviation for normally distributed, continuous data or median and interquartile 
range for skewed data. Baseline characteristics between the treatment groups 
are also presented to assess similarity across randomisation groups. 
Linear regression models are used to compare continuous variables across 
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treatment groups, including ANCOVA (analyses of covariance), employed to 
adjust for baseline characteristics where there is good clinical belief that they 
may be predictive of outcome e.g. age, pre operative quality of life or sensory 
state.  
Similar regression models are used in chapters five and six, for subgroup 
analysis, to identify predictive risk factors. Given the relatively low power for 
testing interactions, these results should be considered exploratory only.  
4.4 Results 
Three and six month assessments were only possible on 148 patients (figure 
4.2.) Two patients were lost to follow up: due to death on day seven following 
surgery and emigration following hospital discharge. Data was imputed for these 
two patients on an ‘average for the group’ basis.  
4.4.1 Missing data 
Inpatient data was missing on five patients, who were unable to provide 
responses or scores: in three cases of prolonged pulmonary ventilation and two 
patients requiring early re-intubation of the trachea.  Therefore, early outcome 
data was not available, but three and six month follow up assessments were 
  117        
possible for these patients.  The remaining withdrawn patients, as set out in the 
CONSORT diagram (Fig 4.2), all agreed to follow up assessments while in 
hospital and at three and six months following surgery. 
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362	pa ents	screened	for	
eligibility	
50	pa ents	analysed	at	
three	and	six	months	
50	pa ents	analysed	at	
three	and	six	months	
50	pa ents	assigned	and	
received	Pregabalin	and	
placebo	ketamine	(P)	
50	pa ents	assigned	and	
received	two	placebos	
(UC	Usual	Care)	
50	pa ents	analysed	at	
three	and	six	months	
150	pa ents	enrolled	and	
randomised	
50	pa ents	assigned	and	
received	Pregabalin	and	
Ketamine	(PK)	
212	pa ents	excluded:	
26	previous	sternotomy	
	 	 		123	renal	impairment	
		42	coexis ng	pain	disorder	
12	concurrent	use	of	
an epilep c	medica on	
2	emergent	surgery	
7	declined	to	par cipate	
1	loss	to	follow	up	(death	on	day	7)	
7	withdrawals:	
2	prolonged	ven la on	
1	re-sternotomy	
1	severe	renal	failure 		
1	severe	somnolence	
1	diplopia	and	dizziness	
	1	pa ent	chose	to	stop	
No	losses	to	follow	up	
5	withdrawals:	
1	Prolonged	ven la on	
2	Drowsiness	and	re-intuba on	
1	Severe	diplopia	
1	pa ent	chose	to	stop		
	
1	loss	to	follow	up	(emigrated	
one	month	post	op.)	
5	withdrawals:	
1	re-sternotomy	
1	severe	renal	failure	
1	severe	somnolence	
2	pa ents	chose	to	stop	
	
 
 
Figure 4.2 CONSORT diagram of patient flow through the RCT 
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4.4.2 Baseline characteristics 
Baseline values were similar among the three groups (table 4.1) including 
quantitative sensory testing (PPT= Pain Pressure Threshold and CPM= 
Conditioned Pain Modulation) as well as psychological measures - see 
subsequent chapters. 
 Trial groupings 
 Usual care 
(UC) 
Pregabalin (P) Pregabalin & 
ketamine (P+K) 
Male sex (%) 36/50 (72%) 41/50 (82%) 40/50 (80%) 
Age (years) 63.4 (11.4) 64.9 (12.8) 61.8 (12.4) 
Weight 
(Kilograms) 
80.1 (15.9) 
 
 
77.9 (14.1) 
 
78.2 (15.1) 
Pre op EQ-5D 
index 
 
0.597 (0.310) 0.563 (0.301) 0.538 (0.322) 
Anxiety: 
Spielberger score 
39.3 (12.5) 
 
38.2 (8.8) 
 
41.2 (11.8) 
Catastrophising:  
Pain 
Catastrophising 
Scale score 
16.4 (12.3) 16.2 (12.3) 17.7 (12.9) 
Percent change 
in PPT with CPM 
37.0 (49.0) 29.7 (25.9) 29.5 (40.9) 
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Presence of 
preoperative 
temporal 
summation at the 
sternotomy site 
17/50 (34%) 15/50 (30%) 14/50 (28%) 
Presence of 
remote temporal 
summation 
(forearm) 
10/50 (20%) 9/50 (18%) 9/50 (18%) 
Duration of 
surgery 
(minutes) 
278 (60) 296 (93) 305 (95) 
LIMA dissection 35/50 (70%) 39/50 (78%) 37/50 (74%) 
Table 4.1 Baseline characteristics of patients as per randomisation group 
Data is presented as portion (percentages) or mean (standard deviation) PPT= pressure pain threshold, 
CPM= conditioned pain modulation, LIMA= left internal mammary 
 
4.4.3 Primary outcome 
Both active arms demonstrated a significant decrease in the prevalence of pain at 
three and six months when compared to the control group, either unadjusted or 
adjusted for covariates in a mixed model (table 4.2) All these results are 
significant at the p <0.001 level.  The factors included in the mixed models are 
those with potential to influence the outcome, namely: age, gender, weight, 
preoperative EQ-5D index, state anxiety, pain catastrophising, % PPT change to 
CPM, Temporal summation (sternotomy site and remotely), duration and type of 
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surgery (involving dissection of chest arteries.) The QST measurements of PPT 
and CPM are set out in detail in subsequent chapters. 
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Figure 4.3 Primary outcomes  
Proportion of patients with pain, at 3 and 6 months, based on the NRS. Logistic 
regression across treatment arms revealing p values < 0.01 as compared to usual 
care. Non-significant differences found between the two active arms. 
Comparisons between the two active arms for the primary outcome reveal no 
difference in efficacy (OR=0.99, 95% CI: -3.00 to 5.00, P=0.62.)  No further 
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comparison is therefore made between the active arms, as this study is not 
powered to detect such changes.  
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4.4.4 Secondary outcomes:  
Both active arms reported significant decrease in acute pain scores when 
compared to the control arm (3.04 on the NRS for group P unadjusted and 2.823 
adjusted; 2.98 for group PK and 3.058 adjusted for the other variables.) These 
differences are significant at a level of p<0.001 (table 4.2). 
In terms of the potential sedating effects of the pregabalin and ketamine in active 
arms, there were no significant differences in time to extubation or length of stay 
on the intensive care unit (figure 4.4).  Statistically significant increases in 
sedation scores were observed in the active arms but are unlikely to be of 
clinically meaningful difference. Details of all adverse events are logged in 
Appendix Six with the reporting organogram for SUSARs set out in Appendix 
Seven.  Despite increased sedation in both active arms, Morphine requirement 
was significantly reduced, as compared to the control group (Table 4.2):
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 Group allocation Between group differences (95% 
CI.)  Unadjusted comparison 
Between group differences (95% 
CI.)   Adjusted comparison* 
 Placebo = 
Usual care 
(UC) 
Pregabalin 
(P) 
Pregabalin & 
ketamine 
(P+K) 
UC vs. P UC vs. P+K UC vs. P UC vs. P+K 
PRIMARY 
OUTCOMES: 
       
Prevalence of 
PPP at 3 months 
following 
surgery  
25/50 (50%) 5/50 (10%) 2/50  
(4%) 
Odds ratio: 
0.111  
(0.038 to 0.326)  
P<0.001 
Odds ratio: 
0.042  
(0.009 to 0.190)  
P<0.001 
Odds ratio: 
0.046 
(0.011 to 0.200)  
P<0.001 
Odds ratio: 
0.002  
(0.000 to 
0.046) 
 P<0.001 
Prevalence of 
PPP at 6 months 
following 
surgery  
23/50 (46%) 4/50  
(8%) 
1/50  
(2%) 
Odds ratio:  
0.130 
(0.044 to 0.383)  
p<0.001 
Odds ratio: 
0.024 
(0.003 to 0.187)  
p<0.001 
Odds ratio:  
0.038 
(0.007 to 0.207)  
p<0.001 
Odds ratio:  
0.001 
(0.000 to 
0.031) 
 p<0.001 
 
  125      
  
SECONDARY 
OUTCOMES: 
       
Acute pain 
score - at rest: 
Sternotomy 
(NRS) 
4.10 (3.13) 
 
 
1.06  
(1.36) 
 
1.12  
(1.80) 
-3.04 (-4.00 to -
2.08)  
p<0.001 
-2.98(-3.99 to -
1.97)  
p<0.001 
-2.82  (-3.79 to -
1.85)  
p<0.001 
-3.06 (-4.05 to 
-2.06) 
p<0.001 
Acute pain 
score - cough: 
Sternotomy 
(NRS) 
4.10 (3.13) 
 
 
1.06  
(1.36) 
 
1.50  
(2.12) 
-2.56 (-3.77 to -
1.35)  
p<0.001 
-3.08  (-4.35 to -
1.81)  
p<0.001 
-2.45(-3.67 to -
1.23)  
p<0.001 
-3.23 (-4.60 to 
-2.00) 
p<0.001 
Acute pain 
score - at rest: 
Saphenectomy 
(NRS) 
3.72 (3.11) 
 
 
0.92  
(1.50) 
 
0.12  
(0.77) 
-2.80 (-3.94 to -
1.67)  
p<0.001 
-2.22  (-3.45 to -
1.00)  
p=0.003 
-2.32 (-3.57 to -
1.07)  
p<0.001 
-2.01 (-3.24 to 
-0.78) 
p=0.002 
Morphine 
consumption at 
24hrs (mg) 
57.86 
(27.63) 
27.86 (14.46) 25.24 (16.74) -30.00 (-38.75 
to -21.24) 
p< 0.001 
-32.62 (-41.68 
to 
-23.55) 
p< 0.001 
-28.05 
(-36.94 to -
19.16) 
p< 0.001 
-32.59 
(-41.76 to -
23.41) 
p< 0.001 
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Side effect 
analysis: 
Extubation time 
(minutes) 
 
407 (196) 424  
(231) 
441  
(266) 
17 (-68 to 102)  
p = 0.689 
34 (-59 to 127)  
p = 0.467 
 
27 (-63 to 117)  
p = 0.556 
11 (-82 to 
103)  
p = 0.824 
 
ICU stay (hours) 
20.6 (12.07) 16.9 (8.75) 17.9 (11.14) -3.71 
 (-7.90 to 0.48) 
p=0.082 
  -2.72  
(-7.33 to 0.109) 
p=0.245 
 
-3.20 
(-7.61 to 1.22) 
p= 0.154 
-2.97 
(-7.58 to 1.63) 
p= 0.202 
Sedation score  Median= 2 
(IQR=0) 
Median= 2 
 (IQR=1) 
 
Median= 2 
 (IQR=1) 
 
Mann Whitney 
p=0.044 
Mann Whitney 
p=0.035 
N/A N/A 
Nausea score 
 
Median= 2 
IQR 2 
Median= 0 
IQR 0 
Median= 0 
IQR 1 
Difference = -2 
P=0.003 
Difference= -2 
p=0.005 
N/A N/A 
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Prevalence of 
diplopia  
4/50  
(8%) 
12/50 (24%) 15/50 (30%) Hazard ratio= 
3.63 
(1.08 to 12.2) 
p=0.037 
NNH=6.25 
Hazard ratio= 
4.93 (1.50 to 
16.2) 
P=0.008 
NNH=4.54 
Hazard ratio= 
4.03 (0.045 to 
15.6) 
P=0.043 
Hazard ratio= 
6.81 (1.68 to 
27.5) 
P=0.007 
Respiratory 
rate at 24 hours 
(breaths/min) 
12.4 
(4.54) 
14.9 
(3.68) 
14.9 
(3.40) 
2.56 (0.918 to 
4.20)  
p= 0.003 
2.50 (0.906 to 
4.09) 
p=0.002 
2.01 (0.50 to 
3.68)  
p=0.011 
2.22 (0.67 to 
3.78)  
p=0.006 
pCO2 = blood 
carbon dioxide 
tension (KPa) 
5.73 
(0.88) 
5.14 
(0.58) 
5.22 
(0.76) 
-0.580 (-0.884 
to -0.292) 
p<0.001 
-0.51 (-0.838 to 
-0.183) 
p=0.003 
-0.524 (-0.82 to 
-0.23)  
p=0.001 
-0.525 (-0.854 
to -0.195) 
p=0.002 
Recovery: 
Extubation time 
(minutes) 
 
407  
(196) 
424  
(231) 
441  
(266) 
17 (-68 to 102)  
p = 0.689 
34 (-59 to 127)  
p = 0.467 
27 (-63 to 117)  
p = 0.55 
11 (-82 to 
103)  
p = 0.82 
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ICU stay (hours)  
20.6 (12.07) 
16.9 (8.75) 17.9 (11.14) -3.71  
(-0.790 to 4.75) 
p=0.082 
-2.72 
( -7.33to 1.89) 
p=0.245 
-3.196 
(-7.61 to 1.22) 
p= 0.154 
 
-2.97 
(-7.58 to 1.63) 
p= 0.202 
Length of stay 
in hospital 
(days) 
Median = 7.5 
(IQR =9) 
Median = 
6.5 
(IQR=4) 
Median = 
6 
(IQR= 3) 
1 day 
Mann Whitney 
P= 0.023 
1.5 days 
P= 0.002 
N/A N/A 
Quality of life:  
EQ-5D Index  
 
 
0.323 
(0.302) 
 
 
0.619  
(0.267) 
 
 
 
0.661  
(0.156) 
 
 
0.296 (0.183 to 
0.409)  
p<0.001 
 
 
0.338 (0.242 to 
0.4330) 
p<0.001 
 
 
0.309 (0.197 to 
0.420)  
p<0.001 
 
 
0.369 (0.277 
to 0.4610) 
p<0.001 
EQ-5D VAS  48.2 (22.1) 68.6 (21.1) 71.2 (12.8) 20.4 (12.0 
to28.0) p<0.001 
23.0 (15.8 to 
28.2) p<0.001 
22.7 (14.5 to 
30.9) p<0.001 
26.3 (19.5 to 
33.2) p<0.001 
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Prevalence of 
neuropathic 
pain at 
sternotomy site 
16/50 (32%) 3/50 (6%) 0/50 (0%) Odds ratio 
0.185 (0.057 to 
0.603) 
P= 0.005 
N/A (zero 
event) 
Odds ratio 
0.126 (0.028 to 
0.560) 
P=0.007 
N/A (zero 
event) 
Prevalence of 
neuropathic 
pain at 
saphenectomy 
8/38 (21%) 1/42 (2%) 
0/41 
(0%) 
Odds ratio 
0.183 (0.036 to 
0.924) 
P=.0040 
N/A (zero 
event) 
Odds ratio 
0.149 (0.008 to 
2.762) p=0.201 
 
N/A (zero 
event) 
Analgesics 
required for 
sternotomy site 
or leg pain 
22/50 (44%) 7/50 (14%) 1/50 (2%) 
Odds ratio 
0.176 (0.067 to 
0.466) p<0.001 
Odds ratio 
0.022 (0.003 to 
0.173) p<0.001 
Odds ratio 
0.115 (0.036 to 
0.370) 
p<0.001 
Odds ratio 
0.001 (zero to 
0.45) 
p<0.001 
Sleep disturbed 
as a result of 
sternotomy site 
or leg pain 
19/50 (38%) 5/50 (10%) 1/50 (2%) Odds ratio 
=0.167 (0.056 
to 0.492) 
p=0.001 
Odds ratio 
0.031 
(0.004 to 0.240) 
p=0.001 
Odds ratio 
0.108 (0.029 to 
0.403) 
p=0.001 
Odds ratio 
0.006 (zero to 
0.092) 
p<0.001 
Table 4.2 Primary and secondary outcomes 
Data is presented as proportion, mean (standard deviation) or median (interquartile range.) Comparisons are presented as odds ratios, mean differences (95% confidence interval) 
or Mann Whitney test result. *Comparison adjusted for age, gender, weight, preoperative EQ-5D index, state anxiety, pain catastrophising, % PPT change to CPM, Temporal 
summation (sternotomy site and remotely), duration and type of surgery 
.
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Figure 4.4 Secondary outcomes of recovery, as per randomisation group.  
Linear regression of y-axis values of hours for extubation time/ ITU stay and 
milligrams for morphine requirement. Statistical significance is only achieved for 
morphine requirement in both arms as compared to placebo/ usual care.  
 
Length of stay was significantly different between control group and each of the 
active arms (Median difference =1 day for group P and 1.5 day for group PK.) 
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Comparison between both active arms however leads to a non-significant 
difference of 0.5 days (p=0.678). 
Both active arms lead to significant differences in quality of life as measured by 
EQ-5D.  This is translated into lower use of analgesics, as well as reduced 
prevalence of sleep disturbance. 
Only one patient died during the conduct of the study and therefore mortality 
comparison across groups was not carried out. 
4.5 Discussion 
This data suggests a large effect of pregabalin on both acute and chronic pain 
outcomes following cardiac surgery, which in this study translated into 
improved quality of life and function at three months.  These differences are 
sustained at six months following surgery.  
The size of these differences in this study is surprising and may in part be 
explained by study design.  Unlike most other studies of preventive analgesia, 
our study was devoid of confounders of other potential preventive analgesia e.g. 
regional anaesthesia.   The aim was also to study a group of surgical patients who 
would be free of preoperative (e.g. cancer) pain but would subsequently 
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experience significant postoperative pain, with a high incidence of PPP (26, 156). 
The additional benefit of this particular surgical model is the inpatient stay 
covers a sufficient period of time to ensure compliance with at least the initial 
trial regimen.  
The currently employed analgesic regimen for cardiac surgery may be 
considered insufficient and out of date, being largely reliant on intravenous 
opioids, with little use of adjunct analgesics (3, 157, 158). This is likely to 
contrast with usual care for other surgical procedures where enhanced recovery 
and short stay (or day case) care is established and practiced e.g. knee surgery .  
It is also possible that there is a unique feature of cardiac surgical patients, which 
may make this particular group of surgical patients more susceptible to the 
preventive effects of pregabalin.  In particular, TS may be pronounced in this 
group (secondary to visceral hypersensitivity from ischaemic pain, in particular) 
and this may be more responsive to pregabalin than other surgical models e.g. 
thoracotomy.  This is a hypothesis based on personal communication with 
Professor David Yarnitsky at the IASP (International Association for the Study of 
Pain) World Congress on Pain in 2014 and therefore requires further 
investigation. 
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There seems to be little difference between the two active interventions, i.e. the 
additional benefit of ketamine appears to be discernable as a small trend but not 
statistically significant at the level of powering in this study, which was not 
designed or powered to detect differences between the two active arms.  
The relative contribution of opioid induced hyperalgesia is discussed in 
following chapters on mechanistics but is likely to have played a role in both 
acute and chronic pain scores. Opioid sparing may be leading to - and not just an 
effect of - improved pain, by reductions in OIH.  In addition to reduced OIH, 
opioid sparing may also facilitate recovery from major surgery, with earlier of 
return of normal bowel function as well as engagement with rehabilitative 
strategies, such as physiotherapy (159). This causality, or ‘chicken or egg  ‘ 
question, is difficult to examine without randomising patients to differing opioid 
regimens – beyond the scope of this study.  
Assessments of pain with movement are recognised as sensitive discriminators 
of post-surgical pain (149, 160) However the effect of pregabalin seems so large 
in this study as to limit the additional benefit of this assessment, leading to 
similar scores as those at rest. 
Interestingly, only a minimal placebo effect is seen in the control arm. This is 
very different to the significant placebo seen in analgesic studies (161, 162) and 
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is difficult to explain.  It is possible to speculate that this is related to the complex 
and prolonged nature of the surgery and recovery, with perhaps reduced ability 
of participants to remember and attribute preventive analgesic effect to the 
placebo.  It is also possible that postoperative cognitive dysfunction which is a 
recognised and common effect of cardiac surgery may have impacted on this 
reduced effect (163, 164) of recall and therefore placebo. 
A nocebo effect is however observed in the control arm with patient reporting of 
diplopia as well as withdrawals due to intolerability to drug (161). 
There is a statistically significant improvement in blood levels of carbon dioxide 
as well as recorded respiratory rate in the active arms, possibly due to the opioid 
sparing effect of the agents.  However these differences are too small to be 
clinically meaningful.   
Tolerability is an issue in this study.  The drug specific effects of diplopia and 
dizziness were significantly increased in both active arms leading to ‘Number 
Need to Harm’ (NNH) of 6.25 and 4.54 for group P and PK respectively.  This 
therefore may justify a dose-finding (or even a ‘duration-finding’) study, to 
improve tolerability of the regimen. 
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4.5.1 Study limitations 
There is an argument to be made for the use of continuous scales such as the 
Visual Analogue Scale (VAS) to increase accuracy, as compared to the 11-point 
NRS. However the use of NRS is proposed by the National Institutes of Health 
‘Toolbox’ for acute pain and analgesic efficacy studies (165). The overall 
consensus in the current literature suggests the appropriate use of NRS in 
unidimensional settings of pain intensity, such as this trial (166). 
Face to face assessment of patients at three and six months was logistically 
impossible given the large geographical catchment area of our hospitals, 
extending throughout South East England and as far as South Wales. It is 
however acknowledged that phone call interviews may lead to reporting bias. 
This was minimised by the use the S-LANSS tool, which is validated for use with 
phone interviews(147), as well as structured, script-based assessments of PPP as 
set out in Appendix Four and Five. 
This study is underpowered for comparisons between the active arms, as this 
would likely have involved many hundreds of patients with associated costs and 
timelines, which were deemed not feasible.  
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A fixed dose regimen was used on all patients regardless of weight. In addition, 
there was no scope within this study to titrate dose to individual response or 
tolerability.  A more complex design may have made this possible, but in fact may 
not be a practical solution for the routine clinical setting. Further studies at fixed 
lower doses or for shorter periods of administration may be useful to find the 
best risk-benefit ratio and most effective solution. 
The powerful effect of the active arms on acute pain and opioid use may have led 
to unblinding of patients and care givers.  Some of this may have been offset by 
the use of active placebo (e.g. benzodiazepines.) An alternative approach is to 
formally assess the extent of blinding with questionnaires. In any future work, I 
would interview patients and investigators to assess the degree of blinding 
maintained throughout the study. 
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4.5.2 Conclusions 
This clinical trial suggests a large effect of pregabalin on both acute and chronic 
pain outcomes following cardiac surgery, which translates into long term 
improved quality of life and function.  While impacting on tolerability, in terms of 
diplopia, the large reduction in opioid use may be leading to overall improved 
recovery and shortened length of stay in hospital. 
Having demonstrated proof-of-concept as regards the preventive properties of 
pregabalin in the cardiac surgical population, this justifies a multi-centre 
pragmatic randomised-controlled trial to definitively assess whether this 
intervention can demonstrate effectiveness in the ‘real world’. 
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Chapter 5  Quantitative Sensory Testing 
of perioperative pain pathways 
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5.1 Introduction 
Pain is a complex and multifaceted sensory, as well as emotional, experience. A 
complete description of the pain experience is therefore unlikely to ever be 
possible.  
Certain aspects of nociceptive processing in humans can however be studied to 
give some insight into the overall pain experience.  
Historically, clinicians took the view of a linear, hard-wired system with a 
‘Descartian’ flow of pain information from the periphery to the central nervous 
system, in order to allow processing and interpretation (Figure 5.1). 
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Figure 5.1 Descarte and the History of Pain Theory 
(http://en.wikipedia.org/wiki/History_of_pain_theory Accessed 10/12/14) 
 
However this ‘Cartesian’ linear explanation of pain transmission is unable to 
explain the variability in response between individuals to a standard stimulus.  It 
is also unable to account for modulation of pain in different circumstances and 
over longer periods of time (167).   
In recent times, work led by Melzack and Wall transformed the understanding of 
the modulation of pain processing pathways. This, in turn, has led to the 
understanding of descending mechanisms, inhibitory or facilitatory, which result 
in reduction or amplification of pain signals, respectively (168). 
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Quantitative Sensory Testing (QST) is one method to assess these pronociceptive 
(or facilitatory) mechanisms, in tandem with opposing antinociceptive (or 
inhibitory) pathways, in order to establish their relative roles in the overall 
perception of pain (169).  This approach to pain testing allows quantitative 
assessment of evoked responses to standardised activation of the nociceptive 
system but with the advantage that, unlike clinical pain, experimental stimulus 
intensity, duration and modality are controlled and fixed over time. Only the 
response is patient-dependent and variable. 
QST can also act as a more objective measure of the efficacy of an analgesic, as 
compared to subjective assessment based on pain scores, or secondary effects 
such as analgesic requirement in the setting of a painful condition (170). 
I reviewed the QST literature to establish the modes and assessment most suited 
to the perioperative setting, as set out in detail in Chapter Two.  
5.1.1 Pain thresholds 
Response to experimental pain can be described at one of three levels: 
1. Pain threshold: stimulus required to elicit baseline pain (i.e. level of first 
perceiving an increasing stimulus to be painful) 
  142        
2. Suprathreshold: fixed stimulus causing pain but with measurement of an 
individual’s response (e.g. pain score) 
3. Pain tolerance: maximum tolerable stimulus, in terms of pain 
These static surrogate measures of the pain experience provide a single snapshot 
of perceived pain.   
An alternative is to dynamically challenge the nervous system, in order to engage 
any modulatory mechanisms, either inhibitory (antinociceptive/analgesic) or 
facilitatory (pronociceptive).  These modulatory neuroplastic mechanisms are 
difficult to measure with static assessments of pain threshold, as they (by 
definition) require comparisons over time or space.  If included though, they do 
however potentially allow an assessment of the whole range of the persistent 
pain experience (figure 5.2): 
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Figure 5.2 Hierarchy of pain processing leading to the pain experience 
 
This dynamic testing, or ‘challenge’ to the nervous system, has led to a shift away 
from symptom-based pain description and towards a mechanism-based 
approach to diagnosing, profiling and potentially treating persistent pain (96). 
The perioperative setting is distinct from widespread pain conditions as the 
source of pain is specific and localised.  Likewise the effects of systemic analgesia 
in widespread pain conditions can be tested at any point on the body but, in the 
case of PPP, require peri-incisional testing. This has implications in terms of 
feasibility of testing around, for example, recently closed and dressed incisions.  
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However these peri-incisional measurements can be compared to more remote 
sites, in order to make the distinction between local (peripheral) and distant 
(central) changes - such as sensitisation. 
5.1.2 Hyperalgesia and Central Sensitisation 
Summation, as one example of the facilitation of pain, can be tested by repetitive 
stimulation. This provides a clinical (or in vivo) means of testing the in vitro 
phenomenon of wind-up, both of which act as indirect indicators for central or 
spreading sensitisation. 
An alternative method for assessing sensitisation away from the site of tissue 
injury is to repeat the threshold-level stimulus - but at some distance from the 
incision.  By approaching the incisional site and recording the point at which 
pain is first elicited, this allows another measure of hyperalgesia termed the 
‘zone of hyperalgesia.’ Again this is relevant only when pain is localised (e.g. 
incisional) as opposed to widespread pain e.g. fibromyalgia. 
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Static measurements can also be useful when compared over time.  A fall in pain 
threshold before and after surgery, for example, constitutes hyperalgesia and 
therefore adds a dynamic, temporal component to the assessment. 
As well as establishing baseline values for comparison postoperatively, these 
pre-operative assessments also provide information for exploring risk factors for 
PPP.  This is described further in the following chapter, in terms of attempts to 
phenotype patients before surgery, and to stratify the risk of developing PPP  
These assessments of central sensitisation and hyperalgesia are by no means 
exhaustive, but instead provide a pragmatic battery of portable tests suitable to 
the testing of high-risk patients in the clinical setting. 
An established and validated protocol exists for performing QST, specifically to 
allow the phenotyping of neuropathic pain patients. This protocol developed by 
the German Research Network on Neuropathic Pain (DFNS) has made the 
translation from a research tool to a clinically applicable measure, albeit 
requiring considerable time and resource in the pain QST laboratory with the 
patient. 
 My aim however was to develop a portable and reproducible (‘at the bedside’ or 
‘point of care’) protocol to allow real-world, pragmatic, clinical assessment in 
  146        
less than hour. I therefore modified the DFNS protocol to suit the perioperative 
pain environment and in particular to incorporate dynamic pain challenges, 
simulating the additional surgical insult which takes place on the background 
setting of a functional (generally pain-free) nervous system. 
This tailored approach is designed to quantify the effects of analgesics on acute 
pain, as well as PPP, and to once again assess the effects of preventive analgesics 
in a prospective randomised controlled study. In this chapter, I present the 
findings from pre and postoperative QST assessments of the patients in the RCT 
described in the last chapter with the aim of studying the mechanisms of effect of 
the preventive analgesic regimens.  
In terms of pain assessments following cardiac surgery, this is the first 
mechanistic (QST) study of preventive analgesia following this type of surgery.  
Extrapolation to other types of chest surgery (e.g. thoracotomy or major breast 
surgery) needs to be treated with caution but this work has potential to assist in 
hypothesis generation for these similar surgical procedures and trajectories of 
PPP (14). 
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5.2 Methods 
As described in the previous chapter, I was granted ethics approval by the East 
London and the City Research Ethics Committee to study patients undergoing 
elective cardiac surgery.  As part of the approved protocol, all patients 
underwent QST assessments on the day before surgery as well as 
postoperatively while recovering from surgery. These tests were performed 
around the site of sternotomy as well as remotely on the forearm. 
The postoperative time period of four days was chosen to ensure that all patients 
were captured before discharge from hospital – given the minimum stay of five 
days in our hospitals.  However this was also late enough to ensure a steady and 
sustained effect of pregabalin, as well as the cessation of the ketamine infusion. 
All testing took place in a quiet environment with the patient in a comfortable 
semi-reclined (45 degree angle) position. Patients were asked to close both eyes 
for the duration of testing. 
5.2.1 Baseline measurements  
These were measured at four standard points on the chest around the planned 
site of surgery (midline sternotomy) at the level of the second and third rib 
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bilaterally and at 5 cm from the midline (marked as X on figure 5.3.) Remote 
measurements were taken on the right forearm at the mid point between the 
wrist and the elbow. 
Incision	
site	 Sternum	
X	 X	
X	 X	
Figure 5.3 QST testing sites 
X marks four testing sites at 5cm from the midline on the second and third rib 
bilaterally. Arrows indicate lateral starting points for zone of hyperalgesia 
testing, travelling at 1cm incremental steps, towards the X point. 
5.2.1.1 Mechanical pain detection thresholds 
Seventeen, progressively rigid, monofilament, von Frey fibres allowed the 
measurement of tactile pain detection thresholds (TPT) at the four standardised 
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points on the chest. These measurements were repeated on the right forearm to 
determine remote TPT.   
The filaments represent stimuli from 0.039 – 4386mN.  The TPT is defined as the 
least force that elicits a sensation of pain. The exact threshold is found by 
repetitive testing of ascending fibre sizes, until the same von Frey fibre elicits 
two similar responses in succession. 
These ascending von Frey filaments were applied perpendicular to the skin for 
one second and to the point of deformation of the fibre until the patient 
described pain.  
5.2.1.2 Central sensitisation assessments 
Temporal summation to mechanical stimulation, again as an indicator of central 
sensitisation, is performed with a von Frey fibre one reading below the TPT. This 
stimulation is performed at a frequency of 2HZ for 60secs, at the four test points 
as well as a control measurement remotely on the forearm.  NRS score increases 
of more than one point are reported as positive TS, as described in the literature 
(5, 82).  
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5.2.1.3 Measurement of pressure pain thresholds (PPT) 
This test measures sensitivity of peripheral pain pathways to increasing 
mechanical pressure. A hand held pressure algometer (Figure 5.4). (Somedic AB, 
Stockholm, Sweden) was used to measure PPTs at the same four standardised 
testing points on the chest as well as the remote (right forearm) site  
 
Figure 5.4 Pressure algometer (Somedic AB, Stockholm, Sweden) 
 
The diameter of the contact tip is 1cm2.  A standard pressure of 30 kPa/sec was 
applied perpendicular to the skin until the subject defined the pressure as pain. 
The mean of four, random-ordered, measurement points was used in analysis. 
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5.2.2 Postoperative assessment with QST 
Assessments were repeated to assess changes in pressure algometry-derived 
thresholds.  The percent change in values from baseline, following surgery, was 
calculated. 
In addition, two dynamic assessments of central sensitisation were carried out: 
Temporal summation at the site of surgery (peripheral sensitisation) in 
addition to remotely: on the forearm (central sensitisation.) The technique, 
described above, was repeated. 
 
 
Zone of secondary hyperalgesia measured with the VFH used to elicit 
pain at the standard four points – but instead stimulating from the lateral chest 
towards- and perpendicular to- the midline sternotomy. The VFH was advanced 
in one-centimeter increments (towards the X point on figure 5.3) until the first 
sensation of pain was achieved.  This distance from the midline sternotomy was 
measured using a paper tape measure. The sum of the four recording at each of 
the test points on the chest is used as a measure of secondary hyperalgesia and 
indicative of central sensitisation changes following surgery. 
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No further QST assessment took place. While pain assessments, in the form of 
structured questions, took place via phone call at three and six months, QST 
assessments were logistically impossible due to the large catchment areas and 
referral region of our hospitals – as far afield as South Wales. 
5.2.3 Statistical analysis 
As set out in chapter four, the study was powered against clinical outcomes of 
PPP and therefore there remains a potential for underpowering of the QST 
aspect of the study. No pilot QST data was however available for power 
calculations. 
Data is described in term of frequencies or means for the group, with 
comparisons based on logistic and linear regression respectively.  
5.3 Results 
The original QST data per patient is set out in Appendix Nine.  On analysis, the 
baseline values for the QST assessments were similar across all three 
randomisation groups, ensuring the groups are similar prior to treatment: 
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 Trial groupings Intra group 
comparisons x3 
 Usual 
care (UC) 
Pregabalin 
(P) 
Pregabalin & 
ketamine 
(PK) 
 
PPT Sternotomy 
site (KPa) 
242 (111) 281 (102) 275 (123) Non significant 
PPT remote (KPa) 232 (114) 290 (124) 266 (140) Non significant 
Percent change 
in PPT with CPM 
37.0 
(49.0) 
29.7 (25.9) 29.5 (40.9) Non significant 
Presence of 
preoperative 
temporal 
summation at 
sternotomy site 
17/50 
(34%) 
15/50 
(30%) 
14/50 (28%) Non significant 
Presence of 
remote 
temporal 
summation 
(forearm) 
10/50 
(20%) 
9/50 
(18%) 
9/50 (18%) Non significant 
Table 5.1 Baseline QST measurements 
Data is presented as mean (SD) or proportions (%) PPT = pressure pain threshold, CPM = 
conditioned pain modulation 
Both active arms demonstrate an increase in PPT when tested at a site remote to 
the incision (table 5.2). The control group however demonstrates a decrease in 
the PPT, indicating hyperalgesia (by definition.)  
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Similar testing at the site of sternotomy however reveals non-significant 
differences in hyperalgesia following surgery in the treatment arms.  It is 
possible to speculate the additional nociceptive pain has balanced out any 
benefit of anti-neuropathic effect of the trial drugs, leaving no overall benefit.
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 Trial groupings Between group differences 
(95% CI) 
Unadjusted comparison 
Between group differences 
(95% CI) 
Adjusted comparison* 
 Placebo = 
Usual care 
(UC) 
Pregabalin (P) Pregabalin & 
ketamine 
(P+K) 
UC vs. P UC vs. P+K UC vs. P UC vs. P+K 
% change  in 
PPT 
sternotomy 
site from 
baseline 
-11.9 
(41.3) 
-3.89 
(36.2) 
-10.3 
(37.6) 
7.99 (-7.42 to 
23.4) 
p=0.306 
1.57 (-14.1 to 
17.2) 
p=0.843 
-2.97 
(-5.74 to 24.64 
p=0.219 
3.39 
 (-12.58 to 19.35 
p=0.67 
%change in 
PPT remote 
from baseline 
-19.6 
(31.8) 
8.70 
(32.9) 
15.7 
(45.9) 
28.3 (11.7 to 
44.8) 
p=0.001 
35.3 (14.9 to 
55.7) 
p=0.001 
25.60 (10.26 to 
40.95) 
p=0.02 
37.766 
(17.115 to 
58.42) 
p=0.001 
New TS at 
sternotomy 
site 
17/50 3/50 2/50 0.136 (0.037 
to 0.503) 
p=0.003 
0.089  
(0.019 to 0.411) 
p=0.002 
0.012 
(0.00 to 0.21 
p=0.003 
0.011 
(0.00 to 0.21) 
p=0.003 
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New TS at 
remote site 
16/50 
(32%) 
5/50 
(10%) 
3/50 
(6%) 
0.236 (0.079 
to 0.708) 
p=0.010 
0.136 (0.037 to 
0.503) 
p=0.003 
0.153 
(0.041 to 0.569) 
p= 0.005 
0.061 
(0.012 to 0.318) 
p = 0.001 
Loss of TS at 
sternotomy 
site 
4/50 
(8%) 
4/50 
(8%) 
7/50 
(14%) 
1.00 (0.236 to 
4.24) p=1.000 
1.872 (0.512 to 
6.85) 
p=0.343 
1.23 (0.885 to 
3.25) p=0.657 
1.855 (0.415 to 
5.44) 
p=0.564 
Loss of TS at 
remote site 
2/50 
(4%) 
6/50 
(12%) 
5/50 
(10%) 
3.27 (0.627 to 
17.0) p=0.159 
2.67 (0.492 to 
14.4) p=0.255 
3.98 (0.549 to 
12.8) p=0.342 
2.01 (0.593 to 
12.9) p=0.337 
Zone 
hyperalgesia 
34.9 
(19.0) 
18.8 
(15.2) 
14.2 
(12.1) 
-16.14 
(-22.97 to -
9.31) 
p <0.001 
-15.60  
(-21.76 to -9.44) 
p <0.001 
-20.73  
(-27.04 to -
14.42) 
p <0.001 
-20.77  
(-27.15 to -
14.39)  
p <0.001 
Table 5.2 QST changes dependent on treatment arm 
Proportions with odds ratios or mean difference (95% CI) and p values 
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Although comparisons for PPP between the two active arms are limited due to 
underpowering- see Chapter Four- I nevertheless carried out an exploratory 
analysis for effect of additional ketamine on zone of hyperalgesia.  This was 
performed as a post hoc analysis, as ketamine is believed to reduce hyperalgesia 
in a more effective manner than other agents, such as pregabalin. 
This exploratory analysis reveals a mean reduction in the zone of 4.59 cm with 
the addition of ketamine (95%CI 10.0 to 0.866) giving a non-significant p value 
of 0.098.  This is again likely to be due to underpowering, but provides a signal 
that ketamine may potentially have an effect on hyperalgesia, if tested in a larger 
study population. The effect of ketamine in isolation is difficult to assess 
adequately, however, as it was administered in a multimodal arm along with 
pregabalin.  
A similar analysis for all other dynamic, as well as static QST measures, between 
the two active arms reveals non-significant differences.  As an example: 
comparison of new TS at the chest reveals a B value of 0.653 (95% CI of 0.104 to 
4.085) p =0.648 and, similarly, new TS remotely gives a B value of 0.574 (95%CI  
0.130 to 2.55) and p= 0.465  
5.4 Discussion 
Both active arms demonstrated the potential to mitigate the development of the 
indirect markers of central sensitisation as shown by the results for TS and Zone 
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of Hyperalgesia. That pre-existing TS was not shown to subside significantly may 
be a reflection of the relatively short interval of four days between baseline and 
post-operative measurements, and/or continuing post-operative pain signals 
maintaining central sensitisation at this time.   
Both drugs seem to increase PPT.  This is surprising and contradicts previous 
work demonstrating the stability of PPT (171), even with analgesics. However 
this may reflect the anti-neuropathic effects of pregabalin or ketamine and 
therefore may give an indication of the mechanism of action of these drugs. 
QST is used to assess small fibre sensory function and therefore is able to 
describe abnormalities in these fibres when associated with pain states.  My 
results therefore add weight to the argument that the early development of PPP 
is unrelated to large fibres changes following nerve injury, transection or 
contusion.  This therefore adds doubt to the hypothesis of inadvertent 
intraoperative nerve injury and the potential for protecting patients by early 
identification and elective transection of nerves (81). One way to reconcile these 
differences is to accept the fact that PPP demonstrates different features 
following different procedures – procedure specific study is the only way to 
confirm this. 
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5.4.1 Limitations 
Pain pressure thresholds were measured instead of supra threshold 
measurements or pain tolerance.  This may have limited the sensitivity of 
assessments (5, 101).  
Published work from settings other than PPP, in particular pre clinical studies, 
use Wind Up Ratios as a means to comparing changes in pain as a result of the TS 
test. I chose to use the alternative TS technique of assessing any increase in pain 
as a positive test (5, 82).  It is possible to speculate that the results may have 
varied with the WUR approach as well as providing continuous ratio data for 
analysis, increasing statistical power, for example, as compared to binary 
outcomes.   
Certain QST assessments were underpowered.  I may have considered powering 
against all secondary outcomes, including QST, rather than simply the primary 
outcome of PPP.  This would however have necessitated a prospective pilot 
study of the RCT prior to the main recruitment. 
QST was found to be impractical around a dressed saphenectomy leg wound and 
therefore this study is only able to comment on post-sternotomy changes. Ideally 
this could have been carried out a later stage e.g. follow-up outpatients clinic 
once all dressings had been removed. 
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5.4.2 Conclusions 
Evidence is presented for an objective and mechanistic assessment of the 
efficacy of pregabalin in preventing PPP.  This ability to measure the sensory 
changes present during surgical pain states hold great potential to allow further 
study of the transition to PPP as well efficacy studies of analgesics, acute as well 
as preventive. 
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Chapter 6  Making Predictions – 
Towards the identification of individuals 
at risk of developing PPP 
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6.1 Introduction 
"Prediction is very difficult, especially if it's about the future." 
 
Figure 6.1 Nils Bohr; Nobel Laureate in Physics 
Available at http://micro.magnet.fsu.edu/optics/timeline/people/bohr.html Accessed on 10/12/14) 
The prevalence of chronic pain in society is increasing, with new as well as 
established therapies not necessarily improving outcomes in patients with 
persistent pain (172).  Neuropathic pain is particularly difficult to treat (173).  
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Likewise, established PPP (of any type) is often resistant to treatment (174). 
Prevention of PPP, in the form of pharmacotherapy, therefore holds great 
promise - but varying tolerability remains an issue due to drug side effects. The 
early identification of high-risk patients to allow targeted therapy is an attractive 
solution to this dilemma.  
Phenotyping of patients based on their psychophysical and neurophysiological 
response to experimental pain is one such approach to risk profiling. 
In the previous chapter, I discussed the use of QST as a method for measuring 
postsurgical pain as well as analgesic response.  Differences in response to 
standardised stimuli were described when antihyperalgesic agents were applied 
to the perioperative setting.  However three questions remain to be answered: 
1. Do pre-operative pain challenges simulate surgical pain and therefore 
predict the nervous system response to subsequent surgical insult? 
2. Do early QST changes following surgery predict long term outcome?  
3. Can we predict PPP with methods other than QST? 
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6.1.1 QST as a means to phenotyping high risk patients 
Quantitative sensory testing (QST) measures input–response relations within 
the nervous system, allowing detection and quantification of nociceptive 
neuroplasticity (96). This nervous system input-response relationship is very 
different though from the overall pain experience and its clinical assessment, in 
terms of pain score or secondary effects on analgesic consumption (175). 
As an experience, pain is both subjective and ubiquitous and therefore its 
objective assessment at any given point in time poses challenge. Dynamic, 
repeated measurements over time can however increase the likelihood of 
capturing the real pain experience by engaging descending pathways, to give an 
integrated response.  
Descending pain modulatory circuits exist to allow filtering of nociceptive 
transmission by the central nervous system, in order to inhibit or facilitate input 
- to varying degrees, under differing conditions. This so-called ‘top down’ control 
of pain is greatly influenced by emotional and cognitive factors as a result of 
connections in the brainstem centres of the medulla. 
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6.1.1.1 Conditioned Pain Modulation 
HIPPOCRATES:  ‘‘If two sufferings take place at the same time, but 
at different points, the stronger makes the weaker silent’’ 
 
Figure 6.2 Hippocrates; Roman portrait bust 
(Available at http://en.wikipedia.org/wiki/Hippocrates Accessed 10/12/14) 
The ability of an organism to moderate and influence pain impulse from the 
periphery in a ‘top-down’ manner is termed “counter irritation” or diffuse 
noxious inhibitory control (DNIC.)  This DNIC-like effect can be simulated in 
humans by applying a painful stimulus while measuring pain in a secondary site, 
using QST. This platform or protocol of testing in humans is termed Conditioned 
Pain Modulation (CPM) and its inefficiency, or limited ability to reduce the 
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intensity of pain experienced in the secondary site, is linked to idiopathic pain 
syndromes such as fibromyalgia and temporomandibular joint (TMJ) pain. This 
phenomenon has been described in terms of an ‘endogenous analgesic system’ 
(49, 106). There is some evidence for its inefficiency in persistent pain following 
injury - as well as return of efficiency following the removal of peripheral painful 
stimulus e.g. in the case of knee replacement for osteoarthritis (176). 
This has led to a field of work investigating the physiological mechanisms 
underlying the ability of some individuals to modulate their response to painful 
stimulus via intact or efficient CPM (105), while others are inefficient – and, at 
the extreme end of the biological spectrum, may be pronociceptive and in fact 
summate (105, 177, 178). 
In addition to this diffuse effect of CPM (mediated at the spino-bulbar-spinal 
level) there is also another important descending pain modulatory circuit 
contributing to the net stimulus reaching the central nervous system. 
The RVM (rostral ventromedial medulla) communicates with the periaqueductal 
gray of the midbrain to generate pro or antinociceptive actions from ON or OFF 
cells, respectively.  The balance shifts from predominantly ON in acute 
inflammation to a more even balance as healing takes place.  However, in 
persistent pain states, an imbalance is maintained, whereby normally mild, 
innocuous stimuli continue to activate ON cells. Pain transmission therefore 
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remains disinhibited, leading to hyperalgesia and allodynia.   
These facilitatory and inhibitory pathways can be examined in isolation in 
preclinical models.  In human experimental models, however, the net effect is 
seen. For example, ischaemic arm pain in humans increases the pain threshold 
measured at the forehead or at the dental pulp (179).  These changes are 
maintained with removal of the conditioning stimulus and therefore reflect more 
than distraction. 
The relative contribution of the different descending modulatory systems is 
variable and dynamic.  Therefore further understanding of their function and 
role before and after surgery in controlling transmission has potential to help 
understand an individual patient’s risk of developing PPP.  
Most of this work has been carried out in patients with established chronic pain, 
especially idiopathic disorders such as TMJ and fibromyalgia.  One study 
investigating new PPP, in pain free patients, demonstrated the correlation 
between preoperative CPM and resulting thoracotomy pain at six months with 
OR of 0.52 (0.33–0.77 95% CI, p = 0.0024 in only 62 patients) (180).   
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6.1.1.2 Temporal summation 
As described in the previous chapter, temporal summation is the in vivo 
equivalent of wind up demonstrated in spinal wide dynamic range (WDR) 
neurons and is enhanced in certain idiopathic pain syndromes.  Although I 
demonstrated changes in this phenomenon with the use of antihyperalgesic 
agents at the time of surgery, there is potential to examine whether pre-existing 
TS, as well as early changes in TS following surgery, can predict the development 
of subsequent PPP. Only one study in the literature demonstrates predictability 
of acute pain with preoperative TS but the patients are not followed up for PPP 
(82). 
When combining ischaemic heart disease patients with those with valve disease, 
there is an even greater consideration to be made for the role of pre-existing 
central sensitisation in the chest from, for example, long standing ischaemic 
visceral pain.  Therefore, it was also necessary to examine all patients 
preoperatively for preexisting sensitisation (in the form of temporal summation, 
for example), in order to take into consideration this potential confounder. 
6.1.2 Psychological vulnerability and resilience as a predictors of risk 
No data is available, to the best of my knowledge, regarding the effects of 
preoperative anxiety or catastrophising on PPP following cardiac surgery.  
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In chapter two, I set out the PPP literature in terms of psychological comorbidity 
and, in particular, trait.  There is good robust evidence for the role of anxiety trait 
in particular (including following cardiac surgery) but with conflicting evidence 
for state anxiety.  The evidence base is also increasing as regards catastrophising 
but with little evidence to date in the cardiac surgical setting (67). The thoracic 
surgery literature is better developed (77).  I therefore investigated the effect of 
state anxiety and catastrophising (using the tools set out in Appendices Two and 
Three) on PPP specifically in the cardiac surgical population. 
6.1.3 Patient and surgical risk factors for PPP 
Finally, the potential roles of patient demographics (age and gender), as well as 
surgical characteristics (of prolonged operation and poorly managed acute pain), 
are discussed in the analysis of a cohort of 174 patients in chapter three.  This 
study allows corroboration of these findings. 
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6.2 Methods 
To address the question of predictability, I analysed five potential predictors: 
1. Perioperative QST changes, as described in the previous chapter 
2. Baseline measurements of CPM 
3. Psychology assessments of state anxiety and catastrophising 
4. Patient demographics of age and gender 
5. Surgical risk factors (duration of surgery, LIMA harvest and acute pain.) 
6.2.1 Perioperative QST changes 
As set in the previous chapter, QST changes were observed as a result of surgery 
and, in particular, the treatment allocated by randomisation. However it is 
possible to speculate that these early perioperative changes may give indication 
of the transition from acute pain to more persistent changes in pain processing 
leading eventually to PPP. This could apply to patients receiving usual care as 
well as those benefitting from preventive analgesia.  
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6.2.2 Conditioned Pain Modulation (CPM) 
A key component of conditioned pain modulation is engagement of the 
endogenous analgesic system to reduce pain intensity or increase threshold to 
pain detection or tolerance. CPM was therefore calculated as the difference in 
algometer-derived PPT reading following the application of the conditioning 
remote noxious stimulus.  
 
Figure 6.3 Pressure algometer (Somedic AB, Stockholm, Sweden) 
 
Conditioning was chosen as ischaemic arm pain (figure 6.4). This is an accepted 
procedure in cardiac surgical patients as part of the remote ischaemic 
preconditioning (RIPC) platform for cardioprotection (181).  Therefore the 
logistics – and indeed risks to the patient of preoperative severe pain increasing 
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risk of stress and ischaemia- were specifically addressed. It also lends itself to 
bedside testing, unlike a thermal testing protocol, for example, where high-risk 
cardiac surgical patients may need to leave the monitored, clinical setting to 
attend the pain QST laboratory. 
The pain challenge component of CPM was achieved by inflating the right arm to 
250mm Hg for 15 minutes - or to the point where a NRS of 5/10 in that arm.  In 
the case that this was not achieved by the end of the 15 minutes of inflation, the 
cuff was further inflated in 10mm Hg increments to eventually achieve this pain 
score.  Two patients remained refractory to this level of ischaemic pain and they 
were asked to clench their right fists in order to achieve adequate intensity of 
ischaemic pain. PPT measurements were repeated at this point (figure 6.3) to 
measure the CPM effect.  
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Figure 6.4 Ischaemic arm pain challenge 
6.2.3 Psychology 
All patients completed the Spielberger state anxiety and Pain Catastrophising 
Scale questionnaires following recruitment to the study (Appendix Two and 
Three respectively.) 
The Spielberger state anxiety inventory (Appendix Two) is a widely used 
instrument for measuring transient and therefore preoperative levels of anxiety. 
The scale contains 20 items, with each question being scored on a four-point 
Likert scale. This instrument has been validated widely and exhibits excellent 
test-retest reliability (182). 
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Catastrophising is a well-known descriptor for baseline neuroticism and a likely 
contributor to persistent pain states (65). Most of the robust evidence, including 
meta-analysis of data, has taken place over the last three years and therefore 
since the start of this study.  However the Pain Catastrophising Scale (Appendix 
Three) is a long-standing, validated tool for assessing pain-specific features - as 
set out in Chapter 2 - and each patient completed this following recruitment to 
the study. 
6.2.4 Patient demographics and features of surgery 
As described in chapter four, baseline features of age, gender, duration of 
surgery and dissection of the chest wall artery (LIMA) are similar across groups 
but this data allows comparison for the ability of these factors to predict 
subsequent PPP. 
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6.3 Results and Discussion 
6.3.1 Perioperative QST changes 
Analysis of QST data (presented in Appendix Nine) was initially carried out for 
all 150 patients and then repeated for the control group, to assess for any 
confounding effect of the active drugs and to allow objective assessment of the 
relationship between QST values (dependent on treatment allocation) and pain 
outcomes.  
Assessments of PPT at the chest, before surgery and changes following surgery, 
in both the control arm and the full set of patients are not powerfully predictive 
of PPP (with the full set of patients only just reaching significance.) 
 All 150 patients Control arm only 
Pre op PPT 0.997 (0.993 to 1.00) 
p=0.104 
0.998 (0.993 to 1.00) 
p=0.430 
Delta PPT (% change) 0.987 (0.974 to 0.999)  
p=0.041 
0.990 (0.975 to 1.00) 
p=0.180 
Table 6.1 Logistic regression analysis of the predictive power of perioperative QST 
changes at the surgical site 
B values, with 95%CI, derived from logistic regression modelling (p value) 
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Different results are found at a site remote to the surgical incision (right 
forearm.) The baseline PPT values at the remote site remain non-predictive but 
changes following surgery are strongly predictive: 
 All 150 patients Control arm only 
Pre op PPT 1.001 (0.997 to 1.00) 
p=0.735 
1.004 (0.997 to 1.01) 
p=0.233 
Delta PPT (% change) 0.936 (0.908 to 0.965)  
p=<0.001 
0.921 (0.873 to 0.971) 
p=0.003 
Table 6.2 Logistic regression analysis of the predictive power of perioperative changes at 
a remote site 
B values, with 95%CI, derived from logistic regression modelling (p value) 
6.3.1.1 Baseline TS measurements  
These measurements were taken at the sternotomy site and remote testing 
points, as set out in table 6.4 below.  
Pre operative recordings at the sternotomy site fail to significantly predict PPP  
(B=0.478 [0.213-1.073] p =0.074). Although statistically non significant, this 
could provide a useful signal of the contribution of ischaemia-driven visceral 
hypersensitivity, for example, as discussed in the conclusions section of this 
chapter. 
Away from the chest, where there is potentially less contribution from visceral 
hypersensitivity of ischaemia, there is no such signal:  B=0.993 [0.365-2.703] 
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p=0.989 
6.3.1.2 Changes in TS measurement 
Development of new TS following surgery is however powerfully predictive of 
subsequent PPP: 
 All 150 patients Control arm only 
New TS Sternotomy site 12.3 (4.38 to 34.8) 
p=<0.001 
7.944 (1.884 to 33.5) 
p=0.005 
New TS remotely 13.75 (5.07 to 37.3)  
p=<0.001 
14.6 (2.82 to 80.0) 
p=0.010 
Table 6.3 Logistic regression analysis of the predictive power of new TS 
B values, with 95%CI, derived from logistic regression modelling  
6.3.1.3 Measures of zone of hyperalgesia  
As well as TS assessments of central sensitisation, the zone of hyperalgesia is 
also highly predictive, with control arm B values of 1.059 (1.02 to 1.10) p= 0.003 
and grouped analysis of 150 patients revealing B= 1.071 (1.043 to 1.10) with 
p<0.001  
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6.3.2 Combined analysis of risk factors unrelated to treatment allocation 
The differences in predictability between the control arms and across all 
randomisation groups could reflect a strong masking effect of the treatment arm. 
One way to examine to examine this is to analyse all 150 patients and repeat the 
analysis in the control arm alone: 
Full 150 patient analysis: 
PREDICTOR B  (95% CI) P value  
Randomisation group B=0.162 [0.077 – 0.339]   p<0.001 ** 
Age  B=0.980 [O.950 – 1.010]   p=0.189 
Sex   B=0.806 [O.323 –2.011]   p=0.645 
Weight (kg) B=1.018 [O.992 – 1.045]   p=0.171 
Pre op Eq-5D index B=0.343 [0.105-1.118] p=0.076 
Spielberger state anxiety B=1.057 [1.019-1.097] p=0.003** 
Catastrophising B=1.055 [1.021-1.089] p=0.001** 
PPT Change with CPM B=0.987 [0.976-0.999] p=0.033* 
Preoperative presence of 
TS Sternotomy site   
B=0.478 [0.213-1.073] p=0.074 
Preoperative presence of 
TS remote  
B=0.993 [0.365-2.703] p=0.989 
Duration of surgery 
(minutes) 
B=1.000 [0.995-1.004] p=0.858 
Surgical technique  B=0.594 [0.255-1.381] p=0.226 
Table 6.4 Predictive factors across all treatment arms 
B values, with 95%CI, derived from logistic regression modelling (p value) 
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Control arm analysis (50 patients): 
PREDICTOR B  (95% CI) P value 
Age  B=0.940 [O.890 – 0.992]   p=0.026* 
Sex   B=1.000 [O.291 –3.437]   p=1.000 
Weight (kg) B=1.025 [O.988 – 1.064]   p=0.183 
 
Pre op Eq-5D index B=0.046 [0.004-0.556] p=0.016* 
Spielberger state anxiety B=1.091 [1.026-1.159] p=0.005** 
Catastrophising B=1.103 [1.038-1.172] p=0.002** 
PPT Change with CPM B=0.984 [0.971-0.998] p=0.026* 
Preoperative presence of 
TS Sternotomy site   
B=0.837 [0.259-2.700] p=0.765 
Preoperative presence of 
TS remote  
B=1.658 [0.405-6.785] p=0.482 
Duration of surgery 
(minutes) 
B=1.011 [1.000-1.021] p=0.045* 
Surgical technique  B=0.826 [0.246-2.776] p=0.758 
Table 6.5 Predictive factors for control arm only 
B values are presented, with 95%CI, derived from logistic regression modelling (p value) 
PPT =pressure pain threshold, CPM = conditioned pain modulation, TS =temporal summation 
6.3.3 Treatment effect analysis 
Another means to consider the potentially powerful effect of the intervention is 
to carry out analysis of ‘treatment effect interaction’ (183). 
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This analysis involves multivariate regression modeling of three separate 
factors: 
 Any given potential predictor 
 Randomisation group 
 PRODUCT of the randomisation group and predictor (randomisation 
group*predictor) 
 
 
 
This technique of analysis reveals products, which are non-significant for all the 
factors in table 4, with the exception of TS at the sternotomy site and duration of 
surgery (p=0.039 and p=0.026 respectively.) As these analyses are carried put 
post hoc and the p values are reasonably close to zero, these exploratory findings 
are not strong enough to draw any further conclusions. 
6.3.4 Is the treatment able to protect vulnerable phenotypes? 
Another established way to quantify the degree of protection provided by the 
intervention is to measure the degree of variance predicted by a particular tool 
across the randomisation groups (107).  I chose the powerful predictability of 
CPM and analysed Pearson’s correlations with PPP scores at three months:  
All 150 patients r=-0.218 i.e. 21.8% of the variance in NRS at three months is 
predicted by CPM response (p=0.007). 
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Next I present a group-by-group analysis of the degree of variance of CPM: 
 UC group  -0.328 = 32.8%  (p=0.020) 
 P group  -0.174 = 17.4% (p=0.231) 
 PK group  -0.089 = 8.9% (p=0.543) 
This decrease in the contribution of CPM to subsequent PPP, in both active arms, 
again demonstrates a potential treatment effect interaction or protective effect 
and introduces the concept of ‘protective’ analgesia rather than simply 
‘preventive’ analgesia (110). 
6.3.5 Is QST able to predict drug efficacy? 
It is difficult to test whether QST can predict drug efficacy, as the treatment arms 
were so effective. However comparing pain and pain free patients in the (pooled) 
active arms may suggest prognostic indicators, in terms of QST measures (table 
6.6): 
 
  182        
Potential QST 
predictor 
PPP patients Pain free patients Between group 
differences 
Pre op TS 
Sternotomy site 
5/7 18/93 7.19 (1.31 to 39.5) 
p=0.023 
Pre op TS remote 4/7 11/93 1.93 (0.343 to 
10.8) p=0.457 
New TS 
sternotomy site 
1/7 4/93 3.71 (0.356 to 
38.6) p=0.273 
New TS remote 2/7 6/93 5.80 (0.924 to 
36.4) p=0.061 
% change with 
CPM 
6.94 (12.8) 31.3 (39.0) 24.3 (-5.19 to 
53.8) 
p=0.105 
% change in 
postoperative PPT 
at sternotomy 
-25.7 (53.2) -5.69 (35.3) 20.0 (-8.53 to 
48.6) 
p=0.167 
% change in 
postoperative PPT 
at a remote site 
-59.5 (31.2) 13.3 (38.8) 72.8 (-5.57 to 
151) 
p=0.068 
Zone of 
hyperalgesia 
24.9 (17.9) 15.9 (13.4) -9.00 (-19.8 to 
1.62) p=0.095  
Table 6.6 Potential predictors in patients receiving active drug 
Proportions or means (SD); Between group differences are presented as odds ratios or mean 
differences (with 95% confidence interval.) Logistic regression for proportions and linear 
regression for continuous data. QST = quantitative sensory testing, PPT= pressure pain threshold, 
CPM = conditioned pain modulation, TS = temporal summation, %= per cent, PPP = persistent 
postsurgical pain. 
6.4 Conclusions 
My main finding from this study suggest that dynamic assessment of patients is 
the most useful preoperative assessment of a patients likelihood of developing 
PPP following cardiac surgery.  
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This could be considered analogous to the use of experimental exercise stress 
testing (CPEX – cardiopulmonary exercise testing) prior to major surgery as a 
lab-based simulation to the whole body stress of undergoing major surgery at a 
later date.  Rather than statically testing individual organ systems (chest x-ray, 
echocardiogram, etc.) the predictability of risk and outcome is greatly increased 
by a dynamic challenge of the whole system, engaging adaptive and 
compensatory mechanisms (figure 6.5). 
 
Figure 6.5 Cardiopulmonary exercise testing before surgery 
(Available at http://www.wikidoc.org/index.php/Cardiopulmonary_exercise_testing Accessed on 10/12/14) 
Static preoperative parameters are not predictive. It is possible to speculate that 
the use of suprathreshold rather than threshold measurements may have 
improved this component of the study (5). 
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However a decrease in PPT following surgery, essentially hyperalgesia, is 
predictive and could potentially be used as a tool for predicting outcomes. This 
contradicts a large study in hernia surgery with follow up assessments at three 
and six months revealing that temperature thresholds were not predictive (5) 
This is likely resulting from surgical site testing (groin) in this latter study of 
hernia surgery but, in my study, may be related to the use of pressure-based 
threshold measurements – this may be more applicable to musculoskeletal pain 
following chest closure. 
CPM is able to predict PPP but not acute pain (according to the literature.) This is 
suggestive of different contributions towards pain persistence.  Tissue damage in 
the immediate postoperative period is reflected in the amount of acute pain 
reported.  It is therefore possible to speculate that a modulation system may not 
yet be able to impact on this new insult. Over time however, it may be able to 
adapt and therefore affect the amount of pain perceived by the individual i.e. PPP 
(107). 
New TS is able to predict PPP whereas pre-existing summation was not 
significant in this study.  This may reflect the fact that visceral hypersensitivity, 
for example, may already be engaging modulatory (mainly inhibitory) pathways, 
which have adapted to this need over time. Therefore they may not be flexible or 
responsive enough to account for additional new surgical insult.  A more likely 
explanation is the fact that this study was underpowered to detect this effect of 
pre-existing TS. Alternatively, there may be a unique feature of ischaemic 
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hypersensitivity (and therefore preexisting summation in these patients), which 
may not be sensitive to the classic TS platform. 
Preoperative quality of life (measured with the EQ-5D tool, as set out in 
Appendix One), state anxiety and catastrophising are all powerfully predictive, 
providing convenient and low resource methods for identifying patients at risk. I 
chose not to test anxiety trait as there exists a solid evidence base for trait but 
with conflicting evidence for the potential role of state anxiety (9) There was 
therefore a potential to overburden study participants with a further redundant 
questionnaire prior to extensive QST testing, both before and following complex 
surgery. However this could also be considered a limitation, as the opportunity 
to corroborate the predictive value of anxiety trait specifically, was not taken. 
Surgical technique does not seem to be predictive.  Patient age and duration of 
surgery could prove useful by increasing vigilance by care providers in the 
perioperative period, as well early and aggressive postoperative intervention, in 
younger patients or those having undergone prolonged surgery. 
Caution must also be exercised regarding extrapolation findings from one to 
other surgical procedures to another and therefore these findings to be 
corroborated in other procedures. 
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6.4.1 Limitations 
6.4.1.1 QST limitations 
CPM measurements were performed before surgery and not repeated in the 
postoperative period- unlike TS assessments. This was based on the idea that TS, 
- as a surrogate of central sensitisation - may be manipulated by antihyperalgesic 
agents, such as pregabalin and ketamine, whereas the descending inhibitory 
pathways are chiefly noradrenaline-mediated and therefore less likely to change 
with the use of these agents.  CPM may well change over time depending on pain 
load, or in tandem with the establishment of hyperalgesia and CS if they 
overwhelm this system. Duloxetine, for example, may be useful in modulating 
this noradrenaline based process and may have proved a more useful arm in this 
current study than the multimodal arm – in particular with repeated measures of 
CPM.   
QST was not performed at three and six months due to reasons of logistics as 
described in the previous chapter.  However it is possible to speculate that 
subsequent changes in descending inhibitory (or facilitatory) mechanisms may 
impact on the emergence of clinically reported PPP in patients with previously 
inhibited ‘subclinical’ hyperalgesia or CS.  
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6.4.1.2 Psychology testing and its limitations  
Self-report questionnaires/ instruments such as the Spielberger and PCS 
instruments described are convenient tools for measuring personality traits but 
have their limitations.  Most important of these are recall bias and social 
desirability. Recall bias is in turn affected by self-deception as well as social 
desirability. Social desirability is the tendency of the individuals to report what 
they think the experimenter wants to hear rather than an accurate self-report. 
This is particularly the case if the interviewer is a professional, especially a 
treating doctor. Structured interviews carried out by a third party may improve 
the accuracy of these measures but add to the complexity of the study, especially 
in the preoperative setting before major surgery. Therefore, it is important to 
bear these in mind when making intra-group comparisons.  However intergroup 
assessments as part of the perioperative RCT are less prone to bias as 
randomisation removes some of this variability. 
I have carried out grouped comparisons based on means or frequencies and not 
examined individual pain experiences or trajectories.  Chapman and colleagues, 
in particular, call for an approach of following individual pain trajectories (184) 
rather than group or population study.   
This also speaks to the idea of personalised medicine or individualised care 
where clinical and research activity aims to profile and identify responders or 
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“vulnerable” individuals e.g. for preventive RCTs.  The findings of this study 
contribute to this notion of personalised medicine where there is potential in the 
future to provide individuals with bespoke risk data and manage this risk 
accordingly. 
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Chapter 7  Conclusions and future work 
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7.1 Overview 
The overarching conclusion of this thesis is that PPP following cardiac surgery, 
while common, can also be predicted and potentially prevented.   
The hope is that this would lead to further work allowing the identification of 
PPP risk in individual patients, informed consent and early intervention to 
prevent long term pain and suffering following elective cardiac surgery. 
“It is easier to find men who will volunteer to die, than to find 
those who are willing to endure pain with patience.” 
 
Figure 7.1 Julius Caesar 
(Image available at http://en.wikipedia.org/wiki/Julius_Caesar Accessed on 10/12/14) 
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This is however the first ever study of the mechanisms of preventive analgesia in 
cardiac surgery and further study is therefore warranted to corroborate these 
findings and further explore dose and duration required to ensure both efficacy 
and tolerability. 
7.2 Summaries of individual chapters 
7.2.1 Study one (Chapter 3) 
39.7% of patients undergoing first time sternotomy in our hospitals describe 
PPP following elective cardiac surgery.  The age of the patient, duration of 
surgery and acute pain during the recovery period all seem to act as strong 
predictors for the development of PPP in his cohort study. 
7.2.2 Study two (Chapter 4.) 
The neuromodulatory effects of pregabalin on CS and hyperalgesia may be 
preventing the transition of acute postsurgical pain to PPP.  In addition, the 
effects of improved analgesia in the perioperative period seems to translate into 
reduced opioid requirement and shorter length of stay in hospital. 
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7.2.3 Study three (Chapter 5.) 
The effect of pregabalin in the perioperative period may be demonstrated by 
measures of: 
4. Increase in PPT at a site remote to the incision 
5. Prevention of the development of new TS 
6. Reduction in the zone of peri-incisional hyperalgesia 
7.2.4 Study four (Chapter 6.) 
The likelihood of developing PPP may be predicted by a combination of the 
following perioperative risk factors: 
1. Perioperative QST changes, namely in PPT (at a site remote to the incision), 
new TS and Zones of Hyperalgesia. 
2. Efficiency of CPM 
3. Preoperative quality of life (measured with EQ-5D) 
4. Levels of state anxiety and catastrophising 
5. Patient age  
6. Surgical risk factors (duration of surgery and acute pain but not surgical 
technique i.e. extent of dissection.)  
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7.3 Strengths and weaknesses 
This thesis demonstrates the significant morbidity and loss of quality-of-life 
associated with PPP following cardiac surgery. It also confirms the prevalence of 
this phenomenon in our patient population. Retroactive prevalence data is 
corroborated by prospective RCT outcomes. 
The randomised controlled trial was carried out in a double- blind, placebo-
matched manner and therefore represents the main strength of this thesis.  
Blinding was ensured by the use of inert placebos, in the form of lactose-
containing capsules and normal saline infusions.  However this carries a risk of 
unblinding of patients, clinical staff and investigator when the active drugs have 
demonstrable sedating and psychoactive properties.  
The use of active placebo with properties similar to the active drug may 
therefore have ensured blinding more thoroughly e.g. benzodiazepines, such as 
oral temazepam or intravenous midazolam. 
However this may have proved unsafe in the cardiac surgical setting, where the 
premedication also included an additional 20mg oral temazepam.  This therefore 
may have led to a significant risk of over sedation during the perioperative 
period in patients receiving placebo. 
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Furthermore, an appropriate active placebo for the psychoactive properties of 
ketamine may not exist.  The absence of a ketamine-only arm in the RCT 
however makes this less important when discussing active placebo in this 
particular study. 
The absence of a separate ketamine arm may be considered a limitation of this 
study.  While the combination of pregabalin and ketamine, as a multimodal 
intervention, represents an important step, the clinical trial may have benefited 
with an additional ‘ketamine only’ arm – accepting that this however adds 
another factor of complexity to a clinical trial.  
Similarly, it may have been useful to assess the effects of duloxetine - in a 
separate or multimodal manner- as a noradrenaline uptake inhibitor.  This is 
particularly pertinent given the powerful effect of CPM efficiency on the 
subsequent development of PPP. It is tempting to speculate that duloxetine may 
rescue patients with inefficient baseline CPM. 
Performing a prospective pilot study may have provided more robust data for 
the power calculation as well as providing pilot QST data for some of the 
underpowered components of the study, as described in chapters five and six. 
It is also important to consider the practical and pragmatic (‘real world’) 
translation of this work.  While these assessments are feasible in the research 
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setting, they may pose difficulties in terms of time, and therefore cost, in the 
clinical environment.  The test protocol duration of sixty minutes may not be 
feasible for all patients in a pre assessment clinic or on the day of admission for 
surgery. 
Given the relatively small number of patients investigated in each arm, these 
findings need to be corroborated in a large, fully powered, multi centre, phase-
three clinical trial, likely requiring many hundreds of patients. 
7.4 Potential for impact 
This work further confirms the phenomenon of PPP as a clinically relevant and 
societally important one. Interestingly this relatively understudied complication 
of surgery remains largely ignored in the consent of patients (185).  At the very 
least, this work should add to the growing body of procedure-specific literature 
on PPP to allow better-informed discussions with patients regarding the risks of 
elective surgery.  
This study represents a phase two clinical trial of pregabalin, specifically for the 
prevention of PPP in cardiac surgery. The next stage for this research question is 
the development of a multi-centre, suitably powered, phase three clinical trial to 
establish clinical effectiveness.  
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Although the QST component of this thesis is labour intensive, this is also worth 
pursuing within a trial infrastructure. In particular, the assessments of PPP at 
three or six months following cardiac surgery remain unexplored in the current 
literature. 
My studies also suggest a number of predictive tools, which may be useful in risk 
stratifying pain-free, pre-operative patients for the development of subsequent 
PPP. 
This also has the potential to subsequently personalise the perioperative pain 
management of the ‘at-risk’ surgical patient in terms of:  
1. Prehabilitation, or ‘Prehab’, including preventive analgesia but also optimising 
treatment of pre-existing pain conditions. 
2. Psychological screening and treatment of anxiety and catastrophising states.  
3. Education and vigilance regarding the expected course of recovery and 
options to seek further help in the case of persistent symptoms at defined time 
points. 
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In addition to profiling of risk in patients and personalising pain medicine before 
the initiation of surgical intervention, there is also scope to screen patients in the 
immediate to early postoperative period for signs of the development of PPP. 
This could take the form of hyperalgesia testing, for example, at the bed site as 
set out in chapter six. 
7.5 Future work 
While caution must be exercised in terms of extrapolating to other types of 
surgery (14), it is possible to hypothesise that similar features may be elicited 
from investigation of other surgical models. This in turn justifies further studies 
to define and identify surgical, procedure- specific cohorts of patients with PPP. 
This work is underway to validate these finding in two specific surgical models, 
also involving surgery on the chest: 
7.5.1 Breast surgery 
Together with colleagues at the cancer hospitals of the Royal Marsden NHS 
Foundation Trust, I have started a clinical trial of a complex intervention to 
prevent PPP following breast surgery.  This encompasses the following complex 
intervention, as compared with usual care, in the hospitals of this specialist 
cancer institution: 
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 Pre operative pain consultation 
 QST assessments centred on CPM and PPT 
 Education  
 Psychological intervention 
 Preventive pregabalin regimen 
 Perioperative paravertebral blockade (initiated preoperatively and to 
continue for 48 hours following surgery.) 
 Daily inpatient pain review 
 Two week follow up call and clinic visits, as required  
7.5.2 Thoracic surgery 
We have assessed the effects of effective paravertebral block in the immediate 
postoperative period on pain scores, analgesic requirement and PPP following 
thoracotomy at the largest UK thoracic surgical unit at Guy’s Hospital in London. 
A study investigating the timing of this block for video assisted thoracoscopic 
surgery (VATS) is also under way. 
As regards the cardiac surgical model, it is perhaps necessary to undertake dose 
finding or ’duration finding’ studies for pregabalin and/ or ketamine to ensure 
the translation of this study’s findings into clinical practice.  The diplopia effects 
of pregabalin at the doses given in this trial may act as a barrier to its adoption 
into routine practice. 
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As described above, the inefficient CPM susceptibility of some patients could also 
be targeted by the investigation of duloxetine and its ability to engage the 
noradrenergic reuptake pathway.  This may also allow examination of changes in 
CPM over time and with the institution of preventive analgesia. 
Looking further afield, non-surgical models may warrant investigation in a 
similar manner to better understand the mechanisms of transition from acute to 
persistent pain states as well as the potential to intervene with similar complex 
interventions e.g. refractory angina, non-cardiac chest pain, cancer pain, and 
opioid-induced hyperalgesia.  
7.6 Concluding remarks 
My work has confirmed the need for procedure specific study of PPP and has 
added to the relatively new body literature on risk factors and the potential to 
predict the onset of this phenomenon.  Prevention, particularly with acceptable 
levels of side effect, remains the holy grail (144). 
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Appendix One. Quality of life assessment: EQ-5D 
Under each heading, please tick the ONE box that best describes your health 
TODAY  
 
MOBILITY 
I have no problems in walking about      
I have slight problems in walking about     
I have moderate problems in walking about     
I have severe problems in walking about      
I am unable to walk about        
 
SELF-CARE 
I have no problems washing or dressing myself    
I have slight problems washing or dressing myself    
I have moderate problems washing or dressing myself    
I have severe problems washing or dressing myself    
I am unable to wash or dress myself      
 
USUAL ACTIVITIES (e.g. work, study, housework,  
family or leisure activities) 
I have no problems doing my usual activities    
I have slight problems doing my usual activities    
I have moderate problems doing my usual activities    
I have severe problems doing my usual activities     
I am unable to do my usual activities      
 
PAIN / DISCOMFORT 
I have no pain or discomfort        
I have slight pain or discomfort       
I have moderate pain or discomfort       
I have severe pain or discomfort       
I have extreme pain or discomfort       
 
ANXIETY / DEPRESSION 
I am not anxious or depressed       
I am slightly anxious or depressed       
I am moderately anxious or depressed     
I am severely anxious or depressed       
I am extremely anxious or depressed      
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 We would like to know how good or bad your health is  
TODAY. 
 This scale is numbered from 0 to 100. 
 100 means the best health you can imagine. 
0 means the worst health you can imagine. 
 Mark an X on the scale to indicate how your health is TODAY.  
 Now, please write the number you marked on the scale in the box 
below.  
                     
 
 
 
YOUR HEALTH TODAY  = 
 
 
 
 
 
 
 
 
 
 
 
10 
0 
20 
30 
40 
50 
60 
80 
70 
90 
100 
5 
15 
25 
35 
45 
55 
75 
65 
85 
95 
The best health        
 you can imagine 
 
The worst health        
 you can imagine 
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Appendix Two. State Anxiety Inventory 
Read each statement and select the appropriate response to indicate how you feel 
right now, that is, at this very moment. There are no right or wrong answers. Do 
not spend too much time on any one statement but give the answer which seems 
to describe your present feelings best. 
 1 2 3 4 
 Not at all  A little  Somewhat  Very Much So  
  
1. I feel calm  1 2 3 4 
2. I feel secure  1 2 3 4 
3. I feel tense  1 2 3 4 
4. I feel strained  1 2 3 4 
5. I feel at ease  1 2 3 4 
6. I feel upset  1 2 3 4 
7. I am presently worrying  
over possible misfortunes  1 2 3 4 
8. I feel satisfied  1 2 3 4 
9. I feel frightened  1 2 3 4 
10. I feel uncomfortable  1 2 3 4 
11. I feel self confident  1 2 3 4 
12. I feel nervous  1 2 3 4 
13. I feel jittery  1 2 3 4 
14. I feel indecisive  1 2 3 4 
15. I am relaxed  1 2 3 4 
16. I feel content  1 2 3 4 
17. I am worried  1 2 3 4 
18. I feel confused  1 2 3 4 
19. I feel steady  1 2 3 4 
20. I feel pleasant  1 2 3 4 
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Appendix Three. Pain Catastrophising Scale 
Everyone experiences painful situations at some point in their lives.  Such experiences 
may include headaches, tooth pain, joint or muscle pain.  People are often exposed to 
situations that may cause pain such as illness, injury, dental procedures or surgery. 
 
We are interested in the types of thoughts and feeling that you have when you are in 
pain.  Listed below are thirteen statements describing different thoughts and feelings 
that may be associated with pain.  Using the scale, please indicate the degree to which 
you have these thoughts and feelings when you are experiencing pain. 
 
 Not 
at all 
To a 
slight 
degree 
To a 
moderate 
degree 
To a 
great 
degree 
All 
the 
time 
I worry all the time about whether 
the pain will end 
0 1 2 3 4 
I feel I can’t go on 0 1 2 3 4 
It’s terrible and I think it’s never 
going to get any better 
0 1 2 3 4 
It’s awful and I feel that it 
overwhelms me 
0 1 2 3 4 
I feel I can’t stand it anymore 0 1 2 3 4 
I become afraid that the pain will get 
worse 
0 1 2 3 4 
I keep thinking of other painful 0 1 2 3 4 
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events 
I anxiously want the pain to go away 0 1 2 3 4 
I can’t seem to keep it out of my 
mind 
0 1 2 3 4 
I keep thinking about how much it 
hurts 
0 1 2 3 4 
I keep thinking about how badly I 
want the pain to stop 
0 1 2 3 4 
There’s nothing I can do to reduce 
the intensity of the pain 
0 1 2 3 4 
I wonder whether something serious 
may happen 
0 1 2 3 4 
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Appendix Four. S-LANSS assessment tool for neuropathic pain 
Study number:                 
Date of assessment:     
 
On a scale of 1- 10, please indicate how bad your pain has been in 
the last week (‘0’ means no pain and ‘10’ means pain as severe as 
it could possibly be.)                 
______ / 10 
 
Medication taken for this specific pain: 
 
 
In the area where you have pain, do you also have ‘pins and needles’, 
tingling or pricking sensations? 
Yes  /  No  
 
 
2·  Does the painful area change colour (e.g. look mottled or more red when 
the pain is particularly bad)?   
  Yes  /  No  
 
 
3·  Does your pain make the affected skin abnormally sensitive to touch?  
(e.g. unpleasant sensations or pain when lightly stroking the skin / wearing 
tight clothes) 
Yes  /  No  
 
 
4·  Does your pain come on suddenly in bursts for no apparent reason when 
you are still? (e.g. like electric shocks, 'bursting' or 'jumping' sensations)  
Yes  /  No  
 
 
5·  In the area where you have pain, does your skin feel unusually hot like a 
burning pain?   
Yes  /  No  
 
 
6·  Gently rub the painful area with yourt index finger and then rub a non 
painful area (e.g an area of skin further away.) How does this rubbing feel in 
the painful area?   
Same  /  Different  
 
 
7·  Gently press on the painful area with your finger tip and then gently press 
on a non painful area (e.g an area of skin further away.) How does this feel in 
the painful area?   Same  /  Different  
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Appendix Five. Case Report Form 
HEART PPPAIN STUDY 
 
Patient study number: 
 
ALL Inclusion criteria satisfied? 
 
Informed Consent  
First time sternotomy for cardiac surgery 
Patient aged 18 - 80 years 
 
Exclude patient if ANY of following: 
 
Emergency surgery (decision to operate taken on the day of surgery) 
Previous sternotomy 
Preoperative renal failure (eGFR  <60 ml/min) 
History of chronic non-anginal pain 
Chronic pain medication other than paracetamol and non-steroidal anti-
inflammatory drugs 
Concurrent use of oxycodone, lorazepam, or ethanol. 
 Concurrent use of any drugs for neuropathic pain e.g. antiepileptics, 
antidepressants 
Allergy to pregabalin, gabapentin or ketamine 
Pregnancy 
Limited understanding of numerical scoring scales 
Previous participation in other trials investigating analgesic agents or any IMP in 
previous three months 
 
Adverse event report: 
 
 
 
 
Serious Adverse Event/ SUSAR report: 
 
 
 
 
 
eGFR abnormalities/ Other reason for withdrawal: 
 
 
 
 
 
 
  219        
QST EXAMINATION 
 
PRE OP     
TPT   Sens        +                   Pain   +  
 
 
PPT  algometer  +   PPT  post CPM       +  
 
 
PAIN DIFF WITH TS Chest       +          Arm:    + 
 
POST OP 
 
TPT    Sens         +                  Pain         +  
 
 
PPT      +   
 
 
PAIN DIFFERENCE WITH TS Chest     +        Arm     +         
 
 
Zone of hyperalgesia (cms)   + 
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Date  ________  and duration of surgery ____________ (mins)   
Harvest site(s) 
Total morphine consumption at 24 hours post surgery  _____mg 
 
VAS sternotomy at 24 hrs at rest  _____ / 10 
VAS sternotomy at 24hr following 3 maximal coughs  _____ / 10 
VAS leg incision at 24 hrs    ________ / 10        N/A 
Sedation score at 24 hrs  ______  (Nil/ mild/ mod/ severe)         pCO2 = _______ 
Nausea scores at 24 hrs ______  (Nil/ mild/ mod/ severe)  RR =              /min 
 
Time to extubation  _____  mins 
Length of stay in ITU ____   hrs 
Length of stay in hospital ____ days 
 
Survival 28 days:   YES  
                                     NO  
 
 
PHONE ASSESSMENT AT 3 MONTHS 
 
Survival:   YES  
                         NO  
 
 
NRS at 3 months  Sternotomy   _____ / 10   Change with 3 coughs/ movement: 
 
    Leg pain  _____/ 10    Change with movement: 
 
 
 
Analgesics used for wound pain 
 
 
Sleep disturbance by wound pain:     YES  
                              NO  
 
PHONE ASSESSMENT AT 6 MONTHS 
 
Survival:   YES  
                         NO  
 
 
NRS at 3 months  Sternotomy   _____ / 10   Change with 3 coughs/ movement: 
 
    Leg pain  _____/ 10    Change with movement: 
 
 
 
Analgesics used for wound pain 
 
 
Sleep disturbance by wound pain:     YES  
                              NO  
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Appendix Six. Individual patient SAE (Serious Adverse Event) log  
 
Study Title: 
 
 
HEART PPPAIN 
                
 
 
Investigator: Dr 
S Anwar 
       
Patient number 3 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
 
  Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
 
  
 
                              
 1 Renal failure 2   
  
4 1   1 
   
  1 
 
  
   
 
    
  
        
   
  date if resolved: 1   
 
  
onset date:___15 
Dec 11                         16-Dec-11     
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Patient number 5 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
 
  Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
 
  
 
                        
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 1   
 1 Sedation 2   
  
4 1     
 
3 
 
    
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__13 
Dec 11                         13th dec 11     
 
                            1 1   
 2 Diplopia 2   
  
4 1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:___13 
Dec 11                         13th dec 11     
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Patient number 6 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
 
  
 
        4 1       3     
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 1   
 1 Somnolence 2   
  
        
   
    
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
   6th Jan 2012                         7th Jan 2012     
                         4   1 1   
 2 Dizziness 2   
  
4 1     
   
    
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
   6th Jan 2012                         7th Jan 2012     
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Patient number 7 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
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te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
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le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Diplopia 1 1 
  
  1     
  
4   1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__23 
Dec 11                         24-Dec-11     
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Patient number 11 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
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e
s
 
n
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t 
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d
 
d
o
u
b
tf
u
l 
p
o
s
s
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p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Sedation 2 1 
  
  1     2 
  
  1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__7th 
Jan 2012                         7th Jan 2012     
                                   
 2 Diplopia 1 1 
  
  1     
 
3 
 
  1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__6th 
Jan 2012                         8th Jan 2012     
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Patient number 19 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
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t 
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d
 
d
o
u
b
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u
l 
p
o
s
s
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p
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b
a
b
ly
 
v
e
ry
 l
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e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Diplopia 2   
 
3   1     
  
4   1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__17 
Jan 2012                         19-Jan-12     
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Patient number 20 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
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t 
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d
 
d
o
u
b
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u
l 
p
o
s
s
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p
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b
a
b
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v
e
ry
 l
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e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                          1   
 1 Reintubation     
  
        
   
    
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset 
date:__19th jan 
2012 3       4 1   1         19th Jan 2012 1   
 
                  
  228        
 
                  
                  
         
Patient number 22 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
 
  
 
                        
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 1   
 1 Diplopia 2   
 
3   1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__21 
Jan 12                         21-Jan-12     
                             1 1   
 2 Dizziness     
  
        
   
    
 
  
   
 
2   
 
3   1     
  
4   date if resolved: 
 
  
 
  
onset date:__21 
Jan 12                         21-Jan-12     
 
                  
  229        
                  
                  
                  
         
Patient number 23 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Diplopia 2 1 
  
  1     
  
4   1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__22 
Jan 12                         22nd Jan 2012     
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Patient number 26 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Resternotomy 3   
  
4 1   1 
   
  1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__22 
Jan 12                         22-Jan-12     
                                   
 2 Diplopia 2   
  
4 1     
 
3 
 
  4 1   
   
 
    
  
        
   
  date if resolved: 
 
  
   22-Jan-12                         22-Jan-12     
 
                  
                  
                  
  231        
         
Patient number 27 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                        1 1   
 1 Diplopia 1   
 
3   1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__21 
Jan 12                         22-Jan-12     
                             1 1   
 2 Dizziness     
  
        
   
    
 
  
   
 
1   
 
3   1     
  
4   date if resolved: 
 
  
 
  
onset date:__21 
Jan 12                         22-Jan-12     
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Patient number 30 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Diplopia 2   
 
3   1     
  
4   1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__29 
Jan 12                         29th jan 2012     
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Patient number 35 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Diplopia 1   
 
3   1     
  
4   1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__31 
Jan 12                         31st jan 2012     
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Patient number 36 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Diplopia 2   
 
3   1     
  
4   1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__2 
Feb 13                         2nd feb 2012     
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Patient number 42 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Resternotomy 3   
  
4   2 1 
   
  1 
 
2 
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__02 
Feb 12                         02-Feb-12     
                                   
 
2 
Pericardial 
tamponade 3   
  
4   2 1 
   
  3 
 
2 
   
 
    
  
        
   
  date if resolved: 
 
  
   onset date:__                               
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Patient number 46 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Dizziness 1 1 
  
  1     
 
3 
 
  1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__8th 
Feb 2012                         8th Feb 2012     
 
                  
  237        
 
                  
                  
         
Patient number 49 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Dizziness 1 1 
  
  1     
 
3 
 
  1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__10 
Feb 12                         10-Feb-12     
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Patient number 50 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
 
  
 
                        
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 1   
 1 Diplopia 2   
 
3   1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__10 
Feb 12                         11-Feb-12     
                             1 1   
 2 Dizziness 2   
 
3   1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__10 
Feb 12                         11-Feb-12     
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Patient number 53 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
 
  
 
                        
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 1   
 1 Diplopia 2   
 
3   1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__16 
Feb 12                         17-Feb-12     
                             1 1   
 2 Dizziness 2   
 
3   1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__16 
Feb 12                         17-Feb-12     
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Patient number 56 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                        1 1   
 1 Diplopia 1   
 
3   1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__15 
Feb 12                         16-Feb-12     
                             1 1   
 2 Dizziness 1   
 
3   1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__15 
Feb 12                         16-Feb-12     
 
                  
                  
  241        
                  
                  
         
Patient number 63 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
                             1     
 2 Unresponsiveness 3   
  
4 1   1 
   
    1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__21 
Feb 12                         21-Feb-12     
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Patient number 67 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Diplopia 3   
  
4 1     
  
4   1 
 
2 
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__24 
Feb 12                         26th Feb 2012     
                                   
 2 Drowsiness 3   
  
4 1     
  
4   1 
 
2 
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__24 
Feb 12                         27Th Feb 2012     
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Patient number 69 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                        1 1   
 1 Diplopia 2   
 
3   1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__26 
Feb 12                         26-Feb-12     
 
                  
                  
                  
  244        
 
                  
         
Patient number 76 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Reintubation 3   
  
4 1   1 
   
  1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__02 
Mar 12                         02-Mar-12     
 
                  
                  
  245        
 
                  
         
Patient number 78 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Diplopia 2   
 
3   1     
   
  1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__03 
Mar 12                         04-Mar-12     
 
                  
                  
                  
  246        
 
                  
         
Patient number 84 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                        1 1   
 1 Diplopia 1 1 
  
  1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__18 
Apr 12                         18-Apr-12     
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Patient number 91 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
 
  
 
                        
1= resolved                        2 = persisting             3 = death                   4 = 
unknown     
 1 Diplopia 2 1 
  
  1     
  
4     1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__04 
May 12                         04-May-12     
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Patient number 94 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 1 Diplopia 2   
 
3   1     
  
4   1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__07 
May 12                         08-May-12     
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Patient number 101 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                              
 
1 
Acute renal 
failure 2   
  
4 1   1 
   
  1 1   
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__19 
May 12                         21st may 2012     
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Patient number 103 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                        1 1   
 1 Diplopia 1 1 
  
  1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__17 
May 12                         17-May-12     
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Patient number 104 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
                             1 1   
 
2 
Ventricle 
fibrillation 3   
  
4 1   1 
   
    
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__16 
May 12                         16-May-12     
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Patient number 110 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                        1 1   
 1 Diplopia 1 1 
  
  1     
 
3 
 
    
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__20 
May 12                         21-May-12     
                             1 1   
 2 Drowsiness 2 1 
  
  1     
 
3 
 
    
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__20 
May 12                         21-May-12     
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Patient number 126 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                        1 1   
 1 Diplopia 2   
 
3   1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__15 
Jun 12                         16-Jun-12     
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Patient number 127 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                        1 1   
 1 Diplopia 2 1 
  
  1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__15 
Jun 12                         15-Jun-12     
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Patient number 134 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                        1 1   
 1 Diplopia 2   
  
4 1     
 
3 
 
    
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__13 
Jul 12                         14-Jul-12     
                             1 1   
 2 Dizziness 2   
  
4 1     
 
3 
 
    
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__13 
Jul 12                         14-Jul-12     
   
 
                        1 1   
 3 Nausea 3   
  
4 1   1 
   
    
 
  
   
 
    
  
        
   
  date if resolved: 
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Patient number 135 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                        1 1   
 
1 
Post-operative 
cardiac arrest 3   
  
4 1   1 
   
    
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__16 
Jul 12                         16-Jul-12     
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Patient number 139 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
   
 
                        1 1   
 1 Diplopia 1 1 
  
  1     
   
    
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__20 
Jul 12                         20-Jul-12     
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Patient number 140 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
 
  
 
                        
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 1   
 1 Diplopia 1   
  
4 1   1 
   
    
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__24 
Jul 12                         25-Jul-12     
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Patient number 144 
   
                  
  Adverse events Severity 
Action Taken with 
trial medication 
Medicine 
taken for 
this AE? Relation to trial med AE outcome 
reported 
as 
serious 
 
  
Has the subject 
reported any 
adverse events?                                                                   
No                                    
Yes  X 
1 = Mild          
2 = 
Moderate  
3 =
Severe 
n
o
n
e
 
d
o
s
e
 a
d
ju
s
te
d
 
te
m
p
o
ra
ry
 s
to
p
 
p
e
rm
a
n
e
n
t 
s
to
p
 
n
o
  
y
e
s
 
n
o
t 
re
la
te
d
 
d
o
u
b
tf
u
l 
p
o
s
s
ib
le
 
p
ro
b
a
b
ly
 
v
e
ry
 l
ik
e
ly
 
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 
n
o
 
y
e
s
 
   Name of Event 
 
1 2 3 4 1 2 1 2 3 4 5   1 2 
 
  
 
                        
1= resolved                        2 = persisting             3 = death                   4 = 
unknown 1   
 1 Diplopia 2 1 
  
  1     
  
4     
 
  
   
 
    
  
        
   
  date if resolved: 
 
  
 
  
onset date:__28 
Jul 12                         28-Jul-12     
 
                  
                  
                  
                  
  260        
Appendix Seven. Reporting SUSAR/ SAE 
Prospective, double-blinded, randomised, placebo controlled trial of pre-emptive 
analgesia to prevent pain following sternotomy for cardiac surgery. 
 
 
 
 
 
 
 
This process was followed in the case of SUSAR (Suspected Unexpected Serious Adverse Reaction)  
or SAE (Serious Adverse Event.) 
CRF (case report form), TMF (trial master file), CI (chief investigator), REC (research ethics committee), 
IMP (investigational medicinal product), MHRA (Medicines and Healthcare products Regulatory 
Agency.) 
  261        
Appendix Eight. Statistical Analysis Plan 
HEART PPPAIN study: 
HEART surgery and Persistent Postsurgical PAIN 
 
Introduction 
This statistical analysis plan sets out the methods to be used to analyse the 
primary and secondary outcomes from the HEART PPPAIN study. This plan is 
based on the study protocol (Prospective, double-blinded, randomised, placebo 
controlled trial of pre-emptive analgesia to prevent pain following sternotomy 
for cardiac surgery. Version 6 14th Sept 2012).  
 
Analyses are in accord with ICH-E9 statistical guidelines for clinical trials and 
updated CONSORT reporting checklist for clinical trials. 
 
Research questions & hypotheses 
The HEART PPPAIN study seeks to answer two associated questions: 
1. What is the clinical efficacy of pregabalin, either alone or in combination with 
ketamine, in preventing the development of persistent postsurgical pain (PPP) 
following sternotomy for cardiac surgery? 
2. What is the predictability of the development of PPP using experimental pain 
modalities at the time of surgery and is it possible to predict the preventive 
effect of pregabalin, as well as additional ketamine, on this phenomenon? 
 
It is hypothesised that pregabalin combined with ketamine is superior to 
pregabalin alone, which in turn is superior to placebo, in preventing the 
transition from acute to chronic pain in and around the scar following cardiac 
surgery.  It is also hypothesised that the individual’s response to pain 
challenges before and immediately after surgery can predict their likelihood 
of developing PPP in the long term. 
 
 
 
 
Description of Outcomes 
 Primary Objective – assess whether the use of a preventive analgesia 
reduces the incidence of PPP at three and six months 
        
 Secondary Objective – assess the effect of preventive analgesia on 
acute pain, recovery, length of hospital stay, quality of life and survival 
outcomes as well as the predictability of pain using quantitative sensory 
testing (QST) 
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Primary Endpoint –  
 Presence of pain on the Numerical Rating Scale (NRS) at the sternotomy 
site at 3 and 6 months following surgery. 
 
Secondary Endpoints – 
 
 ACUTE: 
 Total morphine consumption at 24 hours post surgery  (continuous : ratio) 
 NRS scores at 24 hrs post surgery, at rest and following 3 maximal 
coughs (ordinal) 
 Sedation and nausea scores at 6 hours post surgery (ordinal) 
 Carbon dioxide level in blood (continuous: ratio) 
 Side effects present in the form of dizziness, confusion, blurred vision 
(categorical/binary) 
 Time to extubation (continuous : ratio) 
 Length of stay in intensive care and in hospital  (continuous : ratio) 
 28-day mortality (categorical/binary) 
 
FOLLOW UP AT 3 MONTHS: 
 NRS pain score around leg incision site, if applicable  (ordinal) 
 Neuropathic pain assessment at 3 months post surgery (S-LANSS) 
(ordinal or continuous??) 
 Quality of life and mood on EQ-5D  (ordinal or continuous??) 
 Analgesics taken and sleep disturbance (Categorical/  binary) 
 Survival (categorical/binary) 
 
FOLLOW UP AT 6 MONTHS: 
 Numerical Rating Scale (NRS) pain scores at rest and following 
movement/ cough. (ordinal) 
 Neuropathic pain assessment at 6 months post surgery (S-LANSS)  
(ordinal or continuous??) 
 Quality of life and mood on EQ-5D  (ordinal or continuous??) 
 Analgesics taken and sleep disturbance (Categorical/  binary) 
 Survival (categorical/binary) 
 
Power Calculation 
This study is powered to detect a two-thirds reduction in the percentage of 
patients with pain at 3 and 6 months.  Pilot data revealed a PPP prevalence of 
39.7% in 312 consecutive patients, undergoing elective sternotomy in our centre 
over a six-month period. Based on an alpha of 5% and power of 80%, we 
therefore calculated a sample size per group of 43 patients. To allow for drop off 
and loss to follow up, we will recruit 50 patients per group. 
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Inclusion Criteria:  
 Informed Consent  
 First time sternotomy for all cardiac surgery  
 Patient aged 18 - 80 years 
 
Exclusion criteria: 
 
 Emergency surgery (decision to operate taken on the day of surgery) 
 Previous sternotomy 
 Preoperative renal failure (eGFR  <60 ml/min) 
 History of chronic non-anginal pain 
 Chronic pain medication other than paracetamol and non-steroidal anti-
inflammatory drugs 
 Concurrent use of oxycodone, lorazepam, or ethanol. 
 Concurrent use of any drugs for neuropathic pain e.g. antiepileptics, 
antidepressants 
 Allergy to pregabalin, gabapentin or ketamine 
 Pregnancy 
 Limited understanding of numerical scoring scales 
 Previous participation in other trials investigating analgesic agents or any 
IMP in previous three months 
 
Statistical analysis 
 All analyses will be undertaken using SPSS (version 21) by Dr. Sibtain 
Anwar 
 
Descriptive analyses 
 
Basic descriptive statistics will be carried out. This will include numbers and 
percentages for categorical data, mean and standard deviation for normally 
distributed, continuous data and median and interquartile range for skewed data. 
Baseline characteristics between the treatment groups will also be compared to 
assess the degree to which comparability of randomisation was achieved. 
 
 
Inferential analyses 
 
Regression ANCOVA (analyses of covariance) will be employed. These models 
adjust for baseline characteristics where there is good clinical belief that they may be 
predictive of outcome  
 
Primary outcome: logistic regression +selected covariates depending on group 
differences 
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Secondary outcomes 
1.       Acute 
-          VAS 24 hr = linear regression adjusting for baseline VAS +selected covariates 
as outlined above  
-          Total morphine, time to extubation and LOS in hospital = linear regression 
+selected covariates  
-          Side effect episodes and mortality = binary (yes/no) and therefore logistic 
regression  
 
 
2.       3 months 
-          S-LANSS = linear regression adjusting for baseline VAS +selected covariates 
as outlined above  
-          EQ-5D = linear regression adjusting for baseline VAS +selected covariates as 
outlined above  
-          Mortality = as above 
3.       6 months 
-          S-LANSS = as above 
-          EQ-5D = as above 
-          Mortality = as above 
-          Primary outcome (NRS) = as above 
 
 
 
 
Subgroup analysis: 
 
Given the relatively low power for testing interactions, these results should be 
considered exploratory only.  
 
Independent variables as risk factors for chronic pain at three and six months: 
 
Age (continuous) 
 
Sex (categorical) 
 
Pre op EQ-5D (continuous : interval or ordinal?) 
 
Strait anxiety Spielberger (continuous : interval or ordinal??) 
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Catastrophising score (continuous: ratio or ordinal??) 
LIMA harvesting (categorical/ binary) 
TS (temporal summation) at the sternotomy site prior to surgery (categorical/ 
binary) 
TS (temporal summation) remotely prior to surgery (categorical/ binary) 
Duration of surgery in minutes (continuous: ratio) 
Percentage change in pressure pain thresholds following preoperative ‘CPM’ 
challenge (continuous: ratio) 
 
Dependent variables as risk factors for chronic pain at three and six months: 
 
Acute NRS pain score in first 24 hours (ordinal) 
Percentage change in PPT after surgery (continuous: ratio) 
Change in TDT (continuous: ratio) 
Change in TPT (continuous: ratio) 
Change in Remote TDT (continuous: ratio) 
Change in Remote TPT (continuous: ratio) 
Percentage change in remote PPT after surgery  (continuous: ratio) 
TS (temporal summation) at the sternotomy site after surgery (categorical/ 
binary) 
TS (temporal summation) remotely after surgery (categorical/ binary) 
Zone of hyperalgesia around the incision after surgery (continuous: ratio) 
 
 
Protocol violations and missing data/ loss to follow up: 
 
In a superiority trial, intention-to-treat (ITT) analysis is conventionally used as 
the most conservative approach to minimise the possibility of a type I error, i.e. 
falsely concluding that one treatment is superior to another. ITT includes data in 
the primary analysis from participants who drop out or violate the protocol to 
ensure differences between treatments under test are not falsely inflated and 
ensuring the most rigorous conditions apply before rejection of the null 
hypothesis (i.e. treatment A is not superior to treatment B). However, in non-
equivalence trials the null hypothesis is the opposite, and states that the 
experimental treatment is inferior to the reference treatment. As this is a 
superiority testing study, ITT analysis will be carried without the need for per 
protocol processing of data. 
 
For ITT analysis, missing data will be imputed based on mean or median values 
for the randomisation group of the individual patient, as appropriate for the 
distribution of data.  
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Appendix Nine. Original QST data 
PPT preopS 
PPT 
postCPM PPT postopS PPT preopR PPT postopR TS newsS? TS newR? ZoH PPP? 
376 423 588 557 841 0 0 12 0 
208 361 216 359 353 1 0 14.75 0 
204 216 114 301 252 0 0 35 1 
350 385 218 415 257 0 0 8 1 
282 433 231 389 198 0 0 8.5 0 
182 140 160 255 360 0 0 10.5 0 
164 179 276 437 420 1 0 25 0 
193 335 109 405 511 0 0 9.5 0 
304 443 219 175 140 0 0 23 0 
292 638 265 384 361 0 0 14 0 
232 317 155 255 355 0 0 9 0 
182 216 128 567 562 1 0 10 0 
139 157 103 329 277 0 0 60 1 
271 415 211 538 606 0 0 6.5 0 
275 357 228 447 485 0 0 14 0 
187 441 108 387 429 0 0 54 1 
168 161 164 
  
0 1 12 1 
119 141 106 
  
0 1 45 0 
192 200 114 
  
0 0 32 0 
303 299 388 399 340 0 0 63 0 
216 238 231 412 418 0 1 44.75 1 
100 84 65 385 335 0 0 66 1 
136 141 160 279 344 0 0 22 0 
  267        
214 197 408 412 380 0 1 42.5 1 
201 456 191 515 570 0 0 7 0 
301 413 220 388 431 0 0 32 0 
226 242 301 410 428 0 0 49.5 0 
136.75 143.25 151.75 297 256 0 0 36 0 
129 161 87 370 290 0 0 20 0 
222 216 143 
  
0 0 34 0 
330 337 223 362 408 0 0 11 0 
241 338 281 512 665 0 0 19 0 
255 377 510 444 407 1 0 15 0 
376 571 273 398 475 0 0 9.5 0 
205 213 163 411 394 0 0 0 1 
267 265 97 351 289 0 0 33 1 
201 391 183 498 560 0 0 7.5 0 
215 197 147 309 391 0 0 12 0 
177 319 102 411 466 1 0 48 1 
694 815 279 
  
0 0 24 0 
318 555 336 523 653 0 0 20.5 0 
438 525 437 
  
0 0 0 0 
533 603 425 
  
0 0 0 0 
262 383 94 532 485 1 1 46 1 
105 247 174 480 527 0 0 7.5 0 
233 279 503 298 228 0 0 34.5 1 
425 607 266 482 375 0 0 14 0 
213 410 446 349 404 0 0 14.5 0 
298 558 267 392 361 0 0 38 0 
153 168 131 291 341 0 0 7.5 0 
260 572 186 488 362 0 1 13.5 0 
300 460 148 472 456 0 0 22 0 
205 203 168 312 349 1 0 35 3 
  268        
243 301 235 212 195 0 0 7.5 0 
174 193 171 285 275 0 0 12.5 0 
436 425 109 
  
0 0 0 0 
185 246 103 312 230 1 1 44 1 
141 144 103 295 234 1 0 45 1 
294 452 177 377 459 1 1 31.5 1 
306 461 257 412 440 0 0 20 0 
282.5 324.75 201.25 412 394 0 1 36.5 0 
185.25 415.75 415.75 204 132 0 1 50.5 1 
399.25 390.5 193.5 297 178 1 1 39 1 
160 190.5 101 205 93 0 1 48.5 1 
248.75 513.75 190 253 311 0 0 9.5 0 
398 568 274.75 452 461 0 0 12 0 
189.5 182.25 119.5 180 94 1 0 37 1 
292.5 494 240 295 324 0 0 46 0 
363.25 530.25 216.25 436 565 0 0 15.5 0 
337 275 284 235 292 0 0 9 0 
359.25 438.25 257.25 396 173 0 0 32.5 1 
445.75 432.25 262 387 401 0 0 20 0 
217 209 328 146 178 0 0 12.5 0 
224.25 220.25 237.25 224 139 1 1 56 1 
212.24 414.5 181 251 189 0 0 32.5 0 
234.25 473.25 239.5 220 241 0 0 11.5 0 
412 597.5 338.5 383 391 0 0 11 0 
268.75 466.75 305.25 304 301 0 0 6 0 
417.875 389.625 277.125 
  
0 0 36 0 
255.125 234 151 
  
1 1 26 0 
385.125 368.625 339.875 
  
0 0 26 0 
418.5 437.5 166.5 545 221 0 0 12 1 
227 480.75 300.25 297 306 0 0 22 0 
  269        
495 706 377.75 493 511 0 0 10 0 
293 238 346 301 350 0 0 0 0 
368.5 379.75 353.5 324 411 0 0 10 0 
314.5 262.25 205.5 300 121 0 1 8.5 0 
190.25 310 92.75 189 141 0 0 58 0 
359.5 389.5 311.5 397 409 0 0 4 0 
245.75 494 302 249 418 0 0 6.5 0 
297 421.75 356.25 352 314 0 0 11 0 
305.5 274.75 211.25 397 314 0 0 37 0 
370.75 590 314.75 352 341 0 0 15.5 0 
155 132 267.25 193 304 0 0 0 0 
87.5 120.25 86.5 194 86.5 0 0 29 0 
144.5 392.5 199.25 211 232 0 0 11.5 0 
144.25 187.5 200.5 193 243 0 0 4.5 0 
410 609.25 422 500 498 0 0 5.5 0 
175 181.5 212.25 184 91 1 0 36.5 0 
500.5 560.5 526.25 499 511 0 0 30.5 0 
188 185 285.5 185 219 0 0 5.5 0 
492 493.5 345 481 222 0 1 54 1 
220 206.5 294.25 214 334 0 0 2 0 
175.25 313.75 212 183 255 0 0 9.5 0 
203.5 159.5 212.25 215 197 0 0 31 0 
274.5 307.5 135.25 297 124 0 1 65.5 1 
267.25 446.25 227 290 312 0 0 11.5 0 
387.5 559.75 146.75 294 195 0 0 11 0 
84 108.75 75.25 130 159 0 0 6.5 0 
132 168.5 258.5 113 212 0 0 6.5 0 
128.5 317 121.25 188 203 0 0 10 0 
256.5 452.5 232.5 175 88 1 1 35.5 0 
263.25 255.75 205.5 296 356 0 0 10 0 
  270        
371.5 555.5 292.25 414 456 0 0 12 0 
589.625 765 592.25 589.625 765 0 0 0 0 
502.25 702.75 403.75 412 382 0 0 9.5 0 
368.75 638 229 312 315 0 0 14.5 0 
241 363 269 350 425 0 0 16 0 
198.25 219.25 261.25 274 311 0 0 7.5 0 
390.75 333 185.25 376 254 0 0 39 1 
234.125 234.5 232.875 121 188 0 1 77 0 
283.75 276.75 125.5 
  
0 0 0 0 
264.25 328.875 266 
  
0 0 77 0 
354.75 324 435 
  
0 0 12 0 
742 871.75 240.75 814 152 0 0 5.5 0 
216.5 377 161.75 282 312 0 0 18 0 
179 463.5 234.75 241 305 0 0 13 0 
373.25 378.75 256.25 347 357 0 0 6 0 
209.75 264.5 189.75 281 225 0 0 0 0 
111 97.5 195.5 148 388 0 0 49 0 
128.25 163.5 181 185 299 0 0 4.5 0 
287.75 479.5 194.25 392 481 0 0 11.5 0 
340 695 348.25 311 355 0 0 16 0 
204.25 349.25 232 244 232 0 0 0 0 
277 328.75 205.75 182 219 0 0 12 0 
189.5 218.25 178.75 147 233 0 0 20 0 
100.25 107 110.75 323 109 1 1 42.5 1 
211 337.5 172.5 242 194 0 1 44 0 
139.5 150.5 49 250 421 0 0 44.5 0 
243.25 219.25 202.25 123 149 0 0 9 0 
210.5 196.5 132.75 176 132 1 0 51 1 
158.125 148.625 83.125 
  
1 1 45 1 
145.5 103.5 117.75 145.5 103.5 1 1 44 1 
  271        
265.8 298 185.75 265.8 298 0 0 36 0 
192.5 184.25 204 176 189 0 0 12.5 0 
268.25 193.75 303 362 388 0 0 18.5 0 
193 178 104.5 194 121 0 0 41 0 
253.75 205 239.5 176 388 0 0 14.5 0 
245.75 314 186.75 296 259 0 0 12 0 
318.25 497 85.5 314 102 1 1 5.5 1 
 
QST data is presented on a sequential patient basis.  
PPT = pressure pain threshold in kilo pascals, preopS = preoperatively at the sternotomy site, postCPM = following conditioned pain modulation, postopS = 
postoperatively at the sternotomy site, preopR = preoperatively at a remote site, postopR = postoperatively at a remote site, TS newS? = development of new temporal 
summation at the sternotomy site [0=No, 1= Yes], TS newR? = development of new temporal summation at a remote site [0=No, 1= Yes], ZoH = zone of hyperalgesia in 
centimeters, PPP?= presence of persistent postsurgical pain. [0=No, 1= Yes.] 
 
 
